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Abstract 
 
Toby R. Long, Ph.D. 
Department of Chemistry, April 2010 
University of Kansas 
 
The use of ring-opening metathesis polymerization (ROMP) for polymer-assisted 
solution phase (PASP) synthesis is described herein.  Multiple ROMP-based 
strategies will be discussed in the scope of this dissertation.  These include the 
development and application of a multifaceted oligomeric phosphate as a facilitated 
leaving group in both SN2 and SN2´ processes, as well as an in-situ generated 
sequestration reagent.  We also investigate the use of ROMP in an atom-economical 
approach to generate a diverse collection of cyclic sulfonamides (sultams) whereby a 
vanishing support protocol imparts a traceless, chromatography-free synthesis of 
these motifs. 
Also highlighted within is the ability to use ROMP technology to aid in the 
development of higher-loading magnetic nanoparticles for the purpose of supported 
catalysis.  These cobalt-based ROMPgel nanoparticles were subsequently doped with 
Pd and demonstrated for use in several Suzuki-Miyaura coupling reactions.  The 
nanoparticles were conveniently reclaimed via external magnetic field and recycled 
for later use.   
 Lastly, we present the design, validation, and completion of a 225-member library 
of thiadiazepin-1,1-dioxide-4-ones using both solution- and polymer-assisted 
solution phase protocols.  The library was validated and conducted on an automated 
parallel synthesis platform in which a facile, two-step diversity-rendering sequence 
was performed. 
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Chapter 1 
Recent Advances in Polymer-Assisted Solution Phase Synthesis 
and Automated Protocols 
 2 
1.1  Introduction 
Over the last two decades, both organic synthesis and medicinal chemistry alike 
have been greatly impacted by the development of solid-phase synthesis and 
automated technologies.1  Among these developments, polymer-assisted solution 
phase (PASP) synthesis2 has brought about a new paradigm shift for drug discovery 
outside of the traditional “split and mix” combinatorial techniques of solid-phase 
chemistry.  This has been gathered largely in part by a number of favorable attributes 
that allow for the simplification of synthetic processes including isolation and 
purification procedures.  These attributes have been thoroughly reported throughout 
the literature3 and include (i) having a larger commercially available set of 
immobilized reagents, catalysts, and scavengers at the chemist’s disposal4 (ii) the 
ability to facilitate cleaner and safer reaction profiles through immobilization of 
toxic/hazardous materials5 (iii) reusability of the spent reagent (iv) ease of monitoring 
using conventional techniques (ie. TLC, LC-MS, GC, etc…) (v) and the ability to 
facilitate compound libraries that yield sufficient quantities (25−50 mg) of high-
quality material.6   
The roots of polymer-assisted synthesis dates back to the 1960’s with seminal work 
performed by Bruce Merrifield in the development of facilitated peptide synthesis.7  
Since this time, these pivotal accomplishments have paved the way for the 
development of new facilitated approaches, not only in peptide chemistry8, but have 
also aided in the assembly of complex natural products9 and new synthetic 
materials.10 
 3 
When one compares the attributes of PASP-synthesis to conventional solid-phase 
organic synthesis (SPOS), a clear separation is revealed (Figure 1.1).  PASP-based 
methods eliminate the necessary synthetic steps to attach the substrate to the resin 
support and its subsequent release of the desired product.  The reversed role played 
by PASP synthesis in which the substrates are solution-bound, facilitates overall 
cleaner reaction profiles having virtually eliminated side product formation due to 
incomplete “on-bead” conversions.  
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Figure 1.1  Solid-phase organic synthesis vs. polymer-assisted solution phase 
synthesis 
 
PASP-based methods utilize excess reagents in solution (i), or polymer-bound (ii), 
to drive reactions to completion.  These reagents, along with any byproducts that may 
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form, can conveniently be removed by either filtration, or via polymer-assisted 
chemoselective sequestration (ie. scavenging).11  
Polymer-bound reagents can be categorized into a number of different areas related 
to their function and/or functionality present on the support (Figure 1.2).  These 
include reagents used for oxidation12 and reduction,13 polymer-bound nucleophiles 
(electrophile scavengers),14 polymer-bound electrophiles (nucleophile 
scavengers),14a,15 amide coupling,16 acidic,17 basic,18 and specialized reagents used for 
alkylation,19 dehydration,20 etc…  Many of these chemical entities reside upon 
conventional polystyrene supports (PS) that are inexpensive and relatively easy to 
use.  One caveat of PS-based supports is under certain conditions degradation can be 
observed thus leading to the development of a number of different alternative 
supports including metal-based nanoparticles,21 silica,22 cellulose,23 zeolites,24 and 
monoliths;25 some of which will be discussed herein. 
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Figure 1.2  Representative polymer-bound reagents used in PASP-synthesis 
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To preface this discussion, this opening chapter will provide a brief review of some 
of the most recent and prominent advances in polymer-assisted solution phase 
(PASP) synthesis and automated technologies.  This review will cover seminal 
reports and applications in the areas of  (i) soluble and insoluble polymer-bound 
reagents, catalysts, and scavengers (ii) developments in flow-chemistry and new 
functionalized-materials (iii) as well as and other automated, PASP-friendly 
technologies and their use in small-molecule library development. 
1.2  Recent Advances in Polymer-Bound Reagents, Catalysts and Scavengers 
The use of polymer-supported chemical entities has steadily increased over the last 
several decades and continues to play a vital role in facilitating small-molecule 
synthesis.26  This increase has come as a result of increased demands revolving 
around the drug-discovery process, and the need to produce diverse compound 
collections in a faster, more efficient manner.  Over time, these demands have yielded 
a number of polymer-bound entities that have recently been used in PASP-facilitated 
library synthesis.4b 
Parlow et. al. recently displayed use of a number of different polymer-bound 
reagents in the PASP-facilitated library synthesis of piperazinyl glutamate pyridines 
(Scheme 1.1).27  Polymer-supported carbodiimide (CDI) (1.1) was used as an amide 
coupling reagent to piece together piperazine fragments (1.2) to a number of 
arylcarboxylic acids (1.3) in the presence of HOBt (coupling additive) and NMM.  
The authors used this fragment-based approach to optimize lead molecules (1.4) as 
P2Y12 antagonists for inhibition of platelet aggregation. 
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Scheme 1.1  Use of PASP synthesis in fragment-based lead optimization 
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One of the more overlooked features of PASP-synthesis is the ability to incorporate 
and use otherwise incompatible functionalities together simultaneously in a single-pot 
reaction.28  Highlighted above, the authors report the use of a polymer-bound 
isocyanate in the presence of a polymer-bound amine in a mixed-bed scavenging 
protocol.  Isocyanate 1.5 was used to scavenge out excess HOBt and/or amine starting 
material, while amine 1.6 was used to remove any unreacted carboxylic acid (1.3).  
The decrease in reactivity of the two polymer-bound scavengers towards each other is 
mainly attributed to stabilization thorough overall spatial arrangement of the 
functional groups within the polymer matrix.  The use of excess polymer-bound 
reagents is often a result of low resin-load capacities, but can also be related to this 
reduced reactivity.  This, however, can also come at an advantage to the chemist as 
greater selectivity can sometimes be achieved as compared to the same non-supported 
reagent in solution.29   
Parang and Ahmadibeni recently reported the development of solid-phase reagents 
for regioselective phosphoryation of carbohydrates and nucleosides.30  Traditional 
phosphorylation and/or derivatization31 of carbohydrates can utilize various 
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protection/deprotection schemes to achieve the desired mono-phosphorylated species, 
while unprotected systems often result in multi-phosphorylated compounds that must 
be separated; both scenarios are quite uneconomical for the purpose of library 
development.  Reagent 1.7 was specifically designed to address these limitations 
through development of a more universal method for monophosphorylation of multi-
hydroxylated compounds.   
The activated phosphorus in this reagent is strategically placed for its preemptive 
release as a phosphate (1.9) via acid-mediated generation of a p-quinone methide.  
This resin-trapped methide is then quenched, releasing the newly phosphorylated 
products (1.10), and is then recycled for later use by various phosphitylating reagents. 
Scheme 1.2  Use of a solid-phase phosphoryating reagent 
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Recently, Chiara and Encinas reported on the usefulness of a supported 
dialkylformamide (1.11) as a catalyst for facilitated halogenation of protected sugar 
hemiacetals for the purpose of anomeric substitution (Scheme 1.3).31 This was 
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conducted in the presence of oxalyl chloride, triphosgene, or oxalyl bromide thus 
demonstrating the fidelity of the support under harsh reagent conditions. 
Scheme 1.3  Use of a supported-dialkylformamide catalyst 
O
AcO
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OAc
OH
OAc
N
Me
O
X-reagent
CH2Cl2, rt
O
AcO
AcO
OAc
X
OAc
1.11
1.12 1.13
X = Cl, Br
Yields: 81-100%  
Recycling of this catalyst was also tested whereby 1 equiv. facilitated its use up to 6 
times without any loss of activity (>99% yield for each).  Reagent/catalyst 
recyclability is an important feature in polymer-assisted methods to prevent excess 
reagent waste and reduce the costs associated with their disposal. 
The Huisgen [3+2] cycloaddition between an azide and an alkyne32 (ie. “click” 
reaction)33 represents itself well through its outstanding efficiency and reproducibility 
thereby making it prime for automated synthesis of 1,2,3-triazole-containing small-
molecules.  Triazoles and azoles in general, represent an interesting class of small-
molecule heterocycles that are widely known for their use as powerful antifungal 
agents.34  Recently, Girard and coworkers reported the development of a reusable 
polymer-supported copper catalyst for this reaction class.35  This catalyst, based upon 
an Amberlyst A-21 dimethylamino resin, was tested in numerous alkyne/azide 
cycloadditions using a Chemspeed ASW-2000® parallel synthesizer36.  Utilizing a 
loading capacity of 0.2 mol% CuI, the remaining (unactivated) dimethylamino 
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Scheme 1.4  Use of a bifunctional solid-phase catalyst in Huisgen cycloadditions 
NMe2•CuI
R1 N3R
2 N
N
N
R2
R1
+
CH2Cl2, rt
1.14
1.15 1.16
1.17
1,2,3 - triazoles  
functionalities on the bead act as a resin-bound base, thus defining it as a bi-
functional solid-phase catalyst.  An average yield of 87% was obtained for the 
twenty-three triazoles (1.17) with the majority showing near quantitative conversions.   
In a separate experiment, the catalyst was recycled up to 4 times having resulted in 
yields > 99% for each run.  Use of this bi-functional catalyst in automated library 
synthesis will be further discussed in Chapter 5. 
A modified version of this catalyst has also recently been reported in the production 
of various triazole-containing macrocycles (Scheme 1.5).37   Although the authors 
report iodine incorporation with the use of the previously shown catalyst – no 
evidence supporting this claim was provided. 
Scheme 1.5  Intramolecular triazole formation via A-21•CuPF6 
N
O
N3
O
N(Me)2•CuPF6
1.18
1.19 1.20
toluene, 60 ºC
N
O
N N
NO
55%  
Despite considerable advances in the area of solid-phase reagent development, a 
number of technologies have emerged for use in more homogeneous environments.  
These soluble/partially-soluble reagents allow for greater substrate permeability and 
more favorable reaction kinetics when compared to standard immobilized reagents.    
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Janda and coworkers, over several years, have introduced the concept of employing 
more flexible cross-linkers into PS resins to increase the swelling properties of the 
polymeric support in various solvents.38  The polymer, known commercially as 
JandaJel®, has been used in a number of different applications including catalysis,39 
multi-polymer transformations and peptide synthesis.40  Recently, Janda and 
coworkers reported on the use of this polymeric support in a diversity-building 
cleavage reaction to facilitate the formation of various benzothiazoles (Scheme 1.6). 
Scheme 1.6  PASP-facilitated benzothiazole formation 
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Yields: 21-98%  
This unique strategy was discovered serendipitously by a Lewis-acid promoted 
cleavage of polymer-bound oxazole derivatives (1.21) in the presence of 2-amino 
thiophenol.  Instead of isolating amide 1.22, benzothiazole 1.23 was liberated, 
providing a facile polymer-assisted method towards this interesting class of 
heterocycles.  
A number of homogeneous polymer-bound reagents have also been developed by 
both Barrett41 and Hanson42 using ring-opening metathesis polymerization (ROMP) of 
functionalized norbornenes.  An oligomeric monoamine hydrochloride (OMAm•HCl) 
was reported in 2008 for use as a high-loading, electrophile scavenging reagent 
(Scheme 1.7).42b  Previous attempts to generate this reagent as the free-amine were 
unsuccessful due to its nucleophilic nature and high reactivity towards catalysts in the 
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polymerization event.  However, it was discovered that simple acidification of the 
monomeric free-amine 1.24 resulted in facile polymerization of monomer 1.25 to 
yield OMAm•HCl 1.26.  
Scheme 1.7  Synthesis of oligomeric monoamine hydrochloride (OMAm•HCl) 
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+
NH2
NH2
HA
90-98%
NH2•HCl
1.24 1.25
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This reagent was used to facilitate the removal of a variety of chlorine-containing 
electrophiles (1.27) (benzoyl, benzyl, tosyl) as well as both isocyanates and 
aldehydes.  These were used in excess for alkylation of various primary and 
secondary amines (1.28) (Scheme 1.8).  
Scheme 1.8  Use of OMAm•HCl in scavenging protocols 
NH2•HCl
n
1.3 - 1.5 eq.
scavenge
filter
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R1-NH2
R1-NHR2
+
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In the same year, Hanson and coworkers utilized ROMP-technology to aid in 
library synthesis of potential small-molecule inhibitors of methionine 
aminopeptidase; a metalloenzyme responsible for cell growth and proliferation.  
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Scheme 1.9 highlights the use of an oligomeric coupling reagent (OACC100) for the 
synthesis of various substituted furans, thiophenes, and pyridines (not shown). 
Scheme 1.9  Facilitated amide formation via OACC100 in a parallel format 
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Commercially available 5-bromofuroic acid 1.31, and analogs thereof were coupled 
to a number of different amines - including sulfonamides (1.32) in the presence of 
DMAP and reagent 1.30 to afford newly substituted furans 1.34 in good yields and 
excellent purities.  The use of Amberlyst A-15 (sulfonic acid) was also employed to 
scavenge excess amine starting material 1.32 including DMAP.  Both reagents were 
conveniently removed by SPE filtration. 
1.3  Recent Developments in Flow-Chemistry and Functionalized Materials 
With the advent of solid-phase-assisted synthesis, a number of automated 
technologies1a have further promoted development of these chemistries and enabled 
them quite user-friendly in terms of compound acquisition, organization and care, 
safety, and overall scalability.  These have not only found themselves useful from an 
industrial pharmaceutical setting43 but have also made their way into the academic 
laboratory for facilitating drug discovery efforts.44  Ley and coworkers at Cambridge 
have demonstrated this transferal through a wide array of PASP-based techniques via 
continuous-flow synthetic methodologies (flow-chemistry).45  This PASP-friendly 
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technology (Figure 1.3) uses polymer-bound cartridges that grant the user the ability 
to employ a variety of bound reagents, catalysts, or scavengers including the use of 
micro-scale reactors for performing homogeneous chemistry.46  
BBB
B B B
BBB
B B B
BBB
B B B
CA
Heterogeneous 
Flow-through
A
B
C
DHomogeneous 
Flow-through
microreactor
Column w/ supported reagent/scavenger/catalyst  
Figure 1.3  General flow-chemistry scheme 
High reaction efficiency is often achieved in these systems using precisely controlled 
flow rates and efficient turbulent mixing patterns.  This translates into greater control 
over stoichiometry and reaction kinetics (heat and mass transfer) often resulting in 
less byproduct formation as compared to the same reactions performed in a round-
bottom flask.  Another advantage to flow-chemistry is its ability to scale-out reactions 
via continuous-flow; providing that starting materials are continually being fed into 
the reaction stream.  The ability to transition from milligram to kilogram quantities of 
material is merely a function of time. 
One of most recent achievements by the Ley group demonstrates the power of 
PASP-synthesis in flow with the total synthesis of the (±)-oxomaritidine (Figure 
1.4).47   This synthesis was based upon their initial PASP-synthesis (not in flow) of 
the compound in 1999,48 whereby polymer-supported reagents were used at every 
transformable step in the synthesis.  These accomplishments represent a first in the 
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area of total synthesis having eliminated the need for chromatography or aqueous 
workup at any point in the synthesis.  Other, more complex total-syntheses have also 
been reported by the Ley group in recent years using PASP-based methods.49 
N
O
H
O
O  
Figure 1.4  Natural product (±)-oxomaritidine  
Scheme 1.10 highlights the synthesis of (±)-oxomaritidine in flow utilizing a variety 
of solid-phase reagents and catalysts.  This synthesis was driven by the 
implementation of a number of different commercially available automated systems.  
The Syrris50 AFRICA, a highly-advanced modular flow-chemistry system, was used 
to deliver 4-(2-bromoethyl)phenol (1.35) through an azide exchange resin (column 1) 
to afford azido phenol 1.36.  This was carried into column 3 containing a polymer-
bound phosphine to furnish the aza-Wittig intermediate trapped on the polymer 
support.  Simultaneously, 3,4-dimethoxybenzyl alcohol (1.37) was flowed through 
column 2 containing resin-bound N-alkylammonium perruthenate (PSP) to facilitate 
oxidation to the corresponding aldehyde 1.38.  This is then flowed through column 3 
to furnish imine 1.39 that is then subjected to flow-through hydrogenation utilizing a 
ThalesNano H-Cube flow hydrogenator.51  This unit utilizes a cartridge containing 
10 % Pd on carbon catalyst and generates small amounts of hydrogen gas in situ via 
ionization of water; making the unit safe enough to use in a conventional laboratory 
setting.  
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Scheme 1.10  Flow-through PASP-synthesis of (±)-oxomaritidine. 
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Secondary amine 1.40 in THF was then transferred via flow into a Biotage V-10 
automated evaporation unit14 and subjected to a solvent switch (CH2Cl2).  This 
solution was then flowed through a glass microreactor on the Syrris system with 
TFAA (1.41) to afford trifluoroacylated amide 1.42.  At this stage in the synthesis, the 
use of a back-pressure regulator (BPR) allowed the reaction in CH2Cl2 to operate 
above reflux at 80 ºC.  With microchip ratings up to 300 bar, the ability to superheat 
reactions in this manner is easily achieved − often resulting in drastically increased 
reaction rates.    
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Also placed downstream from the reaction was column 4 containing a silica-
supported primary amine52 scavenger to rid the solution of excess TFAA.  In the final 
steps of the synthesis, amide 1.42 was transformed to the spirotricyclic intermediate 
1.43 with the use of polymer-supported (ditrifluoroacetoxyiodo)benzene (PS-PIFA) 
(column 5).  This was then passed through column 6 containing a supported base to 
facilitate amide cleavage and subsequent 1,4 conjugate addition to afford the natural 
product (±)-oxomaritidine 1.44. 
Also impressive is Ley’s use of flow-chemistry in the first total synthesis of 
neolignan natural product grossamide53 (Scheme 1.11) performed in the same year.  
This synthesis was achieved via amide-bond coupling of ferulic acid (1.45) with 
tyramin (1.47) using polymer-supported HOBt (Reagent 1) whereby the activated 
ester initially formed on the surface of the reagent.  Also reported was the use a 
sulfonic acid resin (Reagent 2) to scavenge out excess amine from the first reaction.  
More importantly, the Ley group has chosen to implement more exotic supported 
systems such as immobilized enzymes to facilitate key synthetic transformations.54  
“Why use synthesis, when nature can do it for you.” This statement has recently 
gained considerable attention with seminal advances in the area of microbial gene 
manipulation to produce natural products with desired chemical profiles.55  Ley’s use 
of a silica-immobilized horseradish peroxidase enzyme in buffered media 
conveniently afforded the natural product grossamide 1.49 without the need for 
purification via chromatography. 
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Scheme 1.11  Ley group flow-through synthesis of grossamide. 
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The modular approach of continuous-flow chemistry allows for an almost unlimited 
incorporation of hardened components including analytical equipment for in situ 
reaction monitoring and “on-the-fly” optimization and purification.  With this notion, 
comes the flexibility to incorporate other types of reactors, equipment, and synthetic 
materials not previously mentioned.   
Kirschning and coworkers, among others56, have recently explored the use of 
functionalized magnetic nanoparticles inside microreactors (Figure 1.5) as solid 
supports for flow-chemical methodologies.57  Using a magnetic field generator paired 
with an inductor, the investigators were able to achieve inductive heating of magnetic 
nanoparticles while in a continuous-flow environment.  This system was also paired 
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with a preparative HPLC that could be used for in-stream reaction analysis as well as 
final purification of products being generated. 
Pump
reactor containing
magnetic nanoparticles
magnetic field
generator
inductor
3-way
valve
1 2 3 4 5
6-port
valve
reaction
vessel
HPLC
analysisstarting materials
and wash solutions  
Figure 1.5  Experimental setup for inductive magnetic manipulation of nanoparticles 
in a continuous-flow scenario. 
 
This method was subsequently applied to a variety of reactions highlighted in 
Scheme 1.12 including transesterification (i), condensation (not shown), Claisen 
rearrangement (ii), Hartwig-Buchwald amination (iii) and enyne metathesis (iv).  
Entry (iii) also highlights an observed increase in yield as compared to conventional 
heating. Included in this set of reactions were a number of Pd-catalyzed 
transformations that were achieved using Pd-functionalized magnetic nanoparticles.  
Previous examples shown merely used the catalyst in solution and the nanoparticles 
acted only as a source of heating.  In this manner, Pd particles were obtained by 
reductive precipitation of ammonium-bound tetrachloropalladate salts to yield the 
catalyst bound nanoparticles 1.58.  The catalyst demonstrated good activity under 
flow-conditions for both the Suzuki-Miyaura (i) and Heck (ii) coupling reactions 
(Scheme 1.12). 
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Scheme 1.12  Reactions performed using inductive heating of magnetic nanoparticles 
in flow. 
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Scheme 1.13  Use of Pd-functionalized nanoparticles in flow. 
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A number of different materials have been used in recent years for facilitating 
solution-phase chemistry,58 especially in the area of flow-chemistry.59  The 
development of these materials has addressed a number of limitations primarily 
associated with the nature of resin-packed columns.  One such material is that of 
monolithic polymers.  These materials were first developed as purification media in 
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LP/HP liquid chromatography60 but have now found their place as alternative 
polymer-derived supports for PASP-based chemistries.60b  Monolithic materials help 
circumvent problems associated with interstitial or void space between beads in 
fixed-bed cartridges that can often lead to undesired channeling.  In this regard, 
monolithics inherently carry a much larger reactive surface area – owing to their 
extensive porosity making them very useful for heterogeneous continuous-flow 
chemistry. (Figure 1.6).  
Void (Interstitial) space
Conventional resin-packed column Monolithic polymer column
Porous media
- very little void space
- large surface area  
Figure 1.6  Resin-packed columns vs. monolithic polymer columns 
Ley and coworkers recently demonstrated the use of monoliths in flow as 
alternative supports for azide-bearing reagents in the Curtius rearrangement.   In this 
manner, the safety profile of the reagent was greatly increased by reducing the 
handling risks associated with azides including impact, shock, and exposure hazards. 
  Monolithic materials have also recently been generated by Buchmeiser et. al. with 
the use of previously mentioned ROMP-technology as a means to generate supports 
for  organocatalysis61.  These supports were prepared within a borosilicate column 
vide supra and subsequently used for numerous flow-thorough metathesis 
transformations.  
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These materials may prove valuable for the future of flow-chemistry in terms of 
developing more convenient PASP synthetic protocols providing that their cost 
effectiveness is on par with other polymer-bound entities and/or recyclability is a 
likely option. 
1.4 Recent Advances in Automated Technologies for Small-Molecule Library           
Development 
Despite considerable advances made in the field of PASP-facilitated continuous-
flow synthesis, one of its current disadvantages is its inability to facilitate the 
production of medium to large compound collections for the purpose of drug 
discovery.  Over the years, a number of automated technologies have been developed 
for this purpose alone,62 but have likewise been used for the proliferation of other 
non-drug seeking chemistries.63  One of the more minor, yet high-implicating 
contributors for small-molecule library development at the present time is the use of 
microwave synthesizers. 
Microwave chemistry over the last decade has seen an explosion of applications and 
devices for facilitating numerous reactions that are often burdensome under 
traditional heating methods.64 Only until recently, however, have commercial 
microwave (multi-mode) synthesizers been developed for the purpose of parallel 
reaction synthesis.65  Mono-mode microwaves (ie. one vial, one condition set) have 
already seen substantial use in the pharmaceutical industry in conjunction with 
various autosamplers and robotics to facilitate sequential compound synthesis.   
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Sauer and coworkers at Abbott Laboratories have recently utilized this technology 
in conjunction with polymer-bound reagents to aid in the formation of numerous 
medicinally relevant heterocycles.66  They also demonstrated the use and thermal 
stability of a new class of polymer-bound catalysts (Pd-bound FibreCat®) for 
microwave assisted Suzuki-Miyaura coupling reactions (Scheme 1.14).67  A number 
of different catalysts were explored including a PS-based Pd source.  These were 
compared to several Pd-bound FibreCat® catalysts (FC-X) where higher conversions 
were observed with the use of EtOH as the primary solvent.  Silica-bound carbonate 
(Si-Carbonate) was also utilized for the purpose of removing excess boronic acid 
(1.66) from the reaction and complete sequestration was noted when a 10-fold excess 
of this supported base was used during crude reaction filtration. 
Scheme 1.14  PASP-microwave assisted Suzuki-Miyaura coupling 
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In 2008, Clapham and Sauer et. al. also demonstrated the use of the previously 
mentioned ThalesNano H-Cube flow-hydrogenator as a means for facilitating high-
throughput parallel deprotection.  The automated system, shown in Figure 1.7, was 
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constructed on a Bohdan® robot68 platform and machined to accept eight custom vial 
racks that accept 12−20 mL scintillation vials for both starting materials and product 
collection on a large scale.   
Figure 1.7  Custom parallel flow-hydrogenation robot69 
 
The automated system was tested for use on two separate pilot-scale libraries: (i) − 
CBZ protected and (ii) − benzyl ether protected (Scheme 1.15).  Good to excellent 
yields were obtained for both libraries, having demonstrated the utility of pairing 
robotic automation with mono-mode systems to successfully achieve parallel 
synthesis. 
 
 
 
 24 
Scheme 1.15  High-throughput deprotection using hydrogenation 
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Fully automated systems, like the one mentioned above, have several advantages 
and disadvantages associated with their use in library production.  Typically, the user 
must either have full working knowledge of the automated system, or a full-time 
dedicated technician must oversee all projects taking place on the parallel platform.  
Despite the more hands-off approach, the technician must be able to troubleshoot and 
correct any foreseeable problem at a moments notice to prevent material loss.  Other, 
more semi-automated systems, however, can be prepared by multiple people and 
often have a lesser amount of problems due to their more simplistic design.   
Recently, Aubé and Hanson et. al. utilized two parallel synthetic platforms, both 
semi- (i) and fully automated (ii), in a library comparison study to synthesize various 
1,4-diazepin-5-ones as γ-turn peptidomimetics (Scheme 1.16).44a  Both the Bohdan 
MiniBlock XT (i)68 and the Chemspeed SLT-100 (ii)36 platforms were tested – each 
having resulted in comparable yields and purities for the three-component reaction 
sequence.  
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Scheme 1.16  Automated parallel synthesis of 1,4-diazepine-5-ones 
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During validation, a number of polymer-supported scavengers were used to aid in 
subsequent purification of crude products.  Polymer-bound isocyanate 1.77 was used 
to remove excess thiophenoxides (1.76) while excess hydroxyazides (1.75) were 
sequestered by polymer-bound triphenylphosphine 1.78.  Using the liquid handling 
capabilities of the Chemspeed robotic platform, the three-component sequence was 
conveniently simplified by introducing a basic wash (NaOH) step − replacing both 
polymer-bound scavengers for the removal of excess starting materials.  The 
hydroxyazides were also easily removed from the crude reaction mixtures via silica 
SPE filtration.  This more cost-efficient method was ultimately chosen for final 
library production – highlighting the flexibility of using various automated platforms 
– even without the use of immobilized scavengers/reagents. 
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1.5  Conclusions 
The development of new materials and automated technologies has produced a 
number of prime examples in recent years where polymer-assisted solution phase 
protocols have played a key role in facilitating the reaction process.  Undoubtedly, the 
bodies of work discussed herein represent the front lines for future advancement in 
the areas of both natural product synthesis and small-molecule library development.  
These contributions will not only enable further advancement in these areas in the 
near future, but will likely have far-reaching implications into other closely related 
scientific disciplines. 
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Chapter 2 
A Multifaceted ROMP-derived Oligomeric Phosphate  
and Its Use in PASP-Facilitated Protocols 
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2.1  Introduction 
Throughout nature, phosphates have been uniquely designed to play vital roles in 
the existence of all living things.  The essence of these unique and irreplaceable 
structures comprise the biomolecular constructs of ADP, ATP, creatine phosphate, 
phospholipid bilayers, and more importantly proteins and genetic material 
(RNA/DNA). The intracellular addition of phosphates (ie. phosphorylation) is 
regulated by numerous protein kinase enzymes which are triggered by extracellular 
stimuli.  The process of phosphorylation is necessary for a wide array of cellular 
functions including signal transduction, cell division, membrane transport, and 
apoptosis (cell death) just to name a few.  In contrast, dephosphorylation, is the action 
of phosphate removal via hydrolysis and is controlled by various protein phosphatase 
enzymes.  Without ultimate control of these two independant processes, life as we 
know it would cease to exist.   
Within the last two decades, organophosphates have emerged as important reagents 
that have found regular employment in synthetic protocols.  Many of these protocols 
reside within the area of natural product synthesis,1 but also play important roles in 
the pharmaceutical2 and agrochemical industries.3  This newly selected use of 
phosphates in synthesis is primarily due to their hydrolytic stability, facile assembly, 
and ideal monoanionic pKa profiles thereby placing them within the circle of other 
commonly employed leaving groups.  
A seminal paper in 1987 by F.H. Westheimer entitled, “Why Nature Chose 
Phosphates”, concludes that organic chemists cannot afford to use compounds as 
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stable as phosphate anions due their lack of reactivity.  Furthermore, Westheimer also 
notes that likewise nature cannot afford to utilize alkyl halides, as their reactivity is 
directly related to their toxicity.4  Synthetic organic chemists, however, have 
presented their case that phosphates can provide more stable, leaving group-armed 
intermediates that are more easily separable from valued material.5  This chapter will 
focus on the development and utilization of a multi-faceted, ROMP-derived 
oligomeric phosphate and its utility as a chemical tag, a sequestration reagent, and a 
supported leaving group in both SN2 and SN2´ processes. 
2.1.1 Background and Significance 
Synthetic oligomeric phosphates and other phosphorous-laden materials have 
primarily found applications in the production of flame-retardant materials,6 but have 
also found themselves useful as immobilized reagents within the realms of both 
pharmaceutical7 and medicinal chemistry.8  Hawthorne and coworkers9 highlight one 
such application in the assembly of boron-rich oligophosphates (Figure 2.1) for use in 
boron-neutron capture therapy (BNCT).   
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Figure 2.1  Boron-rich oligophosphate 
This chemotherapeutic treatment relies on the ability to deliver large quantities of 10B 
atoms directly to the site of the tumor where emission of α-particles takes place.  The 
solubility and biocompatability of these delivery units is of high-importance and thus 
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substantiates the incorporation of the oligophosphate backbone.  Once the process is 
complete, the oligomers are easily metabolized and excreted from the body.  Others 
have also utilized phosphorous-based oligomers in hybrid, solid-phase supports for 
the synthesis of multiple labelled-carbohydrate oligonucleotides (Figure 2.2).10  These 
nucleotide-bearing complexes are currently being studied for their potential use in 
various biomedical, therapeutic, and diagnostic applications.   
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Figure 2.2  Carbohydrate oligonucleotides on hybrid solid-phase support 
As previously discussed, solid-phase synthesis and immobilized reagents have 
played an integral role in combinatorial chemistry and the search for biologically 
relevant molecules.   However, despite huge advances in this area, limitations are 
widely noted throughout the literature.11  Many resin-bound reagents/scavengers 
inheriently carry low load capacities (typically <1 mmol/g) due to the overall 
molecular weight of the primary support, thus requiring the use of a gross excess of 
bound reagent/scavenger.  Solid supports and linkers used in SPOS can be expensive 
to purchase on large-scale and can limit the possible chemistry that can be achieved.  
This is especially true when larger quantities of final product is desired.  Non-ideal, 
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heterogeneous reaction kinetics also hinder many of these reactions and result in 
elongated validation times during the transfer of chemistry from solution.  
Over the years, a number of alternative technologies have been developed as a 
result of the aforementioned limitations of solid-phase systems.  Curran and 
coworkers have developed a unique strategy known as “fluorous synthesis” that is 
based upon the chemical tagging of small-molecules with fluorine atoms in a 
homogeneous environment.12  This concept, first introduced by Horváth and Rabái in 
1994,13 uses F-tagged molecules (substrates/reagents/catalysts) that can be 
differentiated through the use of fluorophilic and fluorophobic solvents or materials 
allowing for their facile separation/purification.  Curran and coworkers recently 
demonstrated the power of this technology for library development of a diverse 
collection of piperazinediones (Figure 2.3).   Using this approach, over 600 diverse 
analogs were efficiently prepared from a single fluorous-tagged scaffold. 
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Figure 2.3  Collection of piperazindiones via fluorous-tagging 
Another powerful technology that has surfaced as an alternative to solid-phase 
chemistries is ring-opening metathesis polymerization (ROMP) of functionalized 
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norbornenes.14  The advantages of this polymer-assisted technology can clearly be 
seen in a number of different attributes: (i) starting materials containing a norbornene 
functionality can easily be prepared and scaled-up via Diels-Alder reaction with 
either cyclopentadiene or furan and a suitable dienophile. (ii) all reaction components 
are contained within a homogenous reaction environment thereby incorporating the 
advantages of solution-phase reaction kinetics (iii) ROMP is a user-friendly technique 
that does not require the use of special equipment or materials.  These attributes 
directly translate into chemistry derived from proven solution phase conditions which 
can be easily translated into the world of facilitated synthesis.  
ROM-polymerization is now a well-defined and well-understood system (Scheme 
2.1) whereby reactions take place under mild conditions without the need for 
cocatalysts, additives, or high-temperatures.  This achievement was made possible 
through early work by Yves Chauvin15 in the fields of organometallics and catalysis 
and later by both Richard R. Schrock16 and Robert S. Grubbs.17  These Nobel-prize 
worthy efforts have resulted in the advancement and preparation of numerous, well-
defined metal carbene catalysts (Figure 2.4).  It is with the development and use of 
these unique complexes that now defines olefin metathesis in synthetic chemistry 
today.  For the remainder of this dissertation, Grubbs’ catalysts 2.3, 2.4, and 2.6 will 
be refered to as 1G, 2G and 3G. 
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Figure 2.4  Mo and Ru-based metathesis catalysts 
The inherent ring strain of various systems18 including norbornene, is the key 
component for achieving ROM-polymerization.  The first step in this process 
involves the dissociation of a phosphine ligand from the precatalyst 2.7.  The 
resulting 14-electron complex 2.8 subsequently adds across the strained olefin of the 
norbornene to form metallocyclobutane intermediate 2.9.  This intermediate was first 
postulated by Chauvin in 197119 and later proven by isolation of a similar titanium-
based Tebbe intermediate by Grubbs and coworkers in 1980.20  This newly formed 
strained intermediate is relieved via the ring-opening event to form the terminal 
“activated” carbene species 2.11.  This intermediate then undergoes propagation with 
additional monomeric units until 2.9 is completely consumed.  This continual process 
then affords living oligomer 2.12 that is still activated with the metal carbene.  This 
carbene containing oligomer is then terminated with the addition of ethyl vinyl ether 
to yield the final oligomeric product 2.14 and allowing Fisher carbene-type complex 
2.13 to easily be discarded.  This well-defined system results in similar initiation (ki) 
and propagation rates (kp) allowing for greater control over molecular weight 
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distribution as compared to previous processes of this type.21  This is readily achieved 
by changing the amount of precatalyst 2.7 being used in the reaction whereby 
oligomeric length n = 100/mol % catalyst.   
Scheme 2.1  Mechanism of ROM-polymerization of norbornene-based systems 
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2.1.2 Capture/ROMP/Release Strategies 
A large portion of our work in the area of ROMP has focused on the development 
of high-loading oligomeric reagents and scavengers.22,23  Alongside these methods, 
however, comes the ability to attach small-molecules to a norbornene tag for the 
purpose of solution-phase trafficking.24  During this event (Figure 2.5), the molecule 
of interest 2.15 (ie. precious scaffold) is tagged or “captured” via norbornene linker 
(NB-tagged 2.16) and then subjected to ROM-polymerization enabling the soluble, 
bound scaffold 2.17 to be operated on synthetically via facilitated methods.  These 
methods allow for the “captured” scaffold to be subjected to facile diversification 
reactions to afford tagged 2.18 under homogeneous conditions and then subsequently 
released yielding the newly diversified scaffold 2.19 and the spent oligomer.  
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Figure 2.5  Phase trafficking via ROMP 
These bimolecular systems are conveniently soluble in organic solvents such as 
CH2Cl2, CHCl3, DMF, THF, and correspondingly insoluble in polar solvents such as 
MeOH, EtOH, EtOAc, and Et2O.  This differential solubility profile allows for a 
facile precipitation/filtration event allowing all other reagents to be washed away 
from the final product typically without the need for additional purification.  One 
such example published within our group (Scheme 2.2) demonstrated the ability to 
utilize a Mitsunobu capturing event of various 1º and 2º alcohols onto a N-hydroxy-
succinamide-derived norbornene tag 2.20.  ROM-polymerization affords 2.21 and 
subsequent release via hydrazine removes the Mitsunobu byproducts rendering the 
newly formed amines 2.22 in moderate to excellent yields without the need for 
chromatography.  
 
 
 46 
Scheme 2.2  Capture-ROMP-release: application to the synthesis of amines 
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2.2  Results and Discussion (I) 
Subsequent work in metathesis-based transformations on bicyclic phosphate tri-
esters led to the development of a phosphate-based tag (Scheme 2.3) for its utility in 
ROMP-derived phase-trafficking.  During the initial stages of development, it was 
determined that the endo isomer of the phosphate-based system was not readily 
polymerized by either catalyst 1G or 2G and focus turned to the synthesis of the 
corresponding exo isomer.  It was hypothesized that both steric and electronic 
interactions of the P=O bond (Figure 2.6) of the resulting endo isomer could interfere 
with catalyst/olefin activation or subsequent propagation step.   
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Figure 2.6  Proposed endo P=O bond interactions w/ catalysts 1G and 2G 
Synthesis of the exo isomer was readily achieved, however, on a large scale via 
thermal isomerization of endo carbic anhydride 2.23 using classical methods25 to 
yield the exo product 2.24 with diastereomeric ratios ranging from 20:1 up to 84:1. 
Reduction of 2.24 with LiAlH4 yielded diol 2.25 as a clear, viscous oil.  
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Phosphorylation of exo diol 2.25 was performed using freshly distilled POCl3 and 
Et3N in the presence of catalytic DMAP and/or N-methylimidazole (NMI) to yield 
phosphorochloridate 2.26 as a white solid in moderate yields.  
Scheme 2.3  Synthesis of the norbornenyl phosphorochloridate tag 
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Initial interest in the utilization of 2.26 was derived from the idea of coupling this 
tag with allyl alcohol, thus setting the stage for a possible capturing event via 
selective cross-metathesis reaction in the presence of the internal norbornene.  A 
number of experiments were performed using catalysts 1G, 2G, 3G and Hoveyda-
Grubbs 2nd generation catalyst 2.5 but all resulted in the subsequent polymerization of 
the norbornene affording only insoluble oligomeric gels.  As a result, focus turned 
towards the installation of allyl alcohol into oligomeric phenyl phosphate ester 2.27.  
This addition was not very reproducible due to various insolubilities at low 
temperatures and difficulty in the purification of oligomeric allylic phosphate ester 
2.28.  From these results, the addition of 3-methyl 2-butene 1-ol into 2.26 was 
attempted, but it easily became apparent that compound 2.29 was unstable and could 
not be isolated.   
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Scheme 2.4  Synthesis of the oligomeric allylic phosphate ester 
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The possibility of polymerizing 2.26 was also explored as previous examples have 
highlighted the fidelity of the Grubbs catalysts in the presence of highly reactive 
functional groups including phosphonyl dichlorides.26  Polymerization in the presence 
of catalyst 1G afforded oligomeric product 2.30 in excellent yield, however solubility 
and purification issues continued to plague the synthesis of 2.28 resulting its overall 
abandonment.  
Interest in the development of supported allylic phosphate esters resided with 
known literature precedence vide supra of the extensive use of this functionality in 
highly selective copper-mediated SN2´ displacements.  In this manner, we planned a 
preemptive “release” mechanism by which an element of diversity (ie. carbon 
nucleophile) could be incorporated into the scaffold within the same step.  In separate 
reports by Tanaka27 and Yamamoto28, each touted the superiority of allylic phosphates 
as leaving groups in comparison to their chloride and sulfonate counterparts in terms 
of regioselectivity, preferential anti-addition relative to the phosphate, geometry of 
the olefin formed, and high levels of chirality transfer.  These highly selective SN2´, γ-
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regioselective displacement reactions occur through use of both mixed zinc-copper 
and magnesium-copper-based reagents.29  The use of CuCN is typical for SN2´ 
displacements demonstrating high preference for addition at the γ-position of the 
electrophilic species.  This reagent is used in the presence of dialkyl zincates to form 
the active nucleophilic cuprate.  Due to the high specificity and nature of the Cu/Zn 
complex,  this reagent was herein chosen for this investigation. 
Figure 2.7 highlights a general mechanism postulated by Corey for the reaction of 
Cu(I) reagents with allylic phosphate esters.  He attributes this highly selective 
transformation to the occupied d-orbitals of copper having overlapped with both the 
π* and σ* orbitals of the allylic ester shown as 2.31.30  Experimental evidence for a 
Cu(III) intermediate has also been reported in which addition of the copper reagent 
first occurs at the γ-position (2.33a).31  Cu(III) complex 2.33a can subsequently 
undergo either reductive elimination to form the γ-coupled 2.34, or can shift to π-allyl 
intermediate 2.33b.  This species is in equilibrium with the α-complex (2.33c), which 
can undergo reductive elimination to afford the α-coupled product 2.35. 
Cu(I)
R3
R2
!"
#"
L
R1
$
%
R1
Cu(III)R2
R3
%
R2R3CuM+
R1
Cu(III)R2
R3
% R1
Cu(III)R2
R3
%
$
R1
R2
R1
R2
%-selective
SN2' coupling
$-selective
SN2 coupling
Corey
Mechanism
OP(OR)2
O
2.31
2.32
2.33 a 2.33 b 2.33 c
2.352.34
R2 = R3 or
R2 = non transferable
ligand
 
Figure 2.7  Mechanisms for copper-mediated displacement of allylic phosphate 
esters 
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After several failed attempts to generate a supported allylic phosphate ester, we 
began to explore a number of scaffolds which contained an internal allylic alcohol 
functionality that could be subsequently coupled to the norbornenyl monochloro-
phosphate tag 2.26.  A model system was first developed to test the fidelity of the 
oligomeric phosphate tag under the harsh conditions of the SN2´ cuprate addition.  A 
cis/trans mixture of cinnamyl alcohol was combined with 2.26 yielding a 
diastereomeric cinnamyl phosphate 2.36 which was polymerized affording oligomer 
2.37.  This was then subjected to Et2CuZn (generated in situ) rendering the release of 
racemic 2.38.  Isolation of the product proved difficult due to its low molecular 
weight, but was later confirmed by GC/MS traces.  Noticeable precipitation of the 
monoanionic phosphate 2.39 also occurred upon the addition of the cuprate at -30 ºC 
and remained insoluble in THF upon warming to rt.  
Scheme 2.5  Model system for SN2´ cuprate release  
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With this successful demonstration, a catch and release sequence was then tested on 
a six-membered phosphonosugar (P-sugar) template, previously developed in our 
laboratory,32 that contains the requisite internal allylic alcohol functionality.  Scheme 
2.5 highlights the resynthesis efforts of this scaffold.   
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The synthesis begins with the highly reactive allyl phosphonyl dichloride 2.40 
whereby addition of excess phenol affords diphenyl phosphonate 2.41.  Allylic 
alcohol 2.43 is generated via treatment of trimethylsulfonium iodide in n-BuLi with 
the corresponding (S)(−) glycidyl epoxide 2.42.  This newly generated allylic 
fragment is coupled to allyl phosphonate 2.41 affording the diallyl fragment 2.44 as a 
mixture of P-epimers.  This is subjected to ring-closing metathesis conditions via 
catalyst 1G affording six-membered allyl phosphonate 2.45 where the major anti(−) 
product in respect to the phenoxy group is separated by silica column 
chromatography.  Transformation to the corresponding syn-diol 2.46 is achieved via 
Sharpless diastereoselective dihydroxylation.33  Lastly, the diol is protected as the 
carbonate using triphosgene and subsequently eliminated via excess base (Et3N) in a 
one-pot process affording the cyclic phosphonate 2.47 containing the requisite 
internal allylic alcohol.    
Scheme 2.5  Resynthesis efforts of the P-sugar template 
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Scaffold 2.47 was next subjected to the capturing event via tag 2.26 rendering 
tagged scaffold 2.48 as a mixture of P-diastereomers (Scheme 2.6). This was then 
polymerized via catalyst 1G yielding the soluble oligomeric phostone 2.49.  The 
nucleophilic cuprate was generated in situ from the corresponding zincate/CuCN 
mixture in THF.  This was then added via cannulation to a solution of 2.49 thereby 
faciliting the diversify/release step affording products 2.50−2.52 in moderate yields, 
good purity and high diastereoselectivity (ds >20:1).  This same catch and release 
process was repeated on other relevant scaffolding demonstrating its general 
compatibility with other heterocyclic systems.34  After addition of the cuprate, an 
interesting observation was made whereby the blue coloration of the resulting copper 
salts began to quickly disappear, but upon quenching the reaction with 10% HCl(aq) 
the salts reappeared once more. 
Scheme 2.6  Capture/ROMP/cuprate release of phosphonate 2.47 
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It was discovered that the resulting monoanionic phosphate oligomer 2.39 must be 
sequestering the copper salts during the progression of the cuprate addition.  Upon 
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quenching the reaction, the phosphate acid once formed relinquishes the copper back 
into solution.  It was noted that without the quench crude filtration of the reaction 
through a silica SPE successfully eliminated the need for the typical acidic workup.  
To test the sequestering ability of the oligomeric phosphate acid by itself, the reagent 
was added to an aqueous solution of known concentration containing CuCl2 salts.  
The reaction mixture was stirred and monitored over several hours using UV/Vis 
detection, however no change in absorption was noted during this time period.  It was 
concluded that the in situ generated monoanionic phosphate 2.39 is likely responsible 
for chelation in this sequestration process. 
2.3  Development and Application of a ROMP-Derived Benzylating Reagent 
Due to its ease of incorporation and removal, benzylation continues to serve as 
one of the most exploited protecting groups in organic synthesis.4b,35,36  In addition, 
the hydrophobic, aromatic properties inherent to the benzyl group make it an ideal 
diversity element in combinatorial chemistry.37  This can be often attributed to various 
structure-activity-relationships (SAR) associated with its size and shape and its ability 
to undergo π-stacking interactions.   The intent to incorporate this element into our 
own facilitated efforts towards pilot-scale library production is demonstrated herein.   
Several reports within our group alone have explored a number of different 
leaving group-armed, ROMP-based supports for achieving facilitated benzylation.  
Each of these reagents are stable, free-flowing powders that can be conveniently 
stored over extended periods of time.  Efforts in our group, lead by Zhang and Moore, 
utilized benzyl sulfonate esters 2.54 (Figure 2.8) as reagents for benzylation derived 
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from oligomeric sulfonyl chloride (OSC) 2.53; a reagent that had previously been 
reported for use as an effective nucleophile scavenger.38  Treatment of this reagent 
with various benzyl alcohols provided a number of different analogs for use in 
benzylation.  Treatment with a variety of amines produced the desired benzylated 
products in excellent yields after crude filtration.   
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Figure 2.8  Facilitated benzylation via oligomeric sulfonate esters 
Another method highlighted below utilized oligomeric sulfonium salts 2.57 to 
achieve facile benzylation.39  Despite the insolubility of this reagent in common 
organic solvents, the notion for its use in flow-through, automated synthetic protocols 
may prove viable in the near future.   
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n
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Figure 2.9  Facilitated benzylation via oligomeric sulfonium salts 
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Phosphates, as previously discussed, have been used extensively throughout the 
literature for SN2´ related pathways but are quite deficient in their use for SN1 or 
direct SN2 displacement reactions.40  Only until recently have phosphates been 
demonstrated as effective leaving groups in Pd-catalyzed C-arylation/benzylation 
reactions; even having demonstrated drastic improvements in yield as compared to 
benzyl bromide.41  In light of this gap, an oligomeric phosphate was pursued as a 
logical starting point for the development of a new reagent for facilitated benzylation.  
In this regard, the development and application of a new ROMP-based oligomeric 
benzyl phosphate (OBP) and its derivatives thereof were pursued as a green 
alternatives to the standard set of commercially available, halogen-based, benzylating 
reagents.  Others have followed this pathway in the search for greener alkylating 
reagents42 but few have exploited their use on polymer-based supports.43  To our 
knowledge there are no reports of phosphate-based benzylating or alkylating reagents 
in the literature. 
 2.4  Results and Discussion (II) 
Initial interest in the development of substituted oligomeric phosphates led to the 
idea of utilizing the oligomeric phosphorochloridate 2.30 as a means for producing 
tertiary amines in a one-pot, two-step protocol from substituted propargylic alcohols 
(Scheme 2.7).  It was with this observation that we began to look more closely at the 
phosphate as an oligomeric leaving group that could be exploited in similar SN2 
displacement reactions; primarily that of benzylation.  
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Scheme 2.7  One-pot synthesis of a propargylic tertiary amine 
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With this idea in hand, we envisaged an oligomeric benzylic phosphate and its 
synthesis starting from benzyl alcohol (Scheme 2.8).  Experimentation began with the 
addition of the phosphorochloridate tag 2.26 into a solution containing benzyl 
alcohol, NMI, and CH2Cl2 at room temperature cleanly affording the benzyl 
phosphate 2.61 in good yields and purity.  Polymerization of 2.61 and other 
phosphate analogs of this type in the presence of catalyst 2G occurred rapidly at room 
temperature resulting in formation of insoluble and unusable gels.  Subsequent ROM 
polymerization with catalyst 1G, however, cleanly afforded the oligomeric benzyl 
phosphate (OBPn) 2.62 with desirable characteristics.44  Following polymerization, 
the reaction was quenched with ethyl vinyl ether (EVE) and stirred for 30 minutes.  A 
basic workup involving the Pederson protocol45 was also investigated and surprisingly 
no degradation of the phosphate was observed.  This was then applied to the system 
on a large-scale and reflux was continued until the purple solution turned clear 
yielding a yellow precipitate.  The resulting solution was washed several times with 
water and the organic polymer-containing layer was dried (MgSO4), concentrated to 
critical viscocity46 and precipitated dropwise into anhydrous Et2O.  The free-flowing, 
white reagent (OBPn) 2.62 was then filtered off, rinsed thoroughly w/ anhydrous 
Et2O, and placed under vacuum to dry.  
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Scheme 2.8  Synthesis of the oligomeric benzyl phosphate (OBPn) 
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The oligomeric benzyl phosphate (OBP20) was tested in benzylation reactions using 
a number of cyclic and acyclic amines as well as O, and S nucleophiles (Table 2.1).  
The reagent was delivered in excess (1.5−3.0 equiv) as either a free-flowing powder47 
or as a stock solution in anhydrous CHCl3, with a catalytic amount of tetra-
butylammonium iodide (Bu4NI).48  New formulations of this reagent and others are 
also currently being explored (Figure 2.10) including a tablet formulation (ROMP-
tabs) that enables the user to take advantage of pre-measured loadings without the 
potential for large-scale inhalation hazards. 
 
 
Figure 2.10  OBP20 ROMP-tabs in comparison to free-flowing OBP20 
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Table 2.1  Facilitated benzylation using oligomeric benzyl phosphate (OBPn) 
O
O
P
O
OBn
20
O
O
P
O
O
20
Nuc-Bn
filter
Nuc, base
Bu4NI, CHCl3, 80 ºC
2.63 a-m2.62
2.39  
nucleophile products 
2.63 
yield (%) purity (%)[a] 
O NH
 
a 99 98 
S NH
 
b 93 98 
N NHPh
 
c 98 99 
HN NH
 
d 95 97 
NH
 
e 80 99 
NH
 
f 73 99 
N
H  
g 98 85 
NH
O
O  h 69 97 
OH  i 80 95 
SLi  j 98 96 
Bn-NH2 k/l 99[b] 4:1[c] 
Ph-NHEt m 81 89 
Cy-NHCH3 n/a nr n/a 
 
[a]Purities calculated using GC and further confirmed by  
1H NMR. [b],[c]Percent conversion and ratio of mono to  
dibenzylated amine calculated by GC/MS. 
 
During benzylation, precipitation of the oligomeric phosphate monoanion 2.39 
typically occured within a 0.5–2 hour period after addition of the nucleophile.  
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Reactions were allowed to cool to rt and the soluble contents were removed via 
syringe and either transferred and concentrated over silica or precipitated into Et2O.  
This mixture was then passed through a silica SPE cartridge and concentrated under 
vacuum to afford the corresponding benzylated products 2.63a−m.  Monoanion 2.39 
was found to be water soluble at elevated temperatures and remained indefinitely 
soluble on cooling to room temperature.  This cleanup procedure is of particular 
importance for large-scale benzylation thus having eliminated the potential need for 
solvent change during the precipitation event.  
A number of monomeric analogs (2.61a− l) of OBP were also prepared using 
several substituted benzyl alcohols (Table 2.2) and the corresponding oligomers 2.62 
a− l were tested accordingly (Table 2.3).  Interestingly, efforts towards production of 
monomeric phosphates 2.61a−d did not afford the desired products.  This is likely 
due to an eliminative degradation pathway although no conclusive evidence for this 
has been obtained.  With this notion, the corresponding oligomers 2.62e− l were 
subjected to established benzylation conditions to afford the desired benzylated 
products in moderate to good yields (Table 2.3). 
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Table 2.2  Synthesis of various OBP analogs 
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Table 2.3  Benzylation of amines using various OBP analogs 
O
O
P
O
OCH2Ar
20
O
O
P
O
O
20
Nuc-CH2-Ar
filter
Nuc, base
Bu4NI, CHCl3, 80 ºC
water soluble
2.64e-l2.62e-l
2.39  
entry sm 2.62 products 2.64  
yield 
(%) 
purity 
(%)[a] 
1 e 
O N
 
e 64 94 
2 f 
O N
O
O   
f 54 89 
3 g 
O N
Br  
g 82 93 
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4 h 
O N
Cl  
h 67 97 
5 i 
O N
F  
i 70 96 
6 j 
O N
NO2  
j 74 93 
7 k 
O N
N
 
k[b] 78 98 
8 k 
N NPh
N
 
k′ [c] 93 98 
9 l 
O N
CF3  
l 68 95 
 
[a]Purities calculated using GC and further confirmed by 1H NMR. 
[b],[c] Despite their simplicity each compound is classified as a NCE. 
 
The integration of ROMP-derived oligomeric reagents for application in small-
molecule library development is of utmost importance to our research.  With this in 
mind, OBP20 was tested on a select benzofused sultam scaffold for benzylation (Table 
2.4).  The reagent was added to a THF solution containing benzothiaoxazepine-1,1-
dioxide (2.65a) in the presence of K2CO3 and Bu4NI and stirred at 80 ºC overnight.  
The resulting mother liquor was precipitated from a Et2O/EtOAc mixture.  
Subsequent filtration employing a silica SPE cartridge, and evaporation of solvent 
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afforded the desired benzylated product 2.66a in excellent yield and high purity.  
With this result in place, sultams 2.65a/b were subjected to benzylation employing 
OBP derivatives 2.62f,i utilizing the condtions established above to afford the desired 
products (2.66b−d) in good to excellent yields and purities. 
 
Table 2.4  Pilot-scale benzylation of benzo-fused sultams 
O
O
P
O
OR3
20
O
NHS
OO
R2
Bu4NI, K2CO3
THF, 80 ºC O
NS
OO
R2R1
R3
2. precip., SPE Filter2.65a/b 2.66a-d
1.
R1
 
entry sm 2.65 R
1 R2 R3 product 2.66 
yield 
(%)[a] 
1 a 4-Br Ph Bn a 99 
2 a 4-Br Ph 3,5-diMeO-Bn b 72 
3 a 4-Br Ph 4-F Bn c 85 
4 b 4-Br iBu 4-F Bn d 97 
 
[a]Yields after filtration via silica SPE. 
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2.5  Conclusion and Future Outlook 
In conclusion we have developed a multifaceted oligomeric phosphate that can 
serve as both a support and a leaving group in SN2´ processes for facilitated “catch 
and release” synthesis, as well as an in situ generated copper sequestration reagent.  It 
has also been demonstrated as an efficient benzylating reagent for a variety of 
nucleophiles and was applied in the pilot-scale diversification of benzo-fused sultams.  
We are currently exploring new ways to widen the scope and utility of this system 
including the development of an oligomeric propargylic phosphate variant and its use 
in facilitated triazole formation and azide scavenging.  Current efforts are also aimed 
at using this reagent in pilot-scale library production.   
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Chapter 3 
A ROMP-Based Strategy Towards Skeletally Diverse Sultams 
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3.1  Introduction 
The emergence of designer polymers and associated technologies continues to bring 
new opportunities for facilitating the drug discovery process.1  Conventionally, this 
goal been achieved by operating on resin-bound substrates (i) with excess reagents or 
treating solution phase substrates with excess immobilized reagents (ii) (Figure 3.1). 
Both scenarios, although deemed uneconomical,2 have been extensively represented 
in the literature as highlighted in previous chapters.  Alternatively, a third scenario is 
presented (iii) that employs the use of excess substrate (normally considered the 
precious component) and is rarely used due to obvious reasons.  However, if excess 
substrate is warranted in a reaction and can be further processed in a parallel, 
chromatography-free manner, ie, “reclaimed”, this unfavorable scenario is then 
deemed quite favorable. This recycling process would allow for the possibility of 
generating a new set of products derived from the parent substrate. 
substrate product(s)
excess
reagents
+
rinse
reagent waste
release
reagents+
product(s)
excess
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+
substratereagents +
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filter
product(s)
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Figure 3.1  General scheme for facilitated reactions (i-iii). 
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Sulfonamides have long been recognized as an important class of compounds in 
drug discovery for their rich biological and chemical profiles.  This has been 
augmented by a number of favorable chemical properties (ie. pKa’s) inherent to these 
structures enabling them to undergo facile coupling/alkylation pathways, stability to 
hydrolysis, overall polarity, and their crystalline nature.  Like their acyclic 
counterparts, sultams (cyclic sulfonamides), despite their absence in nature, exhibit a 
wide-array of potent biological activities (Figure 3.2) including COX-2 inhibition3 
(3.1, 3.2) antiviral and anticancer4 (3.3), treatments for glaucoma5 (3.4) and epilepsy6 
(3.5), as well as calpain I inhibition7 (3.6). This information has opened the door for 
aggressively mining underrepresented chemical space of this particular chemotype. 
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Figure 3.2  Examples of known bioactive sultams 
Within the context of this chapter, a unique, ROMP-based synthetic protocol will 
be presented for use in the atom-economical synthesis of various skeletally diverse 
sultams starting from a single norbornene-based scaffold.  The use of a vanishing 
support protocol is also demonstrated as a traceless means for polymer-assisted 
synthesis. 
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Our continued interest in norbornene-based structures has led to the development of 
new methods employing metathesis as a key reaction in accessing skeletally diverse 
sultams (Scheme 3.1).8  The idea of utilizing ring-strain as a facilitated protocol for 
creating diversity however, is by no means a new concept.  Outside of traditionally 
accomplished Diels-Alder chemistry, many others have also capitalized on the use of 
norbornene-systems as reliable diversity-creating substructures.9a,b 
Scheme 3.1  Cascade metathesis reactions towards diverse sultams  
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Recently, Spring and coworkers demonstrated the power of this concept in the 
search for new antibiotic small-molecule probes.10  This strategy utilized a solid-
supported phosphonate (3.11) for the stereoselective formation of α, β-unsaturated 
acyl imidazolidinones 3.12 (Scheme 3.2).  These twelve compounds were 
subsequently used to produce a 242-member library of a wide array of diverse 
scaffolding.  In this search, three compounds, including 3.14, were identified having 
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displayed antibiotic activity.  Compound 3.14 named (–)-gemmacin, also showed 
inhibitory activity towards a methicillin-resistant strain of Staphylococcus aureus 
(MRSA).  
Scheme 3.2  Norbornene-based DOS strategy for drug discovery 
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Our general method, highlighted in Figure 3.3, incorporates the following diversity-
generating sequence: (i) performing reactions on the internal olefin of an oxa-
norbornene-based scaffold used in excess, (ii) reclamation of this excess scaffold via 
ROMP followed by subsequent diversification via parallel reactions, and (iii) the use 
of a vanishing support protocol (VSP)11 to relinquish the newly diversified collection 
of products in high purity.  The representative oxa-norbornene-based scaffold herein 
is not only inherently armed for diversity but also for ROM-polymerization.  After 
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completion of the parent reaction, which transforms the olefin moiety into a new 
functional group, excess monomeric scaffold (S-1) is sequestered via in situ ROM 
polymerization.11a,12  Filtration of the parent reaction yields pure products (P-1) as 
well as reclaimed oligomeric sultam (O-1) (ie. the precious component.)  In contrast 
to the aforementioned scenarios, the oligomeric sultam does not constitute as waste 
since added diversification can take place and ultimately, additional products (P-2 to 
P-4) can be relinquished via polymer annihilation using a vanishing support protocol 
(VSP).  Overall, this chromatography-free process provides access to diverse sultam 
scaffolds in a parallel manner by integrating the virtues of solid phase and solution- 
phase chemistries through an atom-economical approach. 
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Figure 3.3  Parallel processing via scaffold reclamation 
3.2  Results and Discussion 
The initial route began with the synthesis of tricyclic sultam 3.15 using precedent 
set by Metz and coworkers (Scheme 3.3).13 Treatment of furfuryl amine with 2-
chloroethanesulfonyl chloride and subsequent Boc-protection afforded a vinyl 
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sulfonamide, which upon heating gave the desired intramolecular Diels-Alder adduct 
3.15 with excellent yield and exo-adduct selectivity (dr > 19:1).  This scaffold was 
subjected to reductive Heck conditions14 using Pd(OAc)2, Zn and excess aromatic 
iodides (1.5 equiv.) to afford sultam 3.16 in < 60% yield with excellent regio- and 
diastereoselectivity (dr > 19:1).  During an initial study, however, it was discovered 
that using excess scaffold (1.5 equiv.) increased the yield of this reaction up to 89%.  
However, chromatographic purification became tedious due to the similarity in Rf 
between sultams 3.15 and 3.16.  At this juncture, the notion of sequestering excess 
scaffold became apparent when it was discovered that 3.15 underwent facile ROM-
polymerization.  The method was implemented in a sequence by performing the Heck 
reaction of an aromatic iodide with excess sultam 3.15 in the presence of Pd(OAc)2 
and Zn in DMF at 60 ºC.   
Scheme 3.3  ROMP-facilitated DOS-strategy 
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After completion of the reaction, the mixture was filtered through Celite (to remove 
Zn), concentrated and subjected to in situ ROM-polymerization using catalyst 2G 
where simple precipitation and filtration afforded the desired Heck products 3.16a−j 
in good yields and excellent purity (Table 3.1).  The reclaimed oligomeric scaffold 
3.17 was then subjected to additional processing via reductive ozonolysis,15 to 
generate sultam 3.18.  Moreover, capture of 3.18 with oligomeric benzene sulfonyl 
chloride (OBSC60) followed by release with NaOMe afforded cyclized product 3.19 
in 41% yield over the two-step sequence. 
Table 3.1  Reductive Heck products 3.16a−j 
entry substrate R1 yield %[a] 
1 a p-Ac-Ph 82 
2 b p-F-Ph 77 
3 c p-CO2CH3-Ph 86 
4 d p-OH-Ph 89 
5 e m-F-Ph 82 
6 f 3,5 di-CH3-Ph 76 
7 g p-CH3-Ph 75 
8 h 2-thiophene-Ph 81[b] 
9 i p-CF3O-Ph 73[c] 
10 j p-CN-Ph 65[c] 
[a]Purities > 95%. [b] dr = 3:1, [c] dr = 4:1 
 
Alternatively, oligomer 3.17 underwent facile deprotection, alkylation and reductive 
ozonolysis (ie. VSP) to afford the alkylated sultam 3.21 in excellent yield (Scheme 
3.4).  The purity in both sequences was excellent and X-ray quality crystals (Figure 
3.4) were obtained via simple filtration thru a SiO2 SPE followed by concentration. 
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The diversification reaction in this protocol was further extended to incorporate the 
Suzuki-Miyaura coupling reaction.  Thus, deprotected oligomer 3.20 was also 
alkylated with p-iodobenzyl bromide to yield oligomer 3.22 that was subjected to the 
coupling reaction,16 followed by reductive ozonolysis to afford sultams 3.23a−b in 
excellent yields and purities.   
Scheme 3.4  Incorporation of the Suzuki-Miyaura coupling reaction 
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Overall, this method offers several advantages, including (i) atom economy; where 
all of the oligomer (ie. reclaimed scaffold) is converted to product(s) after 
annihilation, (ii) no additional linker is required (in contrast to traditional SPOS), (iii) 
a single starting scaffold affords four different scaffolds via parallel processing with 
minimal waste stream. 
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Figure 3.4  X-ray crystal structure (3.21) depicted as a single enantiomer 
 
In a proof-of-concept experiment, sultam 3.24, a derivative of 3.15, was subjected 
to Sharpless dihydroxylation conditions with N-methyl morpholine N-oxide (oxidant) 
as the limiting reagent (Scheme 3.5).17  After depletion of the oxidant, diol 3.25 was 
immediately liberated via crystallization during the polymerization event of 3.24 
affording x-ray quality crystals (Figure 3.5) after simple filtration and concentration.  
The reclaimed scaffold 3.26 was then further processed via Suzuki-Miyaura coupling 
as previously described, followed again by reductive ozonolysis to afford products 
3.28a−b in good yields and excellent purity over the three-step sequence.  This proof-
of-concept experiment demonstrated the overall compatibility and functional group 
tolerance of ROM-polymerization processes while having highlighted the purity of 
the initial parent product as a result of the polymerization event.  
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Scheme 3.5  Proof-of-concept purification experiment 
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Figure 3.5  X-ray crystal structure (3.25) depicted as a single enantiomer 
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3.3  Conclusions and Future Outlook 
 
In conclusion, a new atom-economical method utilizing ROM-polymerization and a 
vanishing support protocol has been described.  This strategy allows for parallel 
processing of a reductive Heck product as well as reclamation of excess sultam 
oligomer that is further diversified and annhilated to yield an array of skeletally 
diverse sultam scaffolds.  This method was extended to a diastereoselective 
dihydroxylation reaction demonstrating the compatibility and functional group 
tolerance of ROM-polymerization processes.  Future work focusing on additional 
scaffolds and diversity-generating reaction pathways for library development will be 
reported in due course including new ROMP-derived strategies for facile purification 
and PASP reaction processing. 
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Chapter 4  
The Development and Application of Cobalt-based ROMPgel  
Magnetic Nanoparticles 
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4.1  Introduction  
Developmental research of magnetic nanomaterials for applications in the medical1 
and chemical2 fields has steadily increased in the last several decades.  As a result, 
several strategies have surfaced for the facile assembly of diverse inorganic and 
organic frameworks with inherent magnetic properties.  These studies include 
pioneering efforts made in the area of supported-catalysis where materials such as 
silica, carbon or polymers have been doped with magnetic nanoparticles.3   
In recent years, a substantial number of reports have also focused on defined 
core/shell assemblies based on superparamagnetic iron oxide nanoparticles (SPION), 
such as magnetite.3,4  A lack of magnetic remanence in this material in the absence of 
an external magnetic field is especially beneficial for the dispersability of these 
nanoparticles in a heterogeneous reaction environment.  However, this advantage is 
accompanied by a relatively low saturation moment of these ferrites (MS,bulk ≤ 92 
emu/g).  When compared to bulk, this moment is usually far lower in the nano-sized 
mater due to partial oxidation on the surface, and sometimes diminished further 
through its requisite outer protective shell.5  As a consequence, hybrid materials that 
rely on iron oxide nanoparticles require a high metal content for effective magnetic 
susceptibility, thus limiting functional group load capacity and their use as supported 
reagents.  Nanoparticles derived from pure metals, however, exhibit superior 
magnetic properties as compared to oxides, but their synthesis had been limited to 
small-scale operations.6,7   
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Recently, Grass and coworkers8 reported on a continuous process, in which large 
amounts of carbon coated ferromagnetic nanoparticles (> 30 g/h) are accessible via 
reducing flame-spray pyrolysis.9  Despite the comparatively thin graphene layer (1 
nm), the built-in pyrophoric cobalt cores reveal remarkable thermal and chemical 
stability10 and more importantly, the protective carbon layer surrounding the cobalt 
core had no detrimental effect on the overall magnetization (158 emu/g). From a 
synthetic perspective, Co/C-nanomagnets allow for simple and rapid separation via 
magnetic decantation but are limited by their loading (0.1 mmol/g)8 due to the sheer 
mass of the carbon/cobalt framework.  As a result, their usefulness as magnetically 
recoverable supports in facilitated synthesis was deemed quite limited. 
Reported herein is a brief investigation that was conducted to combine the favorable 
attributes of ROMP technology to facilitate increased load capacities of 
cobalt/carbon-nanoparticles (Co/C-NP) for the purpose of supported-catalysis.  This 
was readily achieved through the development of new ROMP-hybrid, magnetic 
materials that were used as magnetically recoverable and recyclable Pd catalysts in 
Suzuki-Miyaura coupling reactions.  
4.2  Results and Discussion 
In order to combine these two different technologies, we envisaged the covalent 
attachment of a norbornene-tag (Nb-tag) onto the surface of the Co/C-NP (Scheme 
4.1), followed by ROM-polymerization in the presence of a Nb-tagged ligand to 
ultimately immobilize the ligand onto the surface of the Co/C-NPs.  Buchmeiser11 
Grubbs12 and Whitesides,13 all have demonstrated ROM-polymerization on silica 
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surfaces, while Buchmeiser and Barrett have also reported ROM-polymerization on 
polystyrene resins.14  In 2003, Barrett et. al. used a ROMPgel supported triphenyl-
phosphine as a supported ligand for the attachment of Wilkinson’s catalyst.15  
Numerous imidazolium norbornene units (4.2) were also incorporated into the 
polymer backbone to create a bi-functional ROMPgel 4.3 that retained the attributes 
of an ionic liquid (Figure 4.1).  Catalyst 4.4 was successfully used to facilitate 
hydrogenation of a collection of olefin-containing compounds.  
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Figure 4.1  Ionic ROMPgel-supported Wilkinson’s catalyst for hydrogenation 
ROMP-derived oligomers themselves have also been used as surfactants to stabilize 
maghemite nanoparticles, although the magnetization of the resulting composite was 
not reported.16  The covalent attachment of a ROMP-derived oligomer onto magnetic 
nanoparticles, however, is unprecedented.  
Synthesis of the azide-tagged nanoparticles (Scheme 4.1) was achieved in a concise 
two-step reaction based on the covalent attachment of diazonium compounds on 
graphene layers as described previously.8a,17  An azide-loading of 0.1 mmol/g was 
obtained for 4.6 as determined by elemental microanalysis.  This was subjected to the 
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Huisgen [3+2] cycloaddition (“click”) reaction18 to graft propargylated norbornene 
Scheme 4.1  Functionalization of azide-tagged Co/C-nanoparticles with OTPP50 
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derivative 4.7 onto azide functionalized Co/C-NPs 4.6.  In this combined strategy, 
Nb-tagged 4.8 now presented the necessary linkage for which ROM-
copolymerization could be effectively achieved. This reaction was monitored by 
solid-phase IR spectroscopy with the disappearance of the azide peak at ~2100 cm-1.  
Nb-tagged Co/C-NPs 4.8 were then placed in sealed pressure tube in a tempered (60 
°C) ultrasonic bath and the nanopowder was dispersed in degassed CH2Cl2 via 
sonication under an inert atmosphere (argon).  After which time a solution of catalyst 
2G (2 mol% in respect to 4.9) was added to the mixture.  ROM-copolymerization was 
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carried out using PPh3-functionalized norbornene 4.919 (50.0 equiv. in respect to 4.8 
@ 0.1 mmol/g) under conditions suitable for theoretical formation of a grafted 50mer. 
During the course of the reaction, the voluminous, black Co/C-ROMPgel 4.10 was 
formed, leaving behind little residual solvent.  Assuming that all Co/C-nanoparticles 
were coated with the available amount of oligomer, one would expect a Co-content of 
approximately 33% in the resulting hybrid material, a value that was confirmed by 
elemental microanalysis. TEM images confirmed the embedment of Co/C-particles in 
a polymer matrix, reducing the otherwise densely packed clusters to a more spatial 
arrangement (Figure 4.2).  No evidence of cross linking was observed in agreement 
with earlier studies in which metathesis between an immobilized norbornene 
derivative and dissolved olefins was carried out.20 
 
 
 
Figure 4.2  TEM Images of Co/C-nanoparticles 4.5(left) and Co/C-ROMPgel 4.10 
(right) 
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A control experiment utilizing azide-functionalized Co/C-NPs 4.6 instead of Nb-
tagged nanoparticles 4.8 was conducted to ensure that the polymer did not only 
encapsulate the nanomagnets but was instead covalently attached to the carbon shell.  
In contrast to the previous observation, no gel was formed during this control and the 
nanoparticles remained in solution as heterogeneous particulates. The oligomer 
remained soluble in solution until precipitated from MeOH.  The swelling behavior of 
Co/C-ROMPgel 4.10 was found to be in line with the general properties of 
ROMPgels, showing a pronounced volume increase in THF and CH2Cl2 whereas 
solvents such as MeOH or Et2O did not provoke a significant effect.21  
The morphology of this new hybrid material was clearly distinct from both parent 
materials as observed in scanning electron micrographs (SEM) (Figure 4.3). The 
aforementioned oligomeric triphenylphosphine (OTPP50)19b obtained from the control 
experiment (Figure 4.2a) was analyzed next to unmodified Co/C-nanoparticles 4.5 
(Figure 4.2b).  In addition, the specimen stub was coated with atomized silver prior to 
deposition of Co/C-ROMPgel 4.10 to prevent the accumulation of static electric 
charge on the sample and to display its inherent magnetic field (Figure 4.3c).  Energy 
dispersive X-ray (EDX) (Figure 4.2d) and 31P NMR22 confirmed the presence of 
phosphorus in the hybrid material.  The fraction of phosphorus was assessed via 
elemental microanalysis (3.45%), corresponding to 1.1 mmol/g P-loading. Hence, 
approximately 30% of the hybrid material consists of triphenylphosphine (TPP).  The 
immobilized TPP was expected to render the nanocomposite with the ability to serve 
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as a separable reagent/ scavenging agent23 or a ligand, i.e. for the formation of a 
recyclable palladium complex. 
 
Figure 4.3  SEM images of OTPP50 (a), Co/C-nanoparticles 4.5 (b), and Co/C-
ROMPgel 4.10 (c), EDX-Spectrum of 4.10 (d)24 
 
4.2.1  Catalysis with a Co/C-ROMPgel immobilized Pd-complex 
A number of examples of palladium complexes anchored on different magnetic iron 
oxide nanoparticles have been reported in the past years.4,25 However, highly 
functionalized architectures that relied on stabilized ferrite cores were naturally less 
susceptible to magnetic separation as previously discussed.  The doping of such 
complexes with palladium is typically achieved by mixing the metal source together 
with the ligand-functionalized scaffold (Scheme 4.2).  This is often prone to further 
diminish the mass magnetization making for a difficult recovery process.  However, 
P
Co
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the magnetization of composite 4.11, which was measured via vibrating sample 
magnetometer (VSM), was found to be 34 emu/g, a value consistent with the mass 
percentage of the ferromagnetic cobalt core in the sample.  This level is comparable 
to surfactant stabilized SPIONs, however, polymer or silica coated iron oxide NPs 
which resembles 4.11 in terms of durability, exhibit significantly lower 
magnetization.5 
Scheme 4.2  Heterogeneous Palladium-metathesis onto PPh3-functionalized Co/C-
ROMPgel 4.10. The Pd-content of 4.11 was assessed by AAS (0.48 
mmol/g) 
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To determine the catalytic efficacy of Pd-catalyst 4.11, we subjected it to several 
consecutive Suzuki-Miyaura cross-coupling reactions26 of aryl halides with 
phenylboronic acids (Table 4.1).  As it is common in such reactions, iodides are 
consistently more reactive than bromides or chlorides, therefore when iodobenzene 
was chosen as substrate (entries 1, 3, 4 and 6), good to excellent yields were 
achieved.  Importantly, catalyst 4.11 was quantitatively recovered after each reaction 
and reused in the next run, proving the suitability of the new Co/C-ROMPgel as a 
high-capacity support that can be readily recovered and recycled by magnetic 
separation.   
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Table 4.1  Suzuki-Miyaura cross-coupling reactions catalyzed by recyclable Co/C-
ROMPgel immobilized Pd-complex 4.11 
 
X (HO)2B
R
+
R
Co P
Ph
Ph
Pd L
OAc
OAc
4.11
4.12 4.13 4.14a-g
Na2CO3
THF/H2O
65 ºC  
entry run X R time (h) yield (%) 
1 1 I H 2 96 
2 2 Cl H 6 38 
3 3 I 2-Br 2 95 
4 4 I 2-Me 2 90 
5 5 Br H 12 92 
6 6 I 4-t-Bu 4 86 
7 7 I H 4 90 
[a] Reagents and conditions: Phenylhalide (0.5 mmol), phenyl-
boronic acid (0.55), Na2CO3 (1.5 mmol), 1.1 mol% cat 4.11, 65 ºC, 
solvent 3 mL THF/H2O (1:2 v/v)  
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4.3 Conclusions and Future Outlook 
In conclusion we have demonstrated the ability to incorporate the favorable, high-
loading attributes of ROMP technology with cobalt-based, magnetic nanoparticles to 
create a new hybrid material (Co/C-ROMPgel).  We have also highlighted the use of 
this material as a support for Pd-catalysis – having demonstrated its use in Suzuki-
Miyaura coupling reactions and revealed its ability to be recycled via magnetic 
recovery. 
This composite might also be suitable for alternative assemblies that rely on iron 
oxides as magnetic core material.  More importantly, from a synthetic application 
standpoint, these will likely prove useful in automated synthesis where manipulation 
via magnetic field could readily be achieved. 
Currently, this hybrid material is proving useful in a number of other applications 
including the Mitsunobu reaction.  This material allows for the convenient 
sequestration and removal of monomeric norbornene-based reagents (Ph3P and 
DEAD) via in situ ROM-polymerization and magnetic decantation.  This may also 
prove effective as a magnetically recoverable and reusable source of 
triphenylphosphine.  Results of these endeavors will be reported in due course.  
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Chapter 5 
Automated Library Synthesis of Thiadiazepin-1,1-dioxide-4-ones 
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5.1  Introduction 
The continued search for biologically relevant small-molecules is of utmost 
importance for the advancement of human health.1  With this notion, the area of 
diversity-oriented synthesis has emerged in recent years as a powerful strategy to 
embark upon this ever-demanding challenge.2  This objective is currently being 
fueled by various functional group pairing (FG-pairing) strategies that render the 
ability to generate diverse collections of molecules in the fewest number of steps 
possible.3  These key concepts are at the heart of the “Build/Couple/Pair (BCP)” 
strategy set forth by Schreiber and coworkers in 20084 and continues to be the 
impetus for DOS-based library efforts in medicinal chemistry.5  Once such strategy by 
Porco and coworkers3a recently demonstrated a FG-pairing concept for the generation 
of skeletally diverse systems.  
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Figure 5.1  Porco FG-pairing strategy 
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To successfully facilitate a process in this manner, each FG-pairing pathway must 
be compatible with the functionality residing in other regions on the molecule, taking 
in consideration these may provide additional handles for future appendage 
attachment.   
Our strategy entitled “Click, Click, Cyclize”, highlighted below, utilizes a multi-
functional linchpin approach3b,6 wherein a number of sulfonamide precursors have 
been selected as key building blocks for sultam scaffold development.7  This strategy 
was recently demonstrated utilizing a number of different methods: Oxa-Michael and 
Baylis-Hillman,8 aza-Michael,3b ring-closing metathesis (RCM),9 and cascade 
metathesis (ROM-RCM-CM)10 for generation of multiple, skeletally diverse sultams 
in rapid fashion.  
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Figure 5.2  Click/Click/Cyclize DOS strategy 
Until recently, the utility of this strategy had only previously been demonstrated for 
the generation of sultam scaffolds for small-scale (pilot) library production.  This in 
part due to the majority of focus having been placed on new method development and 
pilot-scale library initiatives.  However, with a collection of new methods in hand we 
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were then poised to further exploit these newly generated systems for larger-scale 
library production (100−300 compounds).  In light of this new progression, we 
became interested in the development of a specific, thiadiazepin-1,1-dioxide-4-one 
(sultam) scaffold (5.1) for use in library production.   Herein we describe efforts 
regarding the resynthesis, derivatization, and scaleup of this scaffold and its use in the 
production of a 225-member library using automated PASP and solution-phase 
protocols. 
5.2  Results and Discussion 
Having recently been synthesized in our group3b, sultam motif 5.1 was of great 
interest in light of its similarity to other constrained peptidomimetic structures.11  A 
very similar scaffold of this chemotype had previously been investigated by 
Liskamp12 et. al. in the solid-phase synthesis of linear peptidosulfonamide libraries 
(Scheme 5.1).   Interestingly, Liskamp makes note the amount of molecular diversity 
that can be achieved through the use of α- or β-substituted amino ethane 
sulfonamides as well as their facilitated synthesis by solid-phase (Merrifield) 
supports.   
Scheme 5.1  Solid-phase synthesis of cyclic peptidosulfonamides (sultams)  
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A number of seven-membered diazepinone-based scaffolds identified from 
literature have been shown to have interesting biological properties associated with 
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this core motif (Figure 5.3).  These properties include inhibition of interleukin-1β (IL-
1β)13, modulatory activity of the follicle stimulating hormone receptor (FSHR)14, as 
well as inhibition of the lymphocyte function-associated antigen-1 (LFA-1).15 
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Figure 5.3  Bioactive diazepinone-based structures 
Efforts to synthesize the general sultam motif (5.1) were next revisited to ensure the 
viablity of the current proceedure in regards to scale-up for library production 
(Scheme 5.2).  Using conditions previously employed,3b sulfonylation of the S-valine 
methyl ester 5.4{2} (ie. first “click reaction) was achieved using a masked vinyl 
sulfonyl chloride and DMAP to yield sulfonamide 5.5{2}.  This was then carried over 
without further purification and subjected to alkylation affording tertiary sulfonamide 
5.6{2}.   
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Scheme 5.2  Scaffold resynthesis efforts 
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Previous efforts to facilitate the following aza-Michael addition (5.6−5.7) utilized a 
primary amine in a concentrated solution of MeOH (1M).3b  However, due to complex 
mixtures and incomplete conversions w/ specific amines (Table 5.1, entry 1) at this 
stage we explored the use of catalytic amounts of DBU to aid the synthesis.16  A 
noticeably longer reaction time was found using propargylamine as compared to 
isobutylamine.  However, cleaner, more complete conversions were obtained for both 
using DBU as indicated by both TLC and GC analysis.  
Table 5.1  Aza-Michael optimization 
entry R3 amine equiv. catalyst equiv. solvent 
temp 
(ºC) 
time 
(h) 
conv. 
(%)[a] 
1 propargyl 1.1 x x MeOH 65 14 75 
2 i-Bu 1.1 x x MeOH 65 3 88 
3 i-Bu 1.1 DBU 0.5 CH3CN 25 3 94 
4 propargyl 1.1 DBU 0.5 CH3CN 25 14 91 
5 propargyl 1.2 DBU 0.5 CH3CN 40 14 96 
[a] Conversions (%) calculated by percent area using GC analysis. 
We also explored a direct lactamization approach (Table 5.2) starting from tertiary 
sulfonamide 5.7{2} to save an additional step in the synthesis as previous methods 
utilized a two-step hydrolysis/lactamization from 5.7−5.9.  With this notion, this 
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cyclization would also lend itself to the incorporation of more elements of diversity 
early in the synthesis without the need for aqueous acidic workups.  A number of 
catalysts and conditions were tested at this stage (Table 5.2),17 but despite several 
reports in the literature of similar transformations,18 our efforts were met with little 
success. 
Table 5.2  Efforts towards a direct lactamization route via 5.7{2} 
N
N
S
OO
O
R1
S
N
OO
MeO2C R
1 Br
N
H
conditions
catalyst Br
5.7{2} 5.9{2}
R1= i-Pr
 
entry catalyst equiv additive solvent temp (ºC) 
time 
(h) 
yield 
(%) 
1 TiCl4 0.5 x THF 25 24 NR 
2 TiCl4 1.0 x DCE 150 24 NR 
3 Et3N x x Et3N 90 48 5 
4 2-hydroxypyridine 0.5 x toluene 120 24-48 20-27 
5 2-hydroxypyridine 0.5 x DCE 160 24-48 21 
6 2-hydroxypyridine 0.2-0.5 x DMF 160 24-48 39-56 
7 2-hydroxypyridine 0.2 x dioxane µW 160 1 9 
8 2-hydroxypyridine 0.2 x toluene µW 160 1 45 
9 Otera’s cat 0.05 x toluene µW 160 1 NR 
10 AcOH 1 x toluene µW 160 1 NR 
11 Zr(t-BuO)4 1 x toluene µW 160 1 NR 
12 Zr(t-BuO)4 1 2-hydroxypyridine toluene µW 160 1  15 
13 Zr(t-BuO)4 1 HOAT toluene µW 160 1 NR 
 
Despite having little success in a more direct synthetic route to the scaffold, we 
further pursued optimization of the current procedure involving lactamization via the 
sulfamido-amino acid.  This was subsequently obtained via hydrolysis of amino-ester 
containing 5.7{2} via aqueous LiOH to yield amino acid 5.8{2} as a white-solid after 
neutralization (1M HCl).  Due to its difficulty in separation from lithium salts, 5.8{2} 
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was carried as a crude solid to the lactamization step.  Cyclized product 5.9{2} was 
obtained through the use of DCC as a coupling reagent, but was often contaminated 
with the urea byproduct as evident by 1H-NMR.  With this discovery, EDC was 
explored as an alternative coupling reagent for this step.  Other reagents were also 
explored for lactamization (Table 5.3), including, but not limited to, oligomeric 
phosphorochloridate (OPC) and oligomeric dichlorotriazine (ODCT),19 but each 
resulted in complete racemization of 5.9 as observed by optical rotation.  
Table 5.3  Continued efforts towards lactamization 
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HO
 
entry coupling reagent base solvent temp (ºC) yield (%) (±)[a] 
1 
O
O
P
O
Cl
20  
imidazole CH2Cl2 25 95 √ 
2 O
N
N
N
Cl
Cl
50
 
NMM CH2Cl2 25 48 √ 
3 trichlorotriazine NMM CH2Cl2 25 99 √ 
4 phenyl dichlorophosphate imidazole CH2Cl2 25 90 √ 
5 DCC NMM CH2Cl2 25 84  
6 EDC/HOBt NMM CH2Cl2 25 90  
[a] (±) column displays complete racemization (√) as noted by optical rotation (α = 0.000) replicated x 3. 
EDC was used with 10% HOBt to efficiently access 5.9, but despite its reported use 
in the preservation of chirality, a degree of racemization was also observed by HPLC 
analysis late-stage in project development.20  Racemization has been known to occur 
with the use of HOBt in certain circumstances as reported in the literature.21  From a 
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library development perspective however, the need for providing enantiomerically 
pure material at this stage was not a major concern.  
In the initial library planning stage, we envisaged installation of two functional 
group handles in regions A/B (Figure 5.4) on sultam scaffolds 5.9{1-3} for the 
attachment of diverse appendages.  With this notion, the Huisgen [3+2] 
cycloaddition22,23 and Suzuki-Miyaura coupling reaction24 were both chosen based 
upon their well-precedented efficiency25 and use in library production.26  This choice 
then renders the ability to efficiently link/exchange multiple fragments (azides and 
boronic acids) together selectively based upon potential bioactive lead structures that 
may arise in the future.    
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Figure 5.4  Sultam scaffold design for appendage diversity 
Introduction of the propargyl group into region A prepared scaffolds 5.9{1-3} for 
the preemptive formation of a 1,2,3-triazole linkage via copper-catalyzed Huisgen 
[3+2] cycloaddition.  The bromophenyl functionality was employed in region B to 
provide the necessary functionality for the Suzuki-Miyaura coupling reaction.  This 
group also renders the ability to perform several quick-change operations for 
alternative reaction processing including Buchwald-Hartwig coupling, Heck 
coupling, and other Pd-catalyzed transformations.27  This strategy not only permits us 
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the flexibility to change either of these two appendages but also the functional group 
linkages (ie. handles) on each scaffold via future sulfonamide linchpin operations. 
Each of the three sultam scaffolds (5.9{1-3}, Scheme 5.3) were accessed in which 
alanine 5.4{1}, valine 5.4{2}, and leucine 5.4{3} underwent facile sulfonylation to 
provide vinyl linchpins 5.5{1-3}.  These were further exploited via alkylation to 
afford intermediates 5.6{1-3}.  Each were then subjected to the aza-Michael addition 
via propargylamine rendering sulfonamides 5.7{1-3} in 39−52% yields over the 
three-step process.  Scaffolds 5.9{1-3} were formed via two-step hydrolysis/ 
lactamization28 resulting in good overall yields (61−70%) and excellent purities.  
Using this newly optimized method, each of the three sultam scaffolds were scaled up 
prior to validation to a minimum quantity of 5 grams each resulting in high-quality 
material for library production.29 
Scheme 5.3  Synthesis of sultam scaffolds  for library production  
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With each of the three scaffolds in hand we were poised to validate both regions 
A/B concerning the order of diversification.  The most logical starting point relied on 
 114 
the noted efficiency of the [3+2] cycloaddition for its preemptive use in region A.  It 
was speculated that workup procedures for the Suzuki-Miyaura coupling reaction 
prior to the second diversification could prove costly in terms of transferred yields, 
and therefore region A was deemed as the initial starting point for diversification.  In 
this regard, conditions employing Cu(I) catalyst (Table 5.4, entry 1) were first 
explored and found to be high-yielding but unfortunately afforded an undesirable 
mixture of regioisomers.  The use of Cu(II) catalysts in t-BuOH/H2O, however saw 
complete regioselectivity, but suffered from poorer yields (entry 2) presumably due to 
poor substrate solubility.  The use of DCM (entry 3) or acetone (entries 4−6) as a co-
solvent, however, resulted in near quantitative yields.   
The use of lower catalyst/additive loadings was also explored in consideration to 
final library purification.  It was determined that loadings could be reduced to as low 
as 10 mol% without risking a substantial loss in yield.  Due to the efficient nature of 
this reaction, we were then motivated to explore the use of an immobilized source of 
copper (A-21•CuI)30 that did not require a complex solvent mixture and/or aqueous 
workup.  Conveniently, this bifunctional catalyst also acted as a supported base for 
the reaction wherein its primary functionality contains a tertiary amino group.  These 
polymer-assisted efforts proved highly successful (entry 7) affording triazole-
containing (±) sultam 5.10{1} in excellent yield after SPE filtration. 
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Table 5.4  Validation of Huisgen [3+2] cycloaddition 
N
N
S
Br
OO
O
CH3
N
N
S
Br
OO
CH3
N
N
N
O
R2
R2-N3, catalyst
solvent, rt
12 h
± 5.9{1} ± 5.10{1}  
entry catalyst loading (mol%) additive equiv solvent yield (%) 
1 CuI 10 2,6-lutidine 1.2 CHCl3 88[a] 
2 CuSO4•6H2O 10 Na ascorbate 0.1 t-BuOH/H2O 1:2 45 
3 CuSO4•6H2O 20 Na ascorbate 0.3 t-BuOH/H2O/CH2Cl2 1:1:1 97 
4 CuSO4•6H2O 20 Na ascorbate 0.3 t-BuOH/H2O/acetone 3:4:1 96 
5 CuSO4•6H2O 10 Na ascorbate 0.2 t-BuOH/H2O/acetone 3:4:1 95 
6 CuSO4•6H2O 5 Na ascorbate 0.1 t-BuOH/H2O/acetone 3:4:1 78 
7 A-21•CuI 20 none - CH2Cl2 90 
[a] Resulted in a 4:1 mixture of regioisomers.  
 
Initial efforts to validate conditions for the Suzuki-Miyaura coupling reaction 
(Table 5.5) were explored whereby use of Pd(dppf)Cl2 as catalyst had previously been 
used for sultam diversification of this type (Ch. 3).  Variation in Pd catalyst loadings 
were first explored starting from 1mol% up to 10 mol% (entries 1−3) resulting in only 
moderate yields.  Due to similarity in Rf between starting material and product, 
monitoring reaction progression by TLC proved difficult, and as a result, reaction 
time was increased to 14 hours at 80 ºC using 5 mol% Pd.  This resulted in high-
yielding product formation (5.11b,c{2-3}) as evident in entries 4−5.  Interest in 
compatibility/scope between substrates used in region A (ie. azides) and the Suzuki-
Miyaura coupling reaction revealed that azide bearing esters (entries 6−9) were not 
good substrates for the library as each underwent base-catalyzed hydrolysis to give 
two products after the coupling event; each being separable by chromatography.   
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Table 5.5  Initial validation of the Suzuki-Miyaura coupling reaction 
N
N
S
Br
OO
R1
N
N
N
O
R2 5.10{2-3}
1.  R3-B(OH)2, catalyst
     base, solvent
Suzuki-Miyura coupling
N
N
S
R3
OO
R1
N
N
N
O
R2 5.11a-n{2-3}  
entry R1 R2 R3 catalyst  loading (%) base 
temp 
(ºC) 
time 
(h) 
yield 
(%) 
pdt. 
5.11 
1 i-Bu p-Me-Bn phenyl 1 Cs2CO3 70 8 46 a 
2 i-Bu p-Me-Bn phenyl 5 Cs2CO3 70 8 51 a 
3 i-Bu p-Me-Bn phenyl 10 Cs2CO3 70 8 68 a 
4 i-Bu Cyhex-Me 3-CN-Ph 5 K2CO3 80 14 97 b 
5 i-Bu Cyhex-Me 3-Ac-Ph 5 K2CO3 80 14 99 c 
6 i-Bu (CH2)2OCOMe 2,6 diMePh 5 K2CO3 80 14 38 (51) d 
7 i-Bu (CH2)2OCOMe 3-CN-Ph 5 K2CO3 80 14 81 (19) e 
9 i-Bu (CH2)2OCOMe 3-Ac-Ph 5 K2CO3 80 14 52 (30) f 
10 i-Pr p-MeO-Bn 2,6 diMePh 5 K2CO3 80 14 88 g 
11 i-Pr p-MeO-Bn 2-thiophene 5 K2CO3 80 24 66 h 
12 i-Pr p-MeO-Bn 3-CN-Ph 5 K2CO3 80 14 73 i 
13 i-Pr p-MeO-Bn 3-Ac-Ph 5 K2CO3 80 14 87 j 
14 i-Pr furfuryl 2,6 diMePh 5 K2CO3 80 14 81 k 
15 i-Pr furfuryl 2-thiophene 5 K2CO3 80 24 76 l 
16 i-Pr furfuryl 3-CN-Ph 5 K2CO3 80 14 98 m 
17 i-Pr furfuryl 3-Ac-Ph 5 K2CO3 80 14 97 n 
Entries 6−9: Yield (%) reported as coupled product X to hydrolyzed coupled product (X); each separately isolated.  
Product (pdt.) d–f refers to the non-hydrolyzed products. 
 
A small substrate scope for the Suzuki-Miyaura coupling reaction was also 
performed under these conditions (entries 10−17) using both electron-rich and 
electron-deficient aryl boronic acids.  Notably, the reactivity of 2-thiophene boronic 
acid was significantly lower than the other boronic acids and required longer reaction 
times to yield coupled product.   
Initial attempts to validate these conditions on an automated platform vide infra  
unfortunately resulted in difficult emulsions and extended separation/workup times.  
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In light of this observation, we revisited these conditions (Table 5.6) having 
discovered that variations in the base and solvent affected overall workup times.   It 
was revealed that the use of DME with cesium carbonate provided the most 
convenient workup while retaining reproducibly high product yields.   
Table 5.6  Validation of the Suzuki-Miyaura coupling reaction 
N
N
S
Br
OO
CH3
N
N
N
O
R2 5.10{1}
1.  R3-B(OH)2, 
catalyst (0.1 eq)
  base, solvent
Suzuki-Miyura coupling
N
N
S
R3
OO
CH3
N
N
N
O
R2 5.12{1}
R2 = p-MeOBn
R3 = p-tolyl
 
 
entry catalyst base solvent temp (ºC) 
time 
(h) 
yield 
(%) 
1 Pd(dppf)Cl2 Cs2CO3 DMF/H2O 70 14 85 
2 Pd(dppf)Cl2 Na2CO3 DMF/H2O 70 14 10 
3 Pd(dppf)Cl2 K3PO4 DMF/H2O 85 16 92 
4 Pd(dppf)Cl2 K3PO4 Dioxane/H2O 90 16 90 
5 Pd(dppf)Cl2 Cs2CO3 Dioxane/H2O 75 14 62 
6 Pd(dppf)Cl2 Cs2CO3 Dioxane/H2O 90 16 94 
7 Pd(dppf)Cl2 Cs2CO3 DME/H2O 85 16 89 
8 Pd(PPh3)4 Cs2CO3 DME/H2O 70 14 <5 
9 Pd(PPh3)4 CsF DME/H2O 80 14 61 
 
We also briefly explored the use of a resin-bound source of Pd (FibreCat®)31 
whereby reaction workup consisted of a simple SPE filtration event.  Unfortunately, 
problems related to automation32 quickly became apparent and the notion of using this 
reagent was disbanded.  In the interest of time, no other Pd-functionalized resins were 
explored or tested for library use. 
Based on the optimal conditions chosen for both reactions, we then explored 
combining both into a single-step sequence for ease of parallel synthesis (Scheme 
5.4).  Sultam 5.9{1} was first reacted for 14 h with p-methoxybenzyl azide in the 
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presence of A-21•CuI, followed by filtration of the catalyst and concentration to yield 
crude, triazole-containing sultam 5.10{1}.  This material was then carried forward 
into the Suzuki-Miyaura coupling reaction without further purification.  A basic 
workup was then necessary to remove excess boronic acid from the reaction followed 
by a liquid-liquid extraction using DCM.  The resulting solution was then filtered via 
silica SPE and concentrated to afford sultam 5.12{1} in excellent yield over the 
combined two-step sequence.  Overall, this combined sequence was developed for its 
relevancy in the transfer of these chemistries to parallel methods, in which workup 
and purification are minimized.   
Scheme 5.4  Combined two-step diversification sequence 
N
N
S
Br
OO
O
CH3
N
N
S
Br
OO
CH3
N
N
N
O
R2
NMe2•CuI
(0.2 equiv)
concentrate
NMe2•CuI
0.51 M R2–N3
in CH2Cl2  (1.3 eq)
R2 = p-MeO-Bn
5.9{1}
0.23 M crude
substrate
in DME
0.76 M
Cs2CO3
in H2O
solid
Pd(dppf)Cl2
(0.1 equiv)
0.34 M R3–B(OH)3
(1.5 eq)
R2–N3
85 ºC, 14 h
then conc.
1N aq. NaOH
3 x CH2Cl2
rt, 14 h
then filter
N
N
S
R3
OO
CH3
N
N
N
O
R2
R3 = p-tolyl
R3–B(OH)3
5.12{1}
5.10{1}
96% over two steps  
The combined two-step sequence was then envisaged on the Chemspeed 
Accelerator SLT-100 parallel synthesizer for library production (Figure 5.5).33  The 
chemistry was first validated on this automated platform as a rehearsal 2 x 3 x 3 
member library (Figure 5.6) for a total of 18 compounds.   
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Figure 5.5  Chemspeed Accellerator SLT-100 parallel synthesizer 
Azides 1-3 were chosen based upon members represented in the scope of the final 
library and a small substrate scope for the Suzuki-Miyaura coupling was also 
explored with the choice of electron-deficient and electron-rich phenyl, and alkyl 
boronic acids.  With this information, the [3+2] cycloadditions were prepared and 
reacted in the Chemspeed for 14 h.  Upon completion, the supernatant was removed 
and transferred to the next reaction leaving the catalyst behind in the reactors.  The 
Suzuki-Miyaura coupling reaction was then conducted for 14 h at 85 ºC followed by 
the automated basic workup/extraction procedure.  Silica SPE filtration was carried 
out prior to crude purity analysis and subsequent purification was achieved by 
HPLC/mass directed fractionation (MDF) methods. 
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N
N
S
Br
OO
O
R1
O O
N3
O
N3
O
O N3
F B(OH)2
MeO B(OH)2
B(OH)2
MeO
MeO
5.9{1}
5.9{2}
1
2
3
1
2
3
N
N
S
Br
OO
O
R1
R2 = R3 =
 
Figure 5.6  Rehearsal 2 x 3 x 3 library building blocks 
Chart 5.1 displays the results of the validation efforts revealing an overall 
successful run for the combined two-step automated sequence.  Product yields ranged 
from 23−49% over two-steps with final purities > 90% for 12 of the 18 compounds.  
Boronic acid {3} (cyclopropyl), however, notably revealed a significantly lower 
reactivity as compared to both phenyl boronic acids resulting in incomplete 
conversions for 6 out of the 18 total reactions.   
 
Chart 5.1  Chemspeed rehearsal 2 x 3 x 3 library of thiadiazepin-1,1-dioxide-4-ones  
NMe2•CuI
N
N
S
Br
OO
O
R1
N
N
S
R3
OO
R1
N
N
N
O
R2
R2-N3, CH2Cl2, rt, 14 h
1.
2.  R3-B(OH)2, Pd(dppf)Cl2
     Cs2CO3, DME/H2O
 85 ºC, 14 h
5.13 (1-18)5.9{1}, 5.9{2}  
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Purity determination is UV area percent from HPLC analysis. 
 
With these results in hand, planning began for constructing the 225-member sultam 
library using the Chemspeed platform and the conditions set in place through the 
successful single-step validation sequence.  A number of azides and boronic acids 
were chosen (Figure 5.7) based on various structure and polarity features desired in 
the final products and either purchased or synthesized for use in the final library.  
Based on results of previous validations, alkyl boronic acids and base-labile azides 
were excluded from the final library.  The automated platform was then prepared for 
three sequential 75 compound runs for completion of a 3 x 5 x 15 member library.  
Using conditions previously validated, the library officially transitioned into the 
production phase. 
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NMe2•CuI
N
N
S
Br
OO
O
R1
N
N
S
R3
OO
R1
N
N
N
O
R2
R2-N3, CH2Cl2, rt, 14 h
1.
2.  R3-B(OH)2, Pd(dppf)Cl2
     Cs2CO3, DME/H2O
 85 ºC, 24 h 5.14 (1-225)5.9{1}, 5.9{2}, 5.9{3}  
O O
N3
O
N3
O
O
N3
B(OH)2
N3
N3
O
O
F B(OH)2
N B(OH)2
B(OH)2
S B(OH)2
Cl
B(OH)2
B(OH)2
B(OH)2
B(OH)2
MeO
MeO
N
Cl B(OH)2
Cl
MeO
B(OH)2
N
B(OH)2MeO
N
B(OH)2F
B(OH)2
HO
N
B(OH)2Cl
11
12
13
14
15
1
2
3
4
5 10
9
8
7
61
2
3
4
5
R2 = R3 =
 
Figure 5.7  Building blocks and conditions for the 3 x 5 x 15 library of thiadiazepin-
1,1-dioxide-4-ones. 
After completion of the first run of 75 compounds on the Chemspeed, three random 
samples were chosen and subjected to UPLC/MS for crude purity analysis aside from 
standard MS analysis of the library.  Product masses were confirmed for each of the 
three samples and crude purity analysis resulted in purities of 56%, 69%, and 78% - 
all on par with the rehearsal/validation library.  With this information in hand, the 
remaining two 75 compound runs were prepared and reacted accordingly in the 
Chemspeed.  After purification of the remaining 150 compounds, subsequent analysis 
revealed 166 compounds out of the 225 were obtained in greater than 90% purity with 
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average quantities ≥ 20 mg (using 0.150 mmol of sultams 5.9{1-3}) and an average 
yield of 50% over the two-step sequence.34  Further data analysis revealed no 
definitive trends in respect to yields between substrates and reagents, however, it was 
noted, that thiophene boronic acid (R3 = 5) resulted in very low yields across the 15 
reactions by which it was utilized.  
5.3  Conclusions and Future Outlook 
In conclusion we have successfully completed production of a 225 member library 
of thiadiazepin-1,1-dioxide-4-ones (sultams) utilizing a facile, two-step synthetic 
sequence performed on an automated platform.  We have highlighted the use of a 
multi-functional linchpin and its use in efficiently generating diverse scaffolding for 
library production.  The resulting compounds of this library are in the process of 
being relayed to a number of biological collaborators within the Molecular Libraries 
Screening Center Network (MLSCN) and future efforts will concentrate on targeted 
libraries of this and other related chemotypes as well as their anticipated biological 
evalution. 
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Chapter 6 
Experimentals 
 130 
General Experimental 
All air- and moisture-sensitive reactions were carried out in flame- or oven-dried 
glassware under argon atmosphere using standard gastight syringes, canellas, and 
septa.  THF, CH2Cl2, toluene, CH3CN, and Et2O were purified by passage through a 
Solv-Tek (www.solvtek.com) purification system employing activated Al2O2 (Grubbs, 
R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518−1520).  CHCl3 
was passed through basic alumina and dried over molecular sieves.  All other solvents 
were purchased commercially.  Flash column chromatography was performed with 
SiO2 (Sorbent Technologies 30930M-25, Silica Gel 60 Å, 40-63 µm).  Automated 
flash column chromatography was performed using a Biotage SP1 purification 
system. SPE purification was performed with SiO2 purchased from Sorbent 
Technology (30930M-25, Silica Gel 60A, 40-63 µm) and 6 mL empty cartridges 
were purchased from Silicycle Inc.  Thin layer chromatography was performed on 
silica gel 60F 254 plates.  Visualization of TLC spots was effected using KMnO4 
stain. 1H and 13C NMR spectra were recorded on a Bruker DRX-400 NMR 
spectrometer operating at 400 and 100 MHz respectively as well as a Bruker DRX-
500 spectrometer operating at 500 MHz, 126 MHz respectively.  Gas chromatography 
(GC) was performed using an Agilent Technologies 6890N with data processing on a 
Dell desktop.  GC/mass spectrometry was performed using a Quattro micro GC 
(Micromass UK Limited).  High-resolution mass spectrometry (HRMS) was recorded 
on a LCT Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH).  
Bohdan block assemblies and a Chemspeed Accelerator SLT-100 was used for 
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library preparation and production.  Nanoparticles were analyzed by FTIR 
spectroscopy (1% in KBr using a Tensor 27 Spectrometer, Bruker Optics equipped 
with a diffuse reflectance accessory, DiffusIR™, Pike Technologies), atom 
absorption spectroscopy (Varian SpectrAA 220FS), elemental microanalysis (LECO 
CHN-900), transmission electron microscopy (CM30 ST-Philips, LaB6 cathode, 
operated at 300 kV point resolution ~ 4 Å), scanning electron microscopy (Hitachi S-
2700 equipped with a quartz PCI digital capture) and magnetic hysteresis 
susceptibility (vibrating sample magnetometer, VSM, Princeton Measurements 
Corporation, model 3900).  FTIR spectroscopy on soluble compounds was performed 
using a Shimadzu FTIR-8400S instrument.  Grubbs catalysts (1G, 2G, and 3G) were 
generously provided by Materia Inc. and used without further purification.  Azide 
bearing nanoparticles were prepared at ETH Zurich.  Deuterated solvents were 
purchased from Cambridge Isotope laboratories.  Observed rotations at 589 nm, 20 ºC 
were measured using an AUTOPOL IV Model automatic polarimeter.  HPLC was 
performed using a Chiracel AD column with 95:5 hexanes:IPA with UV monitoring 
at 254 nm. 
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5-norbornene-2-exo, 3-exo-dimethyl phosphorochloridate (2.26) 
To a flame-dried 250 mL RB flask under argon atmosphere was added the exo-
norbornene dimethanol 2.25 (1.0 g, 6.5 mmol) as solution in CH2Cl2 or neat followed 
by addition of CH2Cl2 (33 mL), Et3N (20 mmol) and anhydrous N-methylimidazole 
(NMI) (0.65 mmol).  This was then cooled to 0 ºC and allowed to stir for 10 min.  To 
this was added freshly distilled POCl3 (7.1 mmol) drop-wise over several minutes w/ 
noticeable gas evolution and salt formation.  The reaction was then promptly removed 
from the cooling bath and allowed to stir at rt for 2.5 − 3 hrs monitoring by TLC (2:1 
Hexanes:EtOAc).  Upon completion, the reaction was concentrated by ~ ¾ volume 
and 50 − 75 mL anhydrous THF was added to the flask to precipitate the Et3NH+Cl− 
salts.  This mixture was filtered through a glass frit under vacuum containing celite 
with a minimal amount of dry silica and rinsed several times with fresh anhydrous 
THF (3 x 20 mL).  This was then subjected to a short silica plug (3.5 in) (4:1 
Hexanes:EtOAc up to 1:2 Hexanes:EtOAc) to afford phosphorochloridate 2.26 (808 
mg, 3.4 mmol, 53% yield) as a distinctly smelling white solid and inseparable mixture 
of P-diastereomers (dr = 11:1). 
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5-norbornene-2-exo, 3-exo-dimethyl phosphorochloridate (2.26) 
1H NMR (CDCl3, 400 MHz) δ ppm 6.26 (s, 2H), 4.39 (dd, J = 12.4, 4.2, 1H), 4.31 
(dd, J = 12.4, 4.2, 1H), 4.23 – 4.06 (m, 2H), 2.68 – 2.54 (m, 2H), 2.27 – 2.17 (m, J = 
7.6, 5.8, 4.0, 2H), 1.50 – 1.37 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ ppm 137.3, 
70.6 (d, JCOP = 36.0 Hz), 44.7, 43.5, 41.6; 31P NMR (CDCl3, 162 MHz) δ ppm 7.25, 
2.81 (dr = 11:1); FTIR (thin film) 3076, 2978, 1299, 1253, 1045 cm-1; HRMS 
calculated for C9H12ClO3PNa (M+Na)+ = 257.0110; found 257.0116 (TOF MS ES+) 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-methyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.50) 
 
A 1.0 M solution of CuCN•2LiCl was prepared in dry THF and sealed under argon. 
0.46 mL of this solution (0.46 mmol) was transferred via cannula to a flame-dried 5 
mL RB flask and cooled to -78 ºC.  To this was added Me2Zn (0.38 mL, 0.46 mmol) 
in drop-wise manner via syringe w/ stirring and allowed to slowly warm to -30 ºC.  
This mixture was then added drop-wise via cannulation to a solution of oligomeric-
bound 2.48 (25 mg, 0.046 mmol) in THF (0.2 M) at -30 ºC and allowed to slowly 
warm to rt overnight.  Notable sequestration of the copper salt byproducts was noted 
after several hours.  After such time, the reaction was quenched with 10% HCl, 
extracted w/ EtOAc ( 3 x 8 mL), and dried over MgSO4.  This was then passed 
through a silica SPE to yield the product 2.50 (9.8 mg, 0.028 mmol, 62 %) as a clear 
oil. 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-methyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.50) 
 
[α]20D = -8.0 º (c = 0.46, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.39 – 7.28 (m, 
7H), 7.23 (dd, J = 7.7, 0.9 Hz, 2H), 7.17 (t, J = 7.4 Hz, 1H), 5.89 (dddd, J = 29.5, 
10.6, 5.8, 2.2 Hz, 1H), 5.76 (ddd, J = 10.6, 3.6, 1.9 Hz, 1H), 5.16 – 5.08 (m, 1H), 4.65 
− 4.59 (m, 2H), 3.75 (ddd, J = 10.3, 5.6, 1.6 Hz, 1H), 3.67 (ddd, J = 10.3, 5.2, 1.6 Hz, 
1H), 2.65 – 2.52 (m, 2H), 1.41 (dd, J = 18.9, 7.5 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ ppm 150.6 (d, JCOP = 8.1 Hz), 138.0, 130.1, 128.9 (d, 2JCP = 7.6 Hz), 128.7, 
128.0, 127.9, 125.4 (d, JCCOP = 15.1 Hz), 125.2, 120.4 (d, JCCOP = 4.6 Hz), 80.0 (d, JCOP 
= 8.3 Hz), 73.9, 72.2 (d, JCCOP = 7.6 Hz), 26.8 (d, 1JCP = 133.1 Hz), 16.0 (d, 2JCP = 4.3 
Hz); 31P NMR (162 MHz, CDCl3) δ ppm 21.9; FTIR (thin film) 3030, 2930, 1720, 
1593, 1491, 1454, 1207, 926 cm-1; HRMS calculated for C19H21O4PNa (M+Na)+ = 
367.1075; found 367.1078 (TOF MS ES+). 
 
 136 
P
OPhO
O
OBn
 
(2S,3S,6S)-6-((benzyloxy)methyl)-3-ethyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.51) 
 
A 1.0 M solution of CuCN•2LiCl was prepared in dry THF and sealed under argon. 
0.46 mL of this solution (0.46 mmol) was transferred via cannula to a flame-dried 5 
mL RB flask and cooled to -78 ºC.  To this was added Et2Zn (0.46 mL, 0.46 mmol) in 
drop-wise manner via syringe w/ stirring and allowed to slowly warm to -30 ºC.  This 
mixture was then added drop-wise via cannulation to a solution of oligomeric-bound 
2.48 (25 mg, 0.046 mmol) in THF (0.2 M) at -30 ºC and allowed to slowly warm to rt 
overnight.  Notable sequestration of the copper salt byproducts was noted after 
several hours.  After such time, the reaction was quenched with 10% HCl, extracted 
w/ EtOAc ( 3 x 8 mL), and dried over MgSO4.  This was then passed through a silica 
SPE to yield the product 2.51 (11.2 mg, 0.031 mmol, 68 %) as a clear oil. 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-ethyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.51) 
 
[α]20D = -13.6 º (c = 0.46, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.28 (m, 
6H), 7.28 – 7.20 (m, 3H), 7.17 (td, J = 7.4, 0.7 Hz, 1H), 5.95 – 5.82 (m, 1H), 5.85 – 
5.83 (m, 1H), 5.11 (td, J = 5.2, 2.5 Hz, 1H), 4.60 − 4.55 (m, 2H), 3.74 (ddd, J = 10.3, 
5.7, 1.5 Hz, 1H), 3.66 (ddd, J = 10.3, 5.3, 1.6 Hz, 1H), 2.56 – 2.41 (m, 1H), 2.02 – 
1.86 (m, 1H), 1.79 (ddd, J = 21.2, 14.0, 7.3 Hz, 1H), 1.13 – 0.99 (t, J = 7.4 Hz, 3H).; 
13C NMR (126 MHz, CDCl3) δ ppm 150.5 (d, JCOP = 8.1 Hz), 137.9, 130.0, 128.7, 
128.0, 127.9, 126.9 (d, 2JCP = 7.3 Hz), 126.4 (d, JCCOP = 15.3 Hz), 125.1, 120.3 (d, 
JCCOP = 4.6 Hz), 79.5 (d, JCP = 8.2 Hz), 73.9, 72.0 (d, JCP = 7.5 Hz), 33.8, 32.8, 29.9, 
23.8 (d, JCP = 3.0 Hz), 11.8 (d, JCP = 9.8 Hz); 31P NMR (162 MHz, CDCl3) δ ppm 
20.9; FTIR (thin film) 3029, 2922, 1591, 1491, 1454, 1207, 922 cm-1; HRMS 
calculated for C20H24O4P (M+H)+ = 359.1412; found 359.1414 (TOF MS ES+). 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-isopropyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.52) 
 
A 1.0 M solution of CuCN•2LiCl was prepared in dry THF and sealed under argon. 
0.51 mL of this solution (0.51 mmol) was transferred via cannula to a flame-dried 5 
mL RB flask and cooled to -78 ºC.  To this was added i-Pr2Zn (0.51 mL, 0.51 mmol) 
in drop-wise manner via syringe w/ stirring and allowed to slowly warm to -30 ºC.  
This mixture was then added drop-wise via cannulation to a solution of oligomeric-
bound 2.48 (25 mg, 0.046 mmol) in THF (0.2 M) at -30 ºC and allowed to slowly 
warm to rt overnight.  Notable sequestration of the copper salt byproducts was 
observed after several hours.  After such time, the reaction was quenched with 10% 
HCl, extracted w/ EtOAc (3 x 8 mL), and dried over MgSO4.  This was then passed 
through a silica SPE to yield the product (9.5 mg, 0.026 mmol, 50 %) as a clear oil.  
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-isopropyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.52) 
 
[α]20D = -13.6 º (c = 0.46, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.39 – 7.26 
(m, 7H), 7.25 – 7.21 (m, 2H), 7.16 (t, J = 7.3 Hz, 1H), 5.95 – 5.89 (m, 1H), 5.88 – 
5.76 (m, 1H), 5.13 – 5.08 (m, 1H), 4.65 – 4.54 (m, 2H), 3.78 – 3.69 (m, 1H), 3.65 
(ddd, J = 10.2, 5.5, 1.6 Hz, 1H), 2.56 – 2.47 (m, 1H), 2.41 − 2.28 (m, 1H), 1.09 (dd, J 
= 9.3, 7.5 Hz, 6H).; 13C NMR (126 MHz, CDCl3) δ ppm 150.6 (d, J = 8.4 Hz), 137.9, 
130.0, 128.6, 128.0, 127.9, 127.7 (d, JCCOP = 15.5 Hz), 125.0, 124.3 (d, 2JCP = 7.8 Hz), 
120.3 (d, JCCOP = 4.2 Hz), 79.5 (d, JCOP = 8.2 Hz), 73.9, 72.3 (d, JCCOP = 7.5 Hz), 38.5 
(d, 1JCP = 129.2 Hz) 28.7, 21.0 (d, 2JCP = 13.9 Hz); 31P NMR (162 MHz, CDCl3) δ 
ppm 20.2; FTIR (thin film) 3032, 2961, 1722, 1591, 1491, 1454, 1205, 924 cm-1; 
HRMS calculated for C21H25O4PNa (M+Na)+ = 395.1388; found 395.1373 (TOF MS 
ES+). 
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Procedure for formation of 5-norbornene-2-exo, 3-exo-dimethyl benzyl 
phosphate (2.61) (OBP monomer) and substituted analogues (2.61a, e− l) 
 
To a flame-dried 25 mL RB flask under argon atmosphere was added benzyl alcohol 
(0.88 mL, 8.5 mmol) via syringe followed by addition of DCM (8.5 mL) and 
anhydrous NMI (0.97 mmol).  To this mixture was added phosphorochloridate 2.26 in 
several portions (1.0 g, 4.3 mmol) with stirring.  The reaction turned light yellow in 
color and was complete by TLC in 2-3 hours.  The reaction was then concentrated in 
vacuo and purified by flash chromatography (4:1 Hexanes: EtOAc up to 1:2 Hexanes 
to EtOAc) to afford OBP monomer 2.61 (1.1 g, 3.6 mmol, 85% yield) as a white 
solid. 1H NMR (CDCl3, 400 MHz) δ ppm 7.44 − 7.36 (m, 5H), 6.21 (s, 2H), 5.12 (d, 
J = 7.8 Hz, 2H), 4.16 (dd, J = 12.1, 3.9 Hz, 1H), 4.10 (dd, J = 12.1, 4.0 Hz, 1H), 4.02 
− 3.96 (m, 2H), 2.51 (m, 2H), 2.18 − 2.09 (m, 2H), 1.32 (s, 2H); 13C NMR (CDCl3, 
125 MHz) δ ppm 137.4, 135.7, 128.7, 128.1, 69.1 (d, JCOP = 7.9 Hz), 68.7 (d, JCOP = 
5.1 Hz), 44.7, 43.5, 41.9; 31P NMR (CDCl3, 162 MHz) δ ppm 7.26, 1.07 (dr = 33:1); 
FTIR (thin film) 2962, 2927, 1461, 1274, 1255, 1056, 1006, 975 cm-1; HRMS 
calculated for C16H19O4PNa (M+Na)+ = 329.0919; found 329.0914 (TOF MS ES+) 
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Procedure for formation of OBP20 (2.62) and substituted analogs (2.62e− l) 
 
To a flame-dried 250 mL RB flask under argon was added 3.1 g (9.8 mmol) of OBP 
monomer 2.61 and solubilized in 100 mL of anhydrous, degassed DCM.  To this was 
added 404 mg (0.48 mmol) of cat 1G with water-cooled condenser and immediately 
placed at 50 ºC in an oil bath and allowed to stir for 2-3 hours while monitored via 
TLC (100 % EtOAc, Rf = 0).  Upon completion, the reaction was allowed to cool 
below reflux followed by the addition of 0.5 mL ethyl vinyl ether (5.0 mmol) and 
allowed to stir for 0.5 hr.  After such time was added Na2CO3 (1.1 g, 10 mmol) 
followed by drop-wise addition of tetrakis(hydroxymethyl) phosphonium chloride 
(THPC) (1.4 mL, 10 mmol) 80% in H2O while stirring.  Noticeable gas evolution 
occurred during the addition.  The reaction was refluxed until complete disappearance 
of the purple color was observed.  After which time the reaction was cooled to room 
temperature and washed with deionized water (2 x 30 mL) and brine (1 x 30 mL).  
The organic layer was then dried over MgSO4, filtered through a celite plug, and 
concentrated in vacuo until slight viscosity of the solution is observed.  The resulting 
solution was precipitated drop-wise in Et2O (1 L) with stirring.  Stirring was 
continued for 10 minutes after which time the oligomer was filtered through a 200 
mL medium-sintered glass frit and dried in vacuo to yield the desired oligomeric 
benzyl phosphate (OBP) 2.62 as a white powder in quantitative yield.  Subsequent 
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solubility tests (Table 6.1) confirmed the appropriate solvents to use for the 
benzylation reaction sequence. 
 
Table 6.1  Solubility profile of OBP20  2.62 
 
solvent conditions results 
CH2Cl2 RT w/ stirring soluble 
CHCl3 RT w/ stirring soluble 
THF reflux w/ stirring soluble 
DME reflux w/ stirring miscible 
1,3 
dioxane reflux w/ stirring soluble 
DMF RT w/ stirring soluble 
Toluene reflux w/ stirring insoluble 
CH3CN reflux w/ stirring insoluble 
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General procedure for benzylation using OBP20 (2.62) and substituted analogs 
(2.62e− l) 
 
O NH
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O N Bn
 
 
To a 1-dram vial w/ teflon cap was added OBP20 2.62 (1.3−3.0* equiv) followed by 
addition of tetrabutylammonium iodide (0.1 − 0.2 equiv), K2CO3 or Cs2CO3 (3 equiv), 
and solvent (CHCl3 or THF) (0.3M).  The mixture was stirred rapidly until the 
oligomer dissolved (< 30 s) followed by subsequent addition of amine nucleophile.  
The reaction was sealed under argon and heated to 80 ºC w/ stirring.  Reaction time 
varied between nucleophiles (2−24 hrs) after which time noticeable precipitation of 
the monoanionic oligomeric phosphate occurred.  After such time the reaction was 
cooled to rt and transferred via 1 mL syringe to a 25 mL RB flask containing approx. 
200 mg SiO2 and then concentrated in vacuo.  Alternatively the reaction was 
precipitated into 8−10 mL of diethyl ether with stirring.  The crude mixture of either 
case was then filtered via SiO2 packed 6 mL SPE and rinsed several times with a 
mixture of hexanes:EtOAc (50% up to 100%).  The resulting eluent was then 
concentrated in vacuo to yield the benzylated products in good to excellent yields and 
purities.  *3.0 equiv. was only used for the dibenzylation of piperazine.  All other 
monobenzylations were performed with 1.3−1.5 equiv. of OBP20 or analogs thereof. 
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To a flame-dried pressure tube (2.0–5.0 mL) charged with (S)-7-bromo-3-phenyl-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide 2.65a (50 mg, 0.14 mmol) was 
added K2CO3 (59 mg, 0.42 mmol), Bu4NI (10 mg, 0.042 mmol), OBP20 (86mg, 0.28 
mmol) and THF (1.4 mL, 0.1 M).  The reaction vessel was sealed and stirred at 80 ºC 
overnight.  The reaction was then allowed to cool to rt and 4:1 hexane: EtOAc (3 mL) 
was added, stirred for an additional 10 minutes and the reaction mixture was filtered 
through a silica SPE cartridge.  Evaporation of solvent under reduced pressure 
afforded (S)-2-benzyl-7-bromo-3-phenyl-3,4-dihydro-2H-benzo[b][1,4,5] oxathia-
zepine 1,1-dioxide 2.66a as a white solid (54 mg, 99%). 
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5-norbornene-2-exo, 3-exo-dimethyl (3,4-(methylenedioxy)benzyl) phosphate 
(2.61a) (major P-diastereomer)  
 
1H NMR (CDCl3, 400 MHz) δ ppm 6.87 (s, 1H), 6.82 − 6.77 (m, 2H), 6.22 (m, 2H), 
5.96 (s, 2H), 4.43 (s, 2H), 4.23 − 4.16 (m, 4H), 2.55 (s, 2H), 2.16 − 2.06 (m, 2H), 
1.48 (d, J = 9.2 Hz, 1H), 1.35 (d, J = 7.7 Hz, 1H); 13C NMR (CDCl3, 125 MHz) δ 
ppm 147.7, 147.1, 137.3, 134.9, 132.0, 121.4, 108.5, 108.0, 100.9, 71.6, 68.8 (JCOP = 
6.1 Hz), 44.8, 43.7, 42.1; 31P NMR (CDCl3, 162 MHz) δ ppm 2.25, -3.67 (dr = 12:1); 
FTIR (thin film) 2964, 2902, 2358, 1490, 1442, 1251, 1118, 1039, 1010, 975 cm-1; 
HRMS calculated for C17H19O6PNa (M+Na)+ = 373.0817; found 373.0820 (TOF MS 
ES+). 
*Analogs 2.61a-d were not utilized or polymerized due to their instability 
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5-norbornene-2-exo, 3-exo-dimethyl (2-methylbenzyl) phosphate (2.61e) (major 
P-diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm 7.39 (d, J = 7.1, 1H), 7.28 (d, J = 7.3, 1H), 7.23 
(t, J = 6.9, 2H), 6.22 – 6.18 (m, 2H), 5.16 (d, J = 6.9, 2H), 4.15 (dd, J = 12.1, 4.0, 
1H), 4.10 (dd, J = 12.1, 4.0, 1H), 4.02 – 3.92 (m, 2H), 2.51 (s, 2H), 2.42 (s, 3H), 2.18 
– 2.06 (m, 2H), 1.31 (s, 2H).; 13C NMR (CDCl3, 125 MHz) δ ppm δ 137.4, 136.8, 
133.8, 130.5, 128.9, 126.1, 69.1 (d, JCOP = 7.9 Hz), 67.0 (d, JCOP = 5.0 Hz), 44.7, 43.5, 
41.9, 18.8; 31P NMR (CDCl3, 162 MHz) δ ppm 2.59, -3.58 (dr = 5:1); FTIR (thin 
film) 2964, 1317, 1292, 1257, 1091, 1064, 1010 cm-1; HRMS calculated for 
C17H21O4PNa (M+Na)+ = 343.1075; found 343.1076 (TOF MS ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (3,5-dimethoxybenzyl) phosphate (2.61f) 
(major P-diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm 6.56 (d, J = 2.2 Hz, 2H), 6.45 (t, J = 2.2 Hz, 1H), 
6.22 – 6.19 (m, 2H), 5.05 (dd, J = 7.6, 2.7 Hz, 2H), 4.23 – 4.16 (m, 1H), 4.13 (dd, J = 
12.1, 4.1 Hz, 1H), 4.07 − 4.00 (m, 2H), 3.82 (s, 6H), 2.56 – 2.48 (m, 2H), 2.14 (d, J = 
12.0 Hz, 2H), 1.36 – 1.31 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ ppm 161.2, 138.1, 
137.6, 106.0, 105.6, 100.6, 69.4 (d, JCOP = 7.7 Hz), 68.8 (d, JCOP = 4.7 Hz), 55.6, 45.0, 
43.7, 42.1; 31P NMR (CDCl3, 162 MHz) δ ppm 2.49, -3.65 (dr = 5:1); FTIR (thin 
film) 2966, 2904, 1596, 1460, 1431, 1325, 1292, 1205, 1153, 1058, 1012 cm-1; 
HRMS calculated for C18H23O6PNa (M+Na)+ = 389.1130; found 389.1136 (TOF MS 
ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (4-bromobenzyl) phosphate (2.61g) (major 
P-diastereomer)  
 
1H NMR (CDCl3, 400 MHz) δ ppm 7.51 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.3 Hz, 
2H), 6.20 – 6.17 (m, 2H), 5.05 (d, J = 8.2 Hz, 2H), 4.18 – 4.14 (m, 1H), 4.13 – 4.08 
(m, 1H), 4.04 – 3.93 (m, 2H), 2.54 – 2.48 (m, 2H), 2.17 – 2.07 (m, 2H), 1.31 (s, 2H); 
13C NMR (CDCl3, 125 MHz) δ ppm 137.3, 134.6, 131.7, 129.7, 122.7, 69.1 (d, JCOP = 
8.0 Hz), 67.9 (d, JCOP = 5.2 Hz), 44.7, 43.5, 41.8; 31P NMR (CDCl3, 162 MHz) δ ppm 
2.56, -3.75 (dr = 7.5:1); FTIR (thin film) 3060, 2966, 2879, 1488, 1290, 1253, 1116, 
1066, 1033, 1008, 975 cm-1; HRMS calculated for C16H18O4BrPNa (M+Na)+ = 
407.0024; found 407.0025 (TOF MS ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (4-chlorobenzyl) phosphate (2.61h) (major 
P-diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm 7.37 (s, 4H), 6.22 – 6.20 (m, 2H), 5.08 (d, J = 8.2 
Hz, 2H), 4.18 (dd, J = 4.0, 12.1 Hz, 1H), 4.11 (dd, J = 4.1, 12.1 Hz, 1H), 4.04 − 3.93 
(m, 2H), 2.55 – 2.48 (m, 2H), 2.19 − 2.09 (m, 2H), 1.34 (s, 2H); 13C NMR (CDCl3, 
125 MHz) δ ppm 137.3, 134.7, 134.2, 129.6, 128.9, 69.2 (d, JCOP = 7.9 Hz) 68.1 (d, 
JCOP = 5.0 Hz), 44.8, 43.6, 41.9; 31P NMR (CDCl3, 162 MHz) δ ppm 2.65, -3.79 (dr = 
6.5:1); FTIR (thin film) 3061, 2966, 1493, 1292, 1065, 1032, 1011, 976, 849, 714 
cm-1; HRMS calculated for C16H18ClO4PNa (M+Na)+ = 363.0529; found = 363.0521 
(TOF MS ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (4-fluorobenzyl) phosphate (2.61i) (major P-
diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm 7.44 – 7.38 (m, 2H), 7.10 − 7.05 (m, 2H), 6.21 – 
6.17 (m, 2H), 5.08 (d, J = 8.3 Hz, 2H), 4.17 (dd, J = 12.1, 4.1 Hz, 1H), 4.10 (dd, J = 
12.1, 4.1 Hz, 1H), 4.03 − 3.92 (m, 2H), 2.54 – 2.47 (m, 2H), 2.17 – 2.05 (m, 2H), 
1.32 (s, 2H); 13C NMR (CDCl3, 125 MHz) δ ppm 162.9 (d, 1JCF = 248 Hz) 137.3, 
131.5 (q, 4JCF = 3.3 Hz), 130.3 (d, 3JCF = 8.4 Hz), 115.6 (d, 2JCF = 21.7 Hz), 69.1 (d, 
JCOP = 8.1 Hz), 68.0 (d, JCOP = 5.1 Hz), 44.8, 43.5, 41.9; 31P NMR (CDCl3, 162 MHz) 
δ ppm 2.57, -3.69 (dr = 8:1); FTIR (thin film) 3064, 2976, 2907, 1494, 1463, 1291, 
1253, 1061, 1010, 975 cm-1; HRMS calculated for C16H18O4FPNa (M+Na)+ = 
347.0824; found 347.0826 (TOF MS ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (4-nitrobenzyl) phosphate (2.61j) (major P-
diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm δ 8.28 – 8.24 (m, 2H), 7.60 (d, J = 8.8 Hz, 2H), 
6.28 – 6.17 (m, 2H), 5.20 (d, J = 8.0 Hz, 2H), 4.25 (dd, J = 12.1, 4.0 Hz, 1H), 4.20 
(dd, J = 12.1, 4.0 Hz, 1H), 4.10 − 4.02 (m, 2H), 2.58 – 2.53 (m, 2H), 2.16 (m, 2H), 
1.36 − 1.34 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ ppm 147.9, 142.8, 137.3, 134.9, 
128.2, 123.9, 69.4 (d, JCOP = 8.1 Hz), 67.1 (d, JCOP = 4.7 Hz), 44.8, 43.5, 41.9; 31P 
NMR (CDCl3, 162 MHz) δ ppm 2.65, -3.88 (dr = 42:1); FTIR (thin film) 3396, 
2968, 1606, 1517, 1346, 1286, 1178, 1116, 1035, 1012 cm-1; HRMS calculated for 
C16H18O6NPNa (M+Na)+ = 374.0769; found 374.0770 (TOF MS ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (3-dimethylaminobenzyl) phosphate (2.61k) 
(major P-diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm 7.30 – 7.23 (m, 1H), 6.81 − 6.71 (m, 3H), 6.23 – 
6.19 (m, 2H), 5.08 (d, J = 7.5 Hz, 2H), 4.19 (dd, J = 12.2, 3.9 Hz, 1H), 4.12 (dd, J = 
12.1, 4.1 Hz, 1H), 4.06 − 3.98 (m, 2H), 2.98 (s, 6H), 2.52 (m, 2H), 2.17 − 2.09 (m, 
2H), 1.35 – 1.29 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ ppm 150.6, 137.4, 136.4, 
129.3, 116.0, 112.6, 112.0, 69.3 (d, JCOP = 8.4 Hz), 69.0 (d, JCOP = 5.2 Hz), 44.7, 43.4, 
42.3, 40.4; 31P NMR (CDCl3, 162 MHz) δ ppm 2.44, -3.49 (dr = 6:1); FTIR (thin 
film) 2962, 2900, 2804, 1606, 1502, 1353, 1292, 1253, 1118, 1064, 1010 cm-1; 
HRMS calculated for C18H24NO4PNa (M+Na)+ = 372.1341; found 372.1327 (TOF 
MS ES+). 
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5-norbornene-2-exo, 3-exo-dimethyl (3-trifluoromethylbenzyl) phosphate (2.61l) 
(major P-diastereomer) 
 
1H NMR (CDCl3, 400 MHz) δ ppm 7.67 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 8.0 Hz, 
2H), 6.23 – 6.21 (m, 2H), 5.17 (d, J = 7.9 Hz, 2H), 4.22 (dd, J = 12.0, 4.0 Hz, 1H), 
4.17 (dd, J = 12.1, 4.1 Hz 1H), 4.08 – 3.99 (m, 2H), 2.58 – 2.52 (m, 2H), 2.19 − 2.14 
(m, 2H), 1.37 – 1.34 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ ppm 139.9 (d, 3JCF = 
7.3 Hz), 137.5, 131.0 (q, 2JCF = 32.5 Hz), 128.5, 125.9 (q, 4JCF = 3.7 Hz), 123.8 (q, 1JCF 
= 272 Hz), 69.5 (d, JCOP = 8.0 Hz), 67.9 (d, JCOP = 4.9 Hz), 45.0, 43.8, 42.1; 31P NMR 
(CDCl3, 162 MHz) δ ppm 2.72, -3.81 (dr = 8:1); FTIR (thin film) 3068, 2968, 1622, 
1421, 1327, 1285, 1165, 1117, 1067, 1041, 1012, 976, 903, 852, 712 cm-1; HRMS 
calculated for C17H18F3O4PNa (M+Na)+ = 397.0792; found 397.0790 (TOF MS ES+). 
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N,N-dimethyl-3-(morpholinomethyl)aniline (2.64k) 
1H NMR (CDCl3, 500 MHz) δ ppm 7.21 − 7.18 (m, 1H), 6.74 − 6.70 (m, 2H), 6.66 
(dd, J = 8.1, 2.3 Hz, 1H), 3.77 – 3.70 (m, 4H), 3.48 (s, 2 H), 2.96 (s, 6H), 2.47 (s, 
4H); 13C NMR (CDCl3, 125 MHz) δ ppm 149.0, 136.9, 127.2, 115.9, 111.7, 109.7, 
65.4, 62.3, 52.0, 39.0; FTIR (thin film) 2924, 2802, 1659, 1605, 1497, 1454, 1532, 
1117, 1001, 868, 771, 694 cm-1; HRMS calculated for C13H21N2O (M+H)+ = 
221.1654; found 221.1648 (TOF MS ES+). 
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N,N-dimethyl-3-((4-phenylpiperazin-1-yl)methyl)aniline (2.64k′) 
1H NMR (CDCl3, 400 MHz) δ ppm 7.34 − 7.29 (m, 3H), 7.04 − 7.00 (m, 2H), 6.93 (t, 
J = 7.3, 1H), 6.90 − 6.80 (m, 2H), 6.75 (dd, J = 7.8, 2.1 Hz, 1H), 3.62 (s, 2H), 3.34 – 
3.25 (m, 4H), 3.04 (s, 6H), 2.75 – 2.67 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ ppm 
151.6, 150.9, 129.3, 129.1, 119.7, 117.9, 116.2, 113.6, 111.7 63.7, 53.3, 49.3, 40.9; 
FTIR (thin film) 2877, 2810, 1601, 1501, 1452, 1350, 1229, 758, 692 cm-1; HRMS 
calculated for C19H26N3 (M+H)+ = 296.2127; found 296.2124 (TOF MS ES+) 
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(S)-2-benzyl-7-bromo-3-phenyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-
dioxide (2.66a)  
[α]D20 =  + 48.0 (c = 1.7, CHCl3); 1H NMR (500 MHz, CDCl3) δ ppm 7.78 (d, J = 8.5 
Hz, 1H), 7.35 (dd, J = 7.5, 2.0 Hz, 2H), 7.32 – 7.27 (m, 4H), 7.21 (d, J = 1.8 Hz, 1H), 
7.20 – 7.14 (m, 3H), 7.07 – 7.03 (m, 2H), 5.26 – 5.18 (m, 1H), 4.91 (dd, J = 10.7, 3.9 
Hz, 1H), 4.66 (d, J = 15.2 Hz, 1H), 4.56 (dd, J = 13.5, 4.1 Hz, 1H), 4.18 (d, J = 15.2 
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 155.4, 135.4, 134.7, 131.0, 129.2, 128.7, 
128.6, 128.5, 128.4, 127.9, 127.9, 127.2, 125.9, 124.3, 73.3, 63.8, 53.2; FTIR (thin 
film) 3051, 2980, 1598, 1355, 1340, 1164 cm-1; HRMS calculated for 
C21H18BrNO3SNa (M+Na)+ = 466.0088: found 464.0084 (TOF MS ES+).  
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(S)-7-bromo-2-(3,5-dimethoxybenzyl)-3-phenyl-3,4-dihydro-2H benzo[b] 
[1,4,5]oxathiazepine 1,1-dioxide (2.66b) 
 [α]D20 =  + 17.2 (c = 1.18, CHCl3); 1H NMR (500 MHz, CDCl3) δ ppm 7.80 (d, J = 
8.5 Hz, 1H), 7.43 (dd, J = 7.8, 1.4 Hz, 2H), 7.36 – 7.30 (m, 3H), 7.30 – 7.26 (m, 1H), 
7.22 (d, J = 1.9 Hz, 1H), 6.29 (t, J = 2.3 Hz, 1H), 6.17 (d, J = 2.2 Hz, 2H), 5.31 (dd, J 
= 15.7, 8.8 Hz, 1H), 4.85 (dd, J = 10.9, 4.1 Hz, 1H), 4.70 (d, J = 15.4 Hz, 1H), 4.52 
(dd, J = 13.6, 4.2 Hz, 1H), 4.09 (d, J = 15.4 Hz, 1H), 3.56 (s, 6H); 13C NMR (126 
MHz, CDCl3) δ ppm 160.7, 155.3, 137.7, 134.7, 130.8, 129.0, 128.7, 128.5, 128.0, 
127.1, 125.7, 124.2, 106.0, 100.3, 73.4, 63.9, 55.1, 53.5; FTIR (thin film) 3057, 
2955, 1600, 1358, 1339, 1164 cm-1; HRMS calculated for C23H22BrNO5SNa (M+Na)+ 
= 503.0402; found 503.0405 (TOF MS ES+). 
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 (S)-7-bromo-2-(4-fluorobenzyl)-3-phenyl-3,4-dihydro-2H-benzo[b][1,4,5] oxa 
thiazepine 1,1-dioxide (2.66c)  
[α]D20 = 88.2 (c = 1.04, CHCl3); 1H NMR (500 MHz, CDCl3) δ ppm 7.77 (d, J = 8.5 
Hz, 1H), 7.35 – 7.31 (m, 3H), 7.31 – 7.27 (m, 4H), 7.24 (d, J = 1.9 Hz, 1H), 7.01 (dd, 
J = 8.6, 5.3 Hz, 2H), 6.84 (ddd, J = 10.7, 5.9, 2.5 Hz, 2H), 5.19 – 5.11 (m, 1H), 4.94 
(d, J = 7.0 Hz, 1H), 4.60 (dd, J = 12.9, 3.4 Hz, 1H), 4.58 (s, 1H), 4.15 (d, J = 15.3 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ ppm 162.3 (d, 1JCF = 247 Hz), 134.6, 131.3 (d, 
4JCF = 1.7 Hz), 130.2 (d, 3JCF = 8.3 Hz), 130.1, 129.3, 128.7, 128.6, 127.9, 127.4, 
126.1, 124.6, 115.3, 115.1, (d, 2JCF = 21.5 Hz), 73.2, 63.9, 52.2; FTIR (thin film) 
3057, 2955, 1600, 1358, 1339, 1164 cm-1; HRMS calculated for C21H17BrFNO3SNa 
(M+Na)+ = 483.9994; found 483.9989 (TOF MS ES+). 
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(S)-7-bromo-2-(4-fluorobenzyl)-3-isobutyl-3,4-dihydro-2H-benzo[b][1,4,5] 
oxathiazepine 1,1-dioxide (2.66d) 
 [α]D20 =  + 40.3 (c = 2.25, CHCl3); 1H NMR (500 MHz, CDCl3) δ ppm 7.70 (d, J = 
8.4 Hz, 1H), 7.36 – 7.30 (m, 3H), 7.23 (d, J = 1.8 Hz, 1H), 7.04 – 6.98 (m, 2H), 4.60 
(t, J = 11.9 Hz, 1H), 4.39 (d, J = 14.7 Hz, 1H), 4.31 (dd, J = 13.2, 4.5 Hz, 1H), 4.05 
(d, J = 14.8 Hz, 1H), 3.81 (s, 1H), 1.55 (d, J = 8.5 Hz, 2H), 1.34 (td, J = 13.3, 6.6 Hz, 
1H), 1.29 – 1.22 (m, 1H), 0.65 (dd, J = 18.7, 6.5 Hz, 6H); 13C NMR (126 MHz, 
CDCl3) δ ppm 162.6 (d, 1JCF = 247 Hz), 156.1, 131.7 (d, 4JCF = 3.1 Hz), 131.1, 130.6 
(d, 3JCF = 8.2 Hz), 130.2 127.3 126.7, 124.9, 115.4 (d, 2JCF = 21.5 Hz) 74.4, 59.6, 39.5, 
30.9, 24.7, 22.3, 22.1; FTIR (thin film) 3045, 2970, 1605, 1365, 1335, 1164 cm-1; 
HRMS calculated for C19H21BrFNO3SNa (M+Na)+ = 464.0307; found 464.0308 
(TOF MS ES+). 
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General procedure for palladium-catalyzed reductive Heck and in situ ROMP 
Pd(OAc)2
Ph3P, PMP
Zn, DMF
 60 °C
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3.15 3.16 3.17
+
S-1
+  excess
      3.15
3.16a-j
 
To a 25 mL round-bottom flask, sultam 3.15 (50 mg, 0.174 mmol, 1.5 equiv.), 
aryl iodide (28.3 mg, 0.12 mmol, 1.0 equiv.), Pd(OAc)2 (4 mg, 0.017 mmol, 15 
mol%), PPh3 (9 mg, 0.036 mmol, 30 mol%), PMP (9.3 mg, 0.06 mmol, 0.5 equiv.), 
Zn (227 mg, 3.48 mmol, 10 equiv.) and HCO2H (0.00856 mL, 0.12 mmol, 1.0 equiv.) 
were added under argon and followed by addition of dry DMF (6 mL). The resulting 
mixture was heated w/ stirring at 60 ºC for 14 hours until the iodide was consumed as 
indicated by TLC.  The reaction mixture was allowed to cool to room temperature 
and DMF was evaporated, followed by the addition of 4:1 EtOAc/hexanes (30 mL).  
This mixture was extracted 4 times with brine using 5 mL each. The organic layer 
was separated and dried over MgSO4 and filtered through a pad of Celite. The filtrate 
was concentrated in vacuo and the crude product was treated with catalyst 2G (2.43 
mg, 0.00287 mmol) in deoxygenated CH2Cl2 (0.1 M) at 50 ºC overnight in a round-
bottom flask under argon w/ water condenser.  The reaction mixture was allowed to 
cool to rt and 0.1 mL of ethyl vinyl ether (EVE) was added and stirred at room 
temperature for 30 min.  The reaction mixture was concentrated in vacuo until slight 
viscosity is observed and precipitated drop-wise into Et2O (40 mL).  Simple filtration 
through a medium glass frit afforded the dry (reclaimed) oligomer 3.17.  The filtrate 
was concentrated in vacuo and filtered through a SiO2 SPE with 50% EtOAc/hexanes 
to afford reductive Heck products 3.16a−j.  
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General procedure for Suzuki-coupling (reclaimed scaffold) and Vanishing 
Support Protocol (VSP) 
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3. LiBH4
H H
1. Pd(dppf)Cl2
R2-B(OH)2
R2
HO
3.22
3.23
VSP  
In a 15–20 mL round bottom flask w/ condenser under argon was added 
oligomeric-bound sultam 3.22 (100 mg, 0.25 mmol, 20-mer), Cs2CO3 (155 mg, 1 
mmol), Pd(dppf)Cl2 (37 mg, 50 µmol), boronic acid (155 mg, 1 mmol), and dry 
THF:DMF (5:1 v/v, 2.5 mL, 0.1 M).  The reaction was stirred at 70 ºC for 14-16 
hours and allowed to return to 25 ºC.  The reaction was quenched via addition of 
aqueous NaOH (5 mL, 2.5 M) and stirred for 30-45 min.  The reaction was washed w/ 
additional aqueous NaOH (3 x 5 ml, 2.5 M), dried (MgSO4), and rinsed through a pad 
of Celite w/ multiple portions of CH2Cl2.  The oligomeric-containing filtrate was 
concentrated in vacuo until slightly viscous and precipitated drop-wise into Et2O (200 
mL).  Filtration through medium glass frit and wash w/ Et2O yields a light grey, 
powdered oligomer in excellent yield.  This was added to a 50 mL round bottom 
flask, dissolved in CH2Cl2, and cooled to -78 ºC.  This solution was then subjected to 
ozonolysis via bubbling ozone gently through the solution in the open flask.  After a 
period of 1 hour the solution was allowed to warm to -30 ºC while being purged with 
an argon-filled balloon and 4 in. needle.  Excess solid LiBH4 was added to the flask at 
-30 ºC w/ stir and the flask was sealed over argon.  The resulting solution was stirred 
and allowed to return to room temperature overnight.  The reaction was quenched 
with water over 1 hour, extracted w/ chloroform (3 x 5 mL), and concentrated in 
vacuo to yield the pure dimethanolic sultam product 3.23 in good yields over the 
three-step process (30-48%).  No further purification was carried out. 
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Procedure for Dihydroxylation and in-situ ROMP 
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To a 10 mL round bottom flask was added sultam 3.24 (100 mg, 0.25 mmol), citric 
acid (40 mg, 0.19 mmol), N-methyl morpholine N-oxide (22 mg, 0.125 mmol), OsO4 
(5% in H2O) (5 % by weight, 64 µL), and acetone:DMF (3:1 v/v, 2.5 mL, 0.1 M).  
This mixture was then stirred at RT over argon.  After monitoring over 6 hours via 
TLC, the reaction was quenched with sodium bisulfite (NaHSO3) and stirred at RT 
for an additional 30 min.  This mixture was extracted with CHCl3 (3 x 7 mL), dried 
(MgSO4), and filtered through a pad of Celite.  The filtrate was then concentrated in 
vacuo and reconstituted in deoxygenated CH2Cl2 followed by transfer into a 5 mL 
Kimex pressure tube.  To this was added catalyst 2G (5 mol%, 0.1 M), assuming an 
initial 50% conversion of the dihydroxylated product, and placed over argon w/ 
stirring at 50 ºC for 2 hours.  The reaction was allowed to cool to rt followed by the 
addition of EVE (0.1 mL).  This was allowed to stir for an additional 15−20 min.  The 
white, crystalline product 3.25 precipitated out during the ROM polymerization event 
and was collected by filtration via Büchner funnel with repeated rinsing (CH2Cl2) and 
dried under vacuum to yield (47 mg, 0.11 mmol, 86 %).  The oligomeric-containing 
filtrate (reclaimed) was then concentrated in vacuo until slightly viscous followed by 
drop-wise precipitation in Et2O (100 mL).  Filtration through medium glass frit 
yielded the reclaimed oligomeric scaffold 3.26 (50 mg), which was dried in vacuo for 
20 min.  No further purification was needed. 
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(±) tert-butyl3,6,7,7a-tetrahydro-2H-3a,6-epoxybenzo[d] isothiazole-2-
carboxylate 1,1-dioxide  (3.15)  
 
1H NMR (500 MHz, CDCl3) δ ppm 6.55 (dd, J = 5.8, 1.7 Hz, 1H), 6.27 (d, J = 6.0 
Hz, 1H), 5.20 (dd, J = 4.7, 1.6 Hz, 1H), 4.20 (q, J = 12.3 Hz, 2H), 3.30 (dd, J = 7.6, 
3.2 Hz, 1H), 2.66 (ddd, J = 12.5, 4.6, 3.2 Hz, 1H), 1.81 (dd, J = 12.5, 7.7 Hz, 1H), 
1.48 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 149.7, 140.5, 132.7, 88.1, 84.4, 
79.5, 62.2, 47.1, 30.1, 28.0; FTIR (neat) 1720, 1330, 1170, 1135, 983 cm-1; HRMS 
calculated for C12H17NO5SNa (M+Na)+ = 310.0725; found 310.0698 (TOF MS ES+). 
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(±) tert-butyl-5-(4-acetylphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16a) 
  
1H NMR (500 MHz, CDCl3) δ ppm 7.93 (d, J = 8.2 Hz, 2H); 7.40 (d, J = 8.2 Hz, 2H), 
4.76 (d, J = 5.4 Hz, 1H), 4.35 (d, J = 12.3 Hz, 1H), 3.98 (d, J = 12.3 Hz, 1H), 3.70 
(dd, J = 8.5, 4.1 Hz, 1H), 3.17 (dd, J = 8.7, 5.2 Hz, 1H), 2.78 (dt, J = 13.3, 4.7 Hz, 
1H), 2.62 (s, 3 H), 2.45 (dd, J = 12.6, 8.8 Hz, 1H), 2.31 (dd, J = 13.4, 8.3 Hz, 1H), 
1.91 (dd, J = 12.8, 5.2 Hz, 1H), 1.58 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 
197.5, 149.6, 149.3, 135.9, 128.9, 127.2, 85.7, 84.5, 83.4, 65.2, 48.2, 46.6, 41.9, 35.3, 
28.0, 26.6; FTIR (neat) 1720, 1679, 1332, 1309, 1135 cm-1; HRMS calculated for 
C20H25NO6SNa (M+Na)+ = 430.1300; found 430.1296 (TOF MS ES+). 
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(±) tert-butyl-5-(4-acetylphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16b)  
 
1H NMR (500 MHz, CDCl3) δ ppm 7.16 (dd, J = 8.7, 5.2 Hz, 2H), 6.92 (dd, J = 8.5, 
4.4 Hz, 2H), 4.62 (d, J = 5.0 Hz, 1H), 3.87 (d, J = 12.3 Hz, 1H), 3.58 (dd, J = 8.5, 4.1 
Hz, 1H), 2.99 (dd, J = 8.8, 5.4 Hz, 1H), 2.65 (ddd, J = 13.2, 4.9, 4.6 Hz, 1 H), 2.33 
(dd, J = 12.8, 8.7 Hz, 1H), 2.18 (dd, J = 13.4, 8.4 Hz, 1H), 1.77 (dd, J = 12.8, 5.2 Hz, 
1H), 1.49 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 161.8 (d, 1JCF = 246 Hz), 
160.8, 149.7, 139.9 (d, 4JCF = 3.8 Hz), 128.5 (d, 3JCF = 7.6 Hz), 115.6 (d, 2JCF = 20.2 
Hz), 85.6, 84.5, 83.8, 47.5, 46.6, 42.2, 35.3, 28.0; FTIR (neat) 2983, 1720, 1330, 
1309, 1157, 1132 cm-1; HRMS calculated for C18H22FNO5SNa (M+Na)+ = 406.1100; 
found 406.0997 (TOF MS ES+). 
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(±) tert-butyl 5-(4-(methoxycarbonyl)phenyl)hexahydro-2H-3a,6-epoxybenzo 
[d]isothiazole-2-carboxylate 1,1-dioxide (3.16c)  
 
1H NMR (500 MHz, CDCl3) δ ppm 8.00 (d, J = 8.5 Hz, 2H), 7.34-7.40 (m, 2H), 4.76 
(d, J = 5.0 Hz, 1H), 4.35 (d, J = 12.0 Hz, 1H), 3.94-4.01 (m, 1H), 3.93 (s, 3H), 3.70 
(dd, J = 8.5, 4.1 Hz, 1H), 3.16 (dd, J = 8.8, 5.4 Hz, 1H), 2.77 (d, J = 13.2 Hz, 1H), 
2.45 (dd, J = 12.9, 8.8 Hz, 1H), 2.30 (dd, J = 13.4, 8.4 Hz, 1H), 1.91 (dd, J = 12.9, 5.4 
Hz, 1 H), 1.58 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 166.7, 149.6, 149.1, 
130.1, 128.9, 127.0, 85.7, 84.5, 83.4, 65.2, 52.1, 48.2, 46.6, 41.9, 35.3, 28.0; FTIR 
(neat) 1720, 1332, 1280, 1166, 985 cm-1; HRMS calculated for C20H25NO7SNa 
(M+Na)+ = 446.1249; found 446.1235 (TOF MS ES+). 
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(±)-tert-butyl-5-(4-hydroxyphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-
2-carboxylate 1,1-dioxide (3.16d) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.06 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.5 Hz, 2H), 
4.60 (s, 1 H), 4.23 (d, J = 12.3 Hz, 1H), 3.86 (d, J = 12.3 Hz, 1H), 3.57 (dd, J = 8.4, 
3.9 Hz, 1H), 2.94 (dd, J = 8.7, 5.2 Hz, 1H), 2.63 (dt, J = 13.3, 4.7 Hz, 1H), 2.29 (dd, J 
= 12.6, 8.8 Hz, 1H), 2.16 (dd, J = 13.2, 8.5 Hz, 1H), 1.77 (dd, J = 12.9, 5.0 Hz, 1H), 
1.48 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 154.4, 149.7, 136.5, 128.2, 115.5, 
85.6, 84.5, 83.9, 65.4, 47.5, 46.7, 42.2, 35.3, 28.0; FTIR (neat) 2979, 1722, 1515, 
1371, 1290, 1238 cm-1; HRMS calculated for C18H23NO6SNa (M+Na)+ = 404.1144; 
found 404.1120 (TOF MS ES+). 
 168 
O
S
N
O
O
O
O
H
F  
(±) tert-butyl-5-(3-fluorophenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16e) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.29 – 7.25 (m, 3H), 7.02 (ddd, J = 10.1, 8.8, 4.7 
Hz, 3H), 6.94 (td, J = 8.4, 2.2 Hz, 1H), 4.73 (d, J = 5.2 Hz, 1H), 4.32 (d, J = 12.1 Hz, 
1H), 3.94 (t, J = 9.9 Hz, 1H), 3.66 (dd, J = 8.4, 4.0 Hz, 1H), 3.08 (dd, J = 8.7, 5.2 Hz, 
1H), 2.77 – 2.69 (m, 1H), 2.41 (dd, J = 12.8, 8.8 Hz, 1H), 2.26 (dd, J = 13.4, 8.4 Hz, 
2H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H), 1.56 (d, J = 7.3 Hz, 12H), 1.50 (s, 1H); 13C 
NMR (126 MHz, CDCl3) δ ppm 163.2 (d, 1JCF = 247 Hz), 149.9, 146.7 (d, 2JCF = 7.2 
Hz), 130.5 (d, 2JCF = 8.3 Hz), 122.9 (d, 4JCF = 2.7 Hz), 114.2 (d, 3JCF = 6.2 Hz), 114.1 
(d, 3JCF = 5.4 Hz), 85.8, 84.7, 83.7, 48.1, 46.8, 42.2, 35.3, 28.2; FTIR (thin film) 
2978, 1720, 1371, 1329,1310, 1242, 1138, 984, 735 cm-1; HRMS calculated for 
C18H22FNO5SNa (M+Na)+ 406.1100; found 406.1101 (0.2 ppm). 
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(±) tert-butyl 5-(3,5-dimethylphenyl) hexahydro-2H-3a,6 epoxybenzo [d]iso 
thiazole-2-carboxylate 1,1-dioxide (3.16f) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.22 – 7.07 (m, 4H), 4.70 (d, J = 5.2 Hz, 1H), 
4.31 (d, J = 12.1 Hz, 1H), 3.94 (d, J = 12.1 Hz, 1H), 3.66 (dd, J = 8.4, 4.1 Hz, 1H), 
3.04 (dd, J = 8.7, 5.3 Hz, 1H), 2.78 – 2.63 (m, 1H), 2.38 (dd, J = 12.7, 8.8 Hz, 1H), 
2.33 (s, 3H), 2.29 – 2.21 (m, 1H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H), 1.56 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ ppm 149.7, 144.0, 138.3, 128.5, 124.7, 85.6, 84.4, 83.7, 
65.4, 48.1, 46.7, 41.9, 35.4, 28.0, 28.0, 21.3; FTIR (thin film) 2980, 1724, 1345, 
1310, 1259, 1138, 845, 735 cm-1; HRMS calculated for C20H27NO5SNa (M+Na)+ = 
416.1508; found 416.1510 (0.5 ppm). 
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(±) tert-butyl-5-(p-tolyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16g) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.20 – 7.09 (m, 4H), 4.70 (d, J = 5.2 Hz, 1H), 
4.31 (d, J = 12.1 Hz, 1H), 3.94 (d, J = 12.1 Hz, 1H), 3.65 (dt, J = 17.6, 8.8 Hz, 1H), 
3.04 (dd, J = 8.7, 5.3 Hz, 1H), 2.77 – 2.66 (m, 1H), 2.38 (dd, J = 12.7, 8.8 Hz, 1H), 
2.33 (s, 3H), 2.25 (dd, J = 13.3, 8.4 Hz, 1H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ ppm 149.8, 141.1, 136.6, 129.4, 126.8, 85.6, 84.4, 83.9, 
65.4, 47.8, 46.7, 42.1, 35.4, 28.0, 21.0; FTIR (thin film) 2982, 1722, 1333, 1167, 
1136, 735 cm-1; HRMS calculated for C19H25NO5SNa (M+Na)+ = 402.1351; found 
402.1357 (1.5 ppm). 
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(±) tert-butyl-5-(4-(thiophen-3-yl)phenyl) hexahydro-2H-3a,6-epoxybenzo [d]iso-
thiazole-2-carboxylate 1,1-dioxide (3.16h) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.29 (dd, J = 5.0, 3.0 Hz, 1H), 7.06 – 7.00 (m, 
2H), 4.71 (d, J = 5.2 Hz, 1H), 4.28 (d, J = 12.1 Hz, 1H), 3.95 – 3.90 (m, 1H), 3.67 – 
3.60 (m, 1H), 3.24 (dd, J = 8.6, 5.0 Hz, 1H), 2.75 – 2.69 (m, 1H), 2.38 – 2.32 (m, 
1H), 2.23 (dt, J = 20.7 Hz, 10.4, 1H), 1.89 – 1.82 (m, 1H), 1.56 (d, J = 4.8 Hz, 9H); 
13C NMR (126 MHz, CDCl3) δ ppm 144.6, 126.5, 126.4, 120.2, 85.7, 84.4, 83.3, 
65.3, 46.7, 43.5, 41.3, 35.5, 34.9, 30.6, 29.3, 28.0, 27.9; FTIR (thin film) 2980, 1722, 
1333, 1136, 735 cm-1; HRMS calculated for C16H21NO5S2Na (M+Na)+ = 394.0759; 
found 394.0750 (2.3 ppm). 
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(±) tert-butyl-5-(4-(trifluoromethoxy)phenyl) hexahydro-2H-3a,6-epoxybenzo [d] 
isothiazole -2-carboxylate 1,1-dioxide (3.16i) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.32 – 7.29 (m, 2H), 7.16 (d, J = 8.0 Hz, 2H), 
4.72 (d, J = 5.2 Hz, 1H), 4.31 (d, J = 12.1 Hz, 1H), 3.95 (d, J = 12.2 Hz, 1H), 3.66 
(dt, J = 8.5, 4.3 Hz, 1H), 3.10 (dd, J = 8.7, 5.2 Hz, 1H), 2.77 – 2.71 (m, 1H), 2.42 (dd, 
J = 12.8, 8.8 Hz, 1H), 2.27 (dd, J = 13.4, 8.4 Hz, 1H), 1.88 – 1.83 (m, 1H), 1.56 (s, 
9H); 13C NMR (126 MHz, CDCl3) δ ppm 149.1 (d, 1JCF = 200 Hz), 143.1, 128.6, 
121.5, 85.9, 84.8, 83.8, 65.5, 47.8, 42.4, 35.5, 28.3 cm-1; HRMS calculated for 
C19H22F3NO6SNa (M+Na)+ = 472.1018; found 472.1023 (1.1 ppm). 
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(±) tert-butyl-5-(4-cyanophenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16j) 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.62 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.3 Hz, 
2H), 4.73 (d, J = 5.2 Hz, 1H), 4.32 (d, J = 12.2 Hz, 1H), 3.96 (d, J = 12.2 Hz, 1H), 
3.69 – 3.65 (m, 1H), 3.14 (dd, J = 8.6, 5.2 Hz, 1H), 2.79 – 2.73 (m, 1H), 2.45 (dd, J = 
12.9, 8.8 Hz, 1H), 2.29 (dt, J = 13.5, 6.1 Hz, 1H), 1.87 (dd, J = 12.9, 5.1 Hz, 1H), 
1.57 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 149.5, 132.9, 129.1, 128.1, 118.9, 
111.3, 86.0, 84.9, 83.5, 65.4, 48.5, 46.7, 42.2, 35.5, 29.9, 28.3, 28.2; FTIR (thin film) 
2928, 2359, 1722, 1606, 1332, 1138, 835 cm-1; HRMS; calculated for 
C19H22N2O5SNa (M+Na)+ = 413.1147; found 413.1147 (0.0 ppm). 
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(±) hexahydro-2H-3a,7-epoxyoxepino[3,4-d]isothiazole 1,1-dioxide (3.19) 
1H NMR (500 MHz, CDCl3) δ ppm 4.63 (br s, 1H); 4.47 (d, J = 6.3 Hz, 1H), 3.80 
(dd, J = 9.3, 4.6 Hz, 1H), 3.75 (d, J = 11.7 Hz, 1H), 3.66 (t, J = 11.0 Hz, 1H), 3.61 (t, 
J = 11.2 Hz, 1H), 3.51 (d, J = 11.7 Hz, 1H), 3.23 (dd, J = 13.7, 5.8 Hz, 1H), 3.09 (t, J 
= 11.3 Hz, 1H), 2.63 (dt, J = 12.6, 6.3 Hz, 1H), 2.44 (dd, J = 13.4, 9.6 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ ppm 93.3, 78.4, 70.1, 69.9, 64.3, 44.8, 33.2; FTIR (neat) 
1771, 1615, 1460, 1371, 1312 cm-1; HRMS calculated for C7H11NO4SNa (M+Na) = 
228.0306; found 228.0291 (TOF MS ES+); Purity calculated by GC 93%. 
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            X-Ray Crystal Structure 
(±)-3a,5-bis(hydroxymethyl)-2-(4-methoxybenzyl)hexahydrofuro[2,3-d]isothia- 
zole 1,1-dioxide (3.21) 
 
1H NMR (400 MHz, CO(CD3)2) δ ppm 7.28 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 
2H), 4.33 (dddd, J = 9.5, 6.4, 3.4, 3.4 Hz, 1H), 4.25 (t, J = 4.7 Hz, 1H), 4.24 (d, J = 
13.2 Hz, 1H), 3.91 (t, J = 4.7 Hz, 1H), 3.89 (d, J = 14.1 Hz, 1H), 3.79 (s, 3H), 3.75 (d, 
J = 7.9 Hz, 1H), 3.64 (dd, J = 11.7, 4.7 Hz, 1H), 3.51 − 3.59 (m, 2H), 2.98 (dd, J = 
13.1, 10.7 Hz, 2H), 2.87 (s, 1H), 2.47 (ddd, J = 13.6, 5.9, 1.4 Hz, 1H), 2.36 (ddd, J = 
13.7, 10.0, 9.4 Hz,  1H); 13C NMR (125 MHz, CO(CD3)2) δ ppm 159.5, 129.8, 127.5, 
113.9, 87.7, 81.6, 65.4, 63.2, 62.4, 54.7, 53.3, 46.3, 30.8; FTIR (neat) 3344, 2918, 
1770, 1720, 1612, 1514, 1445, 1304, 1250, 1151, 1028, 822 cm-1; HRMS calculated 
for C15H22NO6S (M+H)+ = 344.1168; found 344.1170 (TOF MS ES+). 
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 (±) 2-((4'-(tert-butyl)-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) 
hexa-hydrofuro[2,3-d]isothiazole 1,1-dioxide (3.23a) 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.65 – 7.43 (m, 6H), 7.36 (d, 7.4 Hz, 2H), 4.46 
(s, 1H), 4.38 (d, J = 13.8 Hz, 1H), 4.07 (d, J = 13.7 Hz, 1H), 3.93 (d, J = 9.6 Hz, 1H), 
3.83 (d, 6.9 Hz, 1 H), 3.78 − 3.45 (m, 3H), 3.10 (d, J = 10.0 Hz, 1H), 2.92 (d, J = 10.2 
Hz, 1 H), 2.63 − 2.48 (m, 2H), 1.37 (s, 9H); 13C NMR (125 MHz, CDCl3) 150.6, 
141.0, 137.5, 133.3, 128.9, 127.4, 126.7, 125.8, 87.7, 81.2, 66.2, 63.6, 62.4, 53.4, 
47.0, 34.6, 30.4, 29.7; FTIR (neat) 3377, 2960, 2924, 2866, 1772, 1612, 1499, 1460, 
1439, 1364, 1310, 1150, 1057, 951, 816, 758 cm-1; HRMS calculated for 
C24H31NO5SNa (M+Na)+ = 468.1821; found 468.1801 (TOF MS ES+). 
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(±) 2-((3'-(1-hydroxyethyl)-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) 
hexa-hydrofuro[2,3-d]isothiazole 1,1-dioxide (3.23b) – mixture of diastereomers 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.60 − 7.53 (m, 3H), 7.47 (d, J = 7.4 Hz, 1H), 
7.41 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 6.8 Hz, 3H) 4.94 (q, J = 6.2 Hz, 1H), 4.40 − 4.25 
(m, 1H), 4.32 (d, J = 14.0 Hz, 1H), 4.00 (d, J = 14.0 Hz, 1H), 3.95 (s, 1H), 3.9 (d, J = 
12.0 Hz, 1H), 3.73 (d, J = 9.2 Hz, 1H), 3.65 (d, J = 11.7 Hz, 1H), 3.56 (d, J = 12.1 
Hz, 1H), 3.51 (d, J = 12.1 Hz, 1H), 3.36 (s, 1H), 3.01 (d, J = 10.7 Hz, 1 H), 2.87 (d, J 
= 10.8 Hz, 1 H), 2.68 (s, 1 H), 2.5 (dd, J = 13.6, 5.5 Hz, 1H), 2.40 − 2.31 (m, 1H), 
1.52 (d, J = 6.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ ppm 146.4, 141.0, 140.9, 
140.6, 133.8, 130.7, 129.1, 129.0, 127.6, 126.2, 124.7, 87.6, 81.2, 70.4, 65.9, 63.4, 
62.2, 61.3, 53.3, 46.9, 30.3, 25.3; FTIR (neat) 3381, 2966, 2924, 2854, 1439, 1306, 
1150, 1076, 797, 752, 706 cm-1; HRMS calculated for C22H28NO6S (M+H) = 
434.1639; found 434.1621 (TOF MS ES+). 
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                                                                          X-Ray Crystal Structure 
(±) 4,5-dihydroxy-2-(4-iodobenzyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole 
1,1-dioxide (3.25) 
  
1H NMR (400 MHz, MeOD) δ ppm 7.70 (d, J = 10.7 Hz, 2H), 7.18 (d, J = 8.3 Hz, 
2H), 4.40 (d, J = 5.4 Hz, 1H), 4.20 (s, 1 H), 3.98 (d, J = 5.9 Hz, 1H), 3.92 (d, J = 5.9 
Hz, 1H), 3.50 (t, J = 4.7 Hz, 1H), 3.48 (d, J = 11.4 Hz, 1H) 3.32 (d, MeOD overlap, 1 
H) 2.22 (dt, J = 5.2, 13.1 Hz, 1H), 2.02 (dd, J = 8.5, 13.1 Hz, 1H); 13C NMR (125 
MHz, MeOD) δ ppm 137.5, 135.7, 130.2, 92.6, 90.0, 83.3, 74.2, 72.6, 47.7, 46.1, 
28.9; FTIR (KBr) 3443, 2181, 2131, 2089, 1607, 1398, 1150, 997, 968, 630 cm-1; 
HRMS calculated for C28H36I2N3O10S2 (2M+NH4)+ = 891.9931; found 891.9932 (TOF 
MS ES+) 
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(±) 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl)hexahydro 
furo[2,3-d]isothiazole 1,1-dioxide (3.28a) 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.55 − 7.48 (m, 4H), 7.35 (d, J = 8.0 Hz, 2H), 
7.11 (t, J = 8.6 Hz, 2H), 4.47 − 4.38 (m, 1H), 4.35 (d, J = 13.9 Hz, 1H), 4.15 (d, J = 
13.9 Hz, 1H), 3.91 (d, J = 11.1 Hz, 1H), 3.79 (d, J = 8.5 Hz, 1H), 3.78 − 3.48 (m, 
3H), 3.06 (d, J = 10.7 Hz, 1H), 2.91 (d, J = 10.7 Hz, 1H), 2.54 (dd, J = 13.1, 5.3 Hz, 
1H), 2.50 − 2.38 (m, 1H); 13C NMR (125 MHz, CDCl3) δ ppm 162.6 (d, 1JCF = 247 
Hz), 140.1, 136.6 (d, 4JCF = 3.4 Hz), 133.7, 129.0, 128.6 (d, 3JCF = 8.1 Hz), 127.4, 
115.7 (d, 2JCF = 21.6 Hz); FTIR (neat) 3381, 2953, 2918, 2849, 1603, 1499, 1308, 
1232, 1150, 1059, 947, 822, 756 cm-1; HRMS calculated for C20H22FNO5SNa 
(M+Na)+ = 430.1100; found 430.1104 (TOF MS ES+). 
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(±) 2-((3'-chloro-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) hexa-
hydrofuro[2,3-d]isothiazole 1,1-dioxide (3.28b) 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.55 (dd, J = 8.9, 2.0 Hz, 3H), 7.46 (dt, J = 7.4, 
1.5 Hz, 1H), 7.42 − 7.32 (m, 4H), 4.49 − 4.42 (m, 1H), 4.38 (d, J = 14.0 Hz, 1H), 4.06 
(d, J = 14.0 Hz, 1H), 3.95 (d, J = 11.9 Hz, 1H), 3.82 (d, J = 8.9 Hz, 1H), 3.73 (d, J = 
11.7 Hz, 1H), 3.68 − 3.57 (m, 2H), 3.07 (d, J = 10.7 Hz, 1H), 2.93 (d, J = 10.7 Hz, 
1H), 2.58 (dd, J = 13.0, 6.0 Hz, 1H), 2.47 (dt, J = 13.8, 9.6 Hz, 1H); 13C NMR (125 
MHz, CDCl3) 142.2, 139.7, 134.7, 134.3, 130.1, 129.1, 127.2, 125.18, 87.6, 81.2, 
66.1, 63.5, 62.3, 53.3, 46.9, 30.4; FTIR (neat) 3354, 2924, 1664, 1595, 1440, 1396, 
1308, 1150, 1037, 787 cm-1; HRMS calculated for C20H22ClNO5SNa (M+Na)+ = 
446.0805; found 446.0812 (TOF MS ES+). 
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Norbornene-tagged Co/C-nanoparticles (4.8) 
The azide-tagged carbon coated cobalt nanoparticles 4.6 (400 mg; 0.1 mmol/g azide-
loading) were suspended in degassed toluene (3 mL) by the use of an ultrasonic bath 
(Sonorex RK 255 H-R, Bandelin) before propargylated bicyclo[2.2.1]hept-5-en-2-
ylmethanol 4.7 (130 mg, 0.8 mmol), triethylamine (20 µL, 0.12 mmol) and CuI (5 
mg, 0.03 mmol) were added. The resulting slurry was sonicated for 48 hr at ambient 
temperature under an argon atmosphere. The nanoparticles were recovered from the 
reaction mixture with the aid of a neodymium based magnet (N48, W-12-N, Webcraft 
GmbH, side length 12 mm) and washed with toluene (6 x 5 mL).  Each washing step 
consisted of suspending the particles in the solvent, ultrasonication (5 min) and 
retracting the particles from the solvent by the aid of the magnet.  After the last 
washing step the particles were dried in vacuo to yield 430 mg of 4.8. IR (ν/cm-1): 
2928, 2817, 2097, 1693, 1598, 1505, 1404, 1377, 1253, 1214, 1175, 1096, 1013, 824, 
71681; elemental microanalysis: 13.57% C, 0.69% H, 1.18% N. 
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PPh3-functionalized Co/C-ROMPgel (4.10)  
200 mg (0.02 mmol) of norbornene-tagged Co/C-nanoparticles 4.8 were dispersed 
in CH2Cl2 (2 mL) by sonication in a sealed microwave reaction vessel under argon 
atmosphere (30 min). A solution of catalyst 2G (17 mg, 0.02 mmol) in CH2Cl2 (1 
mL) was injected and the ultrasound bath tempered to 60 °C while sonication of the 
reaction mixture continued (30 min). (4-exo-(bicyclo[2.2.1]hept-5-en-2-yl)phenyl) 
diphenyl phosphine 4.9 (353 mg, 1.0 mmol) was added and the dispersion was 
subjected to sonication at 60 °C for 2 hrs. Within 50 min the formation of voluminous 
black gel was observed. After 2 hrs the reaction was quenched and a single, jelly-like 
lump was removed from the reaction vessel, crushed and dried in vacuo to yield 490 
mg of 4.10. IR (ν/cm-1): 2929, 2859, 1644, 1584, 1475, 1432, 1400, 1303, 1259, 
1177, 1089, 1064, 962, 894, 852, 760, 691, 655; elemental microanalysis: 55.95% C; 
4.59% H, 0.47% N, 3.45% P. 
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Pd-PPh3-functionalized Co/C-ROMPgel (4.11)  
200 mg of PPh3-functionalized Co/C-ROMPgel 4.10 was allowed to swell in CH2Cl2 
(2 mL) under sonication at 60°C under an atmosphere of argon (30 min) before 
Pd(OAc)2 (40 mg, 0.18 mmol) was added to the reaction vessel.  Sonication was 
maintained for additional 2 hrs before the magnetic ROMPgel was isolated from the 
reaction mixture by the aid of an external magnet and dried in vacuo to yield 212 mg 
of 4.11. IR (ν/cm-1): 2982, 2360, 2155, 1053, 1033, 1014, 696, 674, 664, 652; 
elemental microanalysis: 49.23% C; 4.06% H; 0.43% N. 
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4.12 4.13 4.14a-g
Na2CO3
THF/H2O
65 ºC  
General procedure for the Suzuki-Miyaura cross-coupling reactions catalyzed 
by 4.11:  
 
11 mg of Pd-PPh3-functionalized Co/C-ROMPgel 4.11 (0.48 mmol/g Pd-loading, 
1.1 mol%) was placed in a reaction vessel equipped with a magnetic stir bar and THF 
was added (1 mL). The particles were allowed to swell while stirring (30 min). 
Na2CO3 (160 mg, 1.5 mmol) dissolved in H2O (2 mL), phenylboronic acid (0.55 
mmol) and phenylhalide (0.5 mmol) were added subsequently and the reaction 
mixture was heated to 65 °C in an oil bath while stirring (1500 rpm) continued until 
the reaction was completed (TLC).  The reaction mixture was magnetically decanted 
and the retained material washed with Et2O (5 x 5 mL).  Each washing step consisted 
of suspending the particles in the solvent, ultrasonication (5 min) and decanting the 
solvent from the particles with magnetic assist.  The Et2O portions were extracted 
against the decanted THF/water-mixture and the combined organic layers were dried 
over MgSO4 and concentrated. These were subjected to silica SPE filtration using a 
3:1 mixture of hexanes:EtOAc affording biaryl coupled products 4.14a-g in excellent 
yields and purities.  The recovered nanocatalyst 4.11 was washed with H2O (3 x 5 
mL) as described above and subjected to the next reaction. 
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(S)-methyl 2-(N-(4-bromobenzyl)vinylsulfonamido)-3-methylbutanoate  5.6{2} 
 
[α]20D = -32.0 º (c = 1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.46 – 7.43 (m, 
2H), 7.35 – 7.32 (m, 2H), 6.38 (dd, J = 16.5, 9.9 Hz, 1H), 6.19 (d, J = 16.5 Hz, 1H), 
5.89 (d, J = 9.9 Hz, 1H), 4.45 – 4.37 (m, 2H), 4.07 (d, J = 10.6 Hz, 1H), 3.70 (s, 3H), 
2.05 – 1.93 (m, 1H), 0.86 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ ppm 171.3, 136.2, 135.1, 131.6, 131.0, 127.1, 122.0, 66.5, 51.9, 
48.3, 28.5, 19.7, 19.7; FTIR (thin film) cm-1 2966, 1740, 1489, 1342, 1142, 760; 
HRMS calculated for C15H20BrNO4SNa (M+H)+ = 390.0375; found 390.0369 (TOF 
MS ES+). To a 250 mL RB flask containing crude vinyl sulfonamide linchpin 5.5{2} 
(1.14 g, 5.15 mmol) was added 4-bromobenzyl bromide (1.50 g, 6.18 mmol), K2CO3 
(1.40 g, 10.3 mmol) in CH3CN (51 mL, 0.1 M).  This was allowed to stir at 60 ºC for 
12 − 14 hrs over argon and monitored by TLC.  After which time the reaction was 
cooled to rt and filtered through a pad of celite to afford the crude tertiary 
sulfonamide 5.6{2} as a dark orange oil. 
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(S)-methyl 2-(N-(4-bromobenzyl)-2-(prop-2-yn-1-ylamino)ethylsulfonamido)-3-
methylbutanoate  5.7{2} 
 
[α]20D = -22.4 º (c = 1.10, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.49 – 7.44 
(m, 2H), 7.33 (d, J = 8.4 Hz, 2H), 4.56 (d, J = 15.4 Hz, 1H), 4.40 (d, J = 15.4 Hz, 
1H), 4.11 (d, J = 10.7 Hz, 1H), 3.77 (s, 3H), 3.41 (d, J = 2.3 Hz, 2H), 3.11 – 3.07 (m, 
2H), 3.04 – 2.95 (m, 2H), 2.24 (t, J = 2.4 Hz, 1H), 2.10 – 1.99 (m, 1H), 1.77 (s, 1H), 
0.88 (d, J = 6.5 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H).; 13C NMR (126 MHz, CDCl3) δ 
ppm 171.3, 135.9, 131.6, 131.0, 122.0, 81.3, 72.0, 66.3, 53.3, 52.1, 48.1, 42.5, 38.0, 
28.2, 19.5, 19.3; FTIR (thin film) 3290, 2966, 1738, 1489, 1335, 1138 cm-1; HRMS 
calculated for C18H25BrN2O4SNa (M+Na)+ = 467.0616; found 467.0634 (TOF MS 
ES+).  To a 100 mL RB flask containing the crude tertiary sulfonamide 5.6{2} (1.91 
g, 4.89 mmol) was added 5 mL CH3CN and DBU (373 mg, 2.45 mmol) followed by 
addition of propargylamine (404 mg, 7.34 mmol).   This mixture was allowed to stir 
for 12 hrs over argon at 40 ºC.   After such time, the reaction was concentrated in 
vacuo and subjected to silica column chromatography using 1:3 hexanes to EtOAc up 
to 100% EtOAc affording the amino ester-containing sulfonamide 5.7{2} as clear, 
yellowish oil (1.15 g, 2.57 mmol, 50 % over three steps). 
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(S)-2-(4-bromobenzyl)-3-methyl-5-(prop-2-yn-1-yl)-1,2,5-thiadiazepin-1,1-
dioxide-4-one  5.9{1} 
 
ee = 2%; [α]20D = -18.5 º (c = 0.6, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 7.45 
(d, J = 8.0 Hz, 2H), 7.27 (d, J = 7.8 Hz, 2H), 4.74 (m, 2H), 4.44 (d, J = 16.4 Hz, 1H), 
4.13 (dd, J = 16.4, 11.3 Hz, 1H), 3.98 (d, J = 17.7 Hz, 1H), 3.93 (d, J = 16.5 Hz, 1H), 
3.81 (dd, J = 16.7, 4.3 Hz, 1H), 3.31 (dd, J = 14.4, 5.2 Hz, 1H), 3.25 (m, 1H), 2.35 (t, 
J = 2.5 Hz, 1H), 1.24 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 171.5, 
136.9, 131.7, 129.4, 121.6, 78.2, 73.5, 54.7, 50.0, 47.9, 43.4, 37.5, 16.3; FTIR (thin 
film) 3292, 2988, 2937, 1663, 1337, 1142 cm-1; HRMS calculated for 
C15H17BrN2O3SNa (M+Na)+ = 407.0041; found 407.0045 (TOF MS ES+). 
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(S)-2-(4-bromobenzyl)-3-isopropyl-5-(prop-2-yn-1-yl)-1,2,5-thiadiazepin-1,1-
dioxide-4-one  5.9{2} 
 
ee = 17%; [α]20D = +2.5 º (c = 0.5, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 7.45 
(d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 4.77 (dd, J = 17.4, 2.4 Hz, 1H), 4.38 (d, 
J = 15.5 Hz, 1H), 4.13 (dd, J = 16.7, 11.2 Hz, 1H), 4.03 (d, J = 10.6 Hz, 1H), 3.93 (d, 
J = 15.6 Hz, 1H), 3.89 (dd, J = 17.6, 2.4 Hz, 1H), 3.76 (dd, J = 16.9, 3.5 Hz, 1H), 
3.26 (ddd, J = 14.5, 5.2, 1.1 Hz, 1H), 3.16 (ddd, J = 14.3, 11.4, 2.1 Hz, 1H), 2.30 (t, J 
= 2.5 Hz, 1H), 2.05 (m, 1H), 0.89 (d, J = 6.3 Hz, 3H), 0.70 (d, J = 6.7 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ ppm 169.9, 135.5, 131.7, 131.4, 122.3, 78.3, 73.4, 65.2, 
50.0, 48.5, 43.7, 37.0, 27.1, 20.6, 19.1; FTIR (thin film) 3296, 2964, 1661, 1339, 
1142 cm-1; HRMS calculated for C17H21BrN2O3SNa (M+Na)+ = 435.0354; found 
435.0373 (TOF MS ES+).  To a 10 mL RB was added the amino ester-containing 
sulfonamide 5.7{2} (575 mg, 1.29 mmol) in 0.5 mL of THF.  To this was added 
LiOH•H2O (217 mg, 5.20 mmol) with 0.5 mL deionized H2O and was allowed to stir 
rapidly at rt for 12 hrs.  After such time, THF was removed in vacuo and the reaction 
was transferred a separatory funnel containing 10 mL DCM and 5 mL of deionized 
H2O.  The upper aqueous layer was then neutralized with 10% HCl.  Upon reaching a 
pH value near neutral, a white precipitate formed and was collected by vacuum 
filtration and dried at 70 ºC under vacuum.  This crude sulfonamide amino acid 
5.8{2} (620 mg) (likely containing residual Li salts) was then placed in a 100 mL RB 
under argon containing 30 mL DCM (0.05 M).  To this was added EDC•HCl (550 
mg, 2.87 mmol) and HOBt (20 mg, 0.14 mmol) along with NMM (632 µL, 5.75 
mmol).  Upon addition of NMM, the reaction became completely homogeneous and 
was allowed to stir for 3 − 4 hours with monitoring by TLC.  After such time the 
reaction was concentrated and passed through a short silica plug with a 1:1 mixture of 
hexanes:EtOAc and concentrated to afford the cyclized product 5.9{2} as a white 
crystalline foam (375 mg, 0.91 mmol, 70% over two steps). 
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(S)-2-(4-bromobenzyl)-3-isobutyl-5-(prop-2-yn-1-yl)-1,2,5-thiadiazepin-1,1-
dioxide-4-one  5.9{3} 
 
 ee = 9% [α]20D = -75.0 º (c = 0.6, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 7.45 
(d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H), 4.72 (dd, J = 17.5, 2.2 Hz, 1H), 4.57 
(dd, J = 9.9, 4.6 Hz, 1H), 4.41 (d, J = 15.9 Hz, 1H), 4.12 (dd, J = 16.7, 11.4 Hz, 1H), 
3.94 (dd, J = 17.5, 2.1 Hz, 1H), 3.85 (d, J = 15.9 Hz, 1H), 3.78 (dd, J = 16.9, 4.0 Hz, 
1H), 3.30 (dd, J = 14.3, 5.0 Hz, 1H), 3.22 (m, 1H), 2.35 (t, J = 2.4 Hz, 1H), 1.54 (dt, J 
= 10.3, 3.0 Hz, 1H), 1.40 (m, 2H), 0.87 (d, J = 6.2 Hz, 3 H), 0.57 (d, J = 6.4 Hz, 3 H); 
13C NMR (126 MHz, CDCl3) δ ppm 171.5, 136.4, 131.7, 130.3, 121.9, 78.3, 73.5, 
57.3, 50.0, 48.3, 43.6, 37.7, 37.4, 23.6, 22.8, 21.4; FTIR (thin film) 3292, 2957, 
2868, 1663, 1339, 1144 cm-1; HRMS calculated for C18H23BrN2O3SNa (M+Na)+ = 
449.0510; found 449.0522 (TOF MS ES+). 
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(±) 2-(4-bromobenzyl)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-
methyl-1,2,5-thiadiazepin-1,1-dioxide 4-one   5.10{1} 
1H NMR (400 MHz, CDCl3) δ ppm 7.62 (d, J = 4.5 Hz, 1H), 7.45 – 7.40 (m, 2H), 
7.38 (dt, J = 4.7, 2.4 Hz, 1H), 7.19 (d, J = 8.4 Hz, 2H), 6.50 – 6.45 (m, 1H), 6.40 – 
6.34 (m, 1H), 5.53 (q, J = 15.4 Hz, 2H), 4.89 (d, J = 14.9 Hz, 1H), 4.73 (q, J = 6.8 
Hz, 1H), 4.50 (d, J = 14.9 Hz, 1H), 4.21 (dd, J = 14.8, 9.6 Hz, 1H), 4.17 – 4.08 (m, 
1H), 3.98 – 3.88 (m, 1H), 3.68 – 3.56 (m, 1H), 3.27 – 3.11 (m, 2H), 1.17 (d, J = 6.9 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 172.7, 147.9, 144.9, 144.7, 138.1, 
132.5, 130.2, 123.7, 122.4, 112.0, 111.6, 55.6, 50.5, 48.7, 47.9, 45.7, 45.2, 17.2; 
FTIR (thin film) 3142, 2988, 1659, 1487, 1337, 1142, 735 cm-1; HRMS calculated 
for C20H22BrN5O4SNa (M+Na)+ = 530.0474; found 530.0474 (TOF MS ES+). 
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To 1 dram vials were added 50 mg ea of the corresponding sultams 5.10{1-3} 
followed by the addition of Pd(dppf)Cl2 (4.0 mg, 4.4 µmol) and anhydrous K2CO3 
(24.0 mg, 0.17 mmol) as solids.  To each were added DMF (500 µL) and stirred until 
soluble.  The corresponding boronic acids were each prepared as stock solutions in 
DMF (450 µL) and added to the vials followed by subsequent addition of H2O (190 
µL) to each (0.08 M total).  Reactions were then sealed over Ar atmosphere and 
allowed to react for 14 − 16 hours at 80 ºC on a carousel plate.  After such time the 
reactions were cooled to rt, concentrated and re-constituted in EtOAc/ H2O and 
washed with 1N (aq) NaOH (1 x 5 mL) and deionized water (2 x 5 mL) and 
separated.  The organic layer was passed through a 6 mL silica SPE cartridge (400 
mg) using a Fisher vacuum filtration box.  A two-stage flush was performed: 2:1 
hexanes:EtOAc (2 x 5 mL) – discarded, followed by addition of 100% EtOAc  to 
afford the Suzuki-coupled sultams 5.11a-n{2-3} in good to excellent yields and 
purities (Table 5.5). 
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thiadiazepin-1,1-dioxide-4-ones on the Chemspeed Accelerator platform 
 
 
In the appropriate reactor position in the Chemspeed Accelerator SLT100 (3S x 
5A x 5B = 75 members) was added 25.0 mg of Amberlyst-21 bound CuI (0.03 
mmol), 0.824 mL of a 0.182 M (0.150 mmol) solution in methylene chloride of the 
sultam (S) and 0.824 mL of a 0.362 M (0.300 mmol) solution in methylene chloride 
of the azide (A), and the reaction mixture was vortexed at rt for 14 hours.  The 
vortexing was ceased and the reaction solution was transferred (without Amberlyst-21 
bound CuI) to the appropriate adjacent reactor via syringe.  The remaining 
Amberlyst-21 bound CuI was washed with methylene chloride (2 x 0.824 mL) and 
again the solution was transferred to the appropriate adjacent reactor. The reaction 
mixture was then concentrated and 0.824 mL of 1,2-dimethoxyethane was added to 
the crude triazole product.  Pd(dppf)Cl2 (11.0 mg) was added to the reaction solution 
using the solid-dispensing unit..  This was then followed by addition 0.412 mL of a 
0.728 M (0.300 mmol) solution of cesium carbonate in water and 0.824 mL of a 
0.273 M (0.225 mmol) solution of the boronic acid (B) in 1,2-dimethoxyethane.  The 
reaction mixture was then vortex shaken at 85 °C for 24 hours over argon. The 
reaction mixtures were concentrated and 2 mL of 1N NaOH was added to the 
resulting residue. The mixture was vortexed and extracted with methylene chloride (3 
x 1.5 mL) and the extracts were gravity filtered through a silica SPE plug into CCT 
tubes followed by washing the SPE with ethyl acetate (2 mL). The solutions were 
concentrated and the resulting residues were purified by mass-directed HPLC.  This 
process was repeated 3 times for a total of 225 compounds. 
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(S)-2-([1,1'-biphenyl]-4-ylmethyl)-3-isobutyl-5-((1-(4-methylbenzyl)-1H-1,2,3-
triazol-4-yl)methyl)-1,2,5-thiadiazepin-4-one 1,1-dioxide  5.11a{3} 
 
[α]20D = -3.2 º (c = 0.41, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 7.5 Hz, 
2H), 7.52 (d, J = 8.9 Hz, 3H), 7.45 (t, J = 7.5 Hz, 2H), 7.36 (d, J = 8.0 Hz, 3H), 7.14 
(dd, J = 19.4, 7.9 Hz, 4H), 5.54 (d, J = 14.6 Hz, 1H), 5.38 (d, J = 14.6 Hz, 1H), 4.93 
(d, J = 14.8 Hz, 1H), 4.56 (dd, J = 10.1, 4.4 Hz, 1H), 4.44 (d, J = 14.8 Hz, 1H), 4.28 – 
4.07 (m, 2H), 3.95 (dd, J = 16.5, 4.0 Hz, 1H), 3.51 (d, J = 15.7 Hz, 1H), 3.24 (dd, J = 
14.4, 5.1 Hz, 1H), 3.11 – 3.00 (m, 1H), 2.23 (s, 3H), 1.60 – 1.49 (m, 1H), 1.48 – 1.34 
(m, J = 6.4 Hz, 1H), 1.32 – 1.20 (m, 1H), 0.83 (d, J = 6.4 Hz, 3H), 0.48 (d, J = 6.6 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 171.8, 144.0, 140.9, 140.6, 139.2, 136.5, 
131.4, 130.1, 129.0, 129.0, 128.3, 127.5, 127.2, 127.1, 122.8, 57.3, 54.3, 49.7, 48.4, 
44.9, 44.3, 37.7, 23.5, 22.8, 21.4, 21.2; FTIR (thin film) 3055, 2955, 1657, 1336, 
1144, 758 cm-1; HRMS calculated for C32H37N5O3SNa (M+Na)+ = 594.2515; found 
594.2517 (TOF MS ES+). 
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(S)-4'-((5-((1-(cyclohexylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-isobutyl-1,1-
dioxido-4-oxo-1,2,5-thiadiazepin-2-yl)methyl)-[1,1'-biphenyl]-3-carbonitrile  
5.11b{3}  
 
[a]20D = -32.2° (c = 1.00, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 7.83 (s, 1H), 
7.78 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.52 (t, J = 7.8 Hz, 
1H), 7.47 (q, J = 8.2 Hz, 4H), 4.92 (d, J = 14.9 Hz, 1H), 4.59 (dd, J = 9.9, 4.5 Hz, 
1H), 4.52 (d, J = 14.9 Hz, 1H), 4.37 (d, J = 15.9 Hz, 1H), 4.21 − 4.11 (m, 3H), 3.97 
(dt, J = 15.6, 3.3 Hz, 1H), 3.66 (d, J = 15.9 Hz, 1H), 3.31 − 3.25 (m, 2H), 1.91 − 0.93 
(m, 14H), 0.83 (d, J = 6.3 Hz, 3H), 0.49 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ ppm 171.5, 143.0, 141.8, 138.0, 137.8, 131.3, 130.7, 130.5, 129.6, 128.9, 
126.9, 123.2, 118.7, 112.8, 57.2, 56.5, 53.4, 49.4, 48.2, 44.8, 44.2, 38.6, 37.6, 30.4, 
30.4, 25.9, 25.3, 23.4, 22.5, 21.2; FTIR (thin film) 2928, 2853, 1655, 1337, 1144, 
1049, 793, 768, 735 cm-1; HRMS calculated for C32H40N6O3SNa (M+Na)+ = 
611.2780; found 611.2780 (TOF MS ES+). 
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(S)-2-((3'-acetyl-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(cyclohexylmethyl)-1H-1,2,3-
triazol-4-yl)methyl)-3-isobutyl-1,2,5-thiadiazepin-1,1-dioxide 4-one  5.11c{3} 
 
[a]20D = -31.8° (c = 1.00, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 8.14 (s, 1H), 
7.91 (d, J = 7.7 Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.56 − 7.50 (m, 4H), 7.44 (d, J = 
8.0 Hz, 2H), 4.89 (d, J = 14.9 Hz, 1H), 4.59 (dd, J = 9.9, 4.5 Hz, 1H), 4.52 (d, J = 
14.9 Hz, 1H), 4.37 (d, J = 15.9 Hz, 1H), 4.21 − 4.11 (m, 3H), 3.96 (dt, J = 17.2, 3.3 
Hz, 1H), 3.68 (d, J = 15.9 Hz, 1H), 3.27 − 3.24 (m, 2H), 2.64 (s, 3H), 1.88 − 0.93 (m, 
14H), 0.84 (d, J = 6.4 Hz, 3H), 0.51 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
δ ppm 198.0, 171.6, 143.0, 141.1, 139.3, 137.5, 137.1, 131.6, 129.0, 128.9, 127.2, 
126.9, 126.6, 123.2, 57.2, 56.5, 53.4, 49.4, 48.3, 44.7, 44.1, 38.6, 37.6, 30.4, 30.4, 
26.7, 25.9, 25.3, 23.4, 22.6, 21.2; FTIR (thin film) 2928, 2853, 1682, 1657, 1337, 
1144, 1049, 797, 768, 735 cm-1; HRMS calculated for C33H43N5O4SNa (M+Na)+ = 
628.2933; found 628.2920 (TOF MS ES+).  
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(S)-2-(4-((2-((2',6'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-3-isobutyl-1,1-dioxido-4-
oxo-1,2,5-thiadiazepin-5-yl)methyl)-1H-1,2,3-triazol-1-yl)ethyl acetate  5.11d{3} 
 
[a]20D = -34.6° (c = 1.00, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 7.70 (s, 1H), 
7.46 (d, J = 7.9 Hz, 2H), 7.17 − 7.09 (m, 5H), 4.86 (d, J = 14.8 Hz, 1H), 4.64 − 4.61 
(m, 4H), 4.51 − 4.48 (m, 3H), 4.18 (dd, J = 16.6, 11.2 Hz, 1H), 4.00 (ddd, J = 16.6, 
4.8, 1.8 Hz, 1H), 3.65 (d, J = 15.6 Hz, 1H), 3.35 − 3.20 (m, 2H), 2.04 (s, 3H), 2.00 (s, 
6H), 1.68 − 1.63 (m, 1H), 1.50 − 1.40 (m, 1H), 1.32 − 1.28 (m, 1H), 0.86 (d, J = 6.5 
Hz, 3H), 0.54 (d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 172.0, 170.3, 
143.6, 141.3, 140.4, 135.9, 135.8, 129.0, 128.5, 127.2, 127.0, 123.4, 62.2, 57.4, 49.5, 
49.3, 48.6, 44.7, 44.0, 37.6, 23.2, 22.9, 21.0, 20.8, 20.6; FTIR (thin film) 2955, 2926, 
2868, 1744, 1655, 1366, 1337, 1231, 1144, 771 cm-1; HRMS calculated for 
C30H39N5O5SNa (M+Na)+ = 604.2570; found 604.2545 (TOF MS ES+) 
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(S)-2-(4-((2-((3'-cyano-[1,1'-biphenyl]-4-yl)methyl)-3-isobutyl-1,1-dioxido-4-oxo-
1,2,5-thiadiazepin-5-yl)methyl)-1H-1,2,3-triazol-1-yl)ethyl acetate  5.11e{3} 
 
[a]20D = -33.7° (c = 1.00, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 7.61 (s, 1H), 
7.57 (d, J = 7.3 Hz, 1H), 7.47 (s, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.33 − 7.25 (m, 4H), 
4.68 (d, J = 14.9 Hz, 1H), 4.44 − 4.37 (m, 4H), 4.26 − 4.20 (m, 3H), 3.98-3.82 (m, 
1H), 3.76 (d, J = 17.0 Hz, 1H), 3.49 (d, J = 16.0 Hz, 1H), 3.09 − 3.02 (m, 2H), 1.82 
(s, 3H), 1.35 − 1.30 (m, 1H), 1.27 − 1.20 (m, 1H), 1.15 − 1.09 (m, 1H), 0.63 (d, J = 
6.5 Hz, 3H), 0.29 (d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 171.7, 
170.3, 143.5, 141.8, 138.0, 137.9, 131.3, 130.7, 130.5, 129.6, 128.9, 126.9, 123.4, 
118.8, 112.8, 62.1, 57.2, 49.4, 49.2, 48.3, 44.6, 44.0, 37.6, 36.4, 31.3, 29.6, 23.4, 22.6, 
21.2, 20.6; FTIR (thin film) 2957, 2934, 1744, 1657, 1366, 1337, 1231, 1144, 735 
cm-1; HRMS calculated for C29H34N6O5SNa (M+Na)+ = 601.2209; found 601.2191 
(TOF MS ES+). 
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(S)-2-(4-((2-((3'-acetyl-[1,1'-biphenyl]-4-yl)methyl)-3-isobutyl-1,1-dioxido-4-oxo-
1,2,5-thiadiazepin-5-yl)methyl)-1H-1,2,3-triazol-1-yl)ethyl acetate  5.11f{3} 
 
[a]20D = -36.0° (c = 1.00, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ ppm 8.15 (s, 1H), 
7.92 (d, J = 7.7 Hz, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.68 (s, 1H), 7.58 − 7.47 (m, 5H), 
4.86 (d, J = 14.9 Hz, 1H), 4.63 − 4.57 (m, 4H), 4.47 − 4.41 (m, 3H), 4.19 − 4.14 (m, 
1H), 3.98 (d, J = 15.0 Hz, 1H), 3.73 (d, J = 15.9 Hz, 1H), 3.29 − 3.21 (m, 2H), 2.64 
(s, 3H), 2.02 (s, 3H), 1.61 − 1.56 (m, 1H), 1.51 − 1.45 (m, 1H), 1.38 − 1.33 (m, 1H), 
0.85 (d, J = 6.5 Hz, 3H), 0.53 (d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
ppm 198.1, 171.8, 170.3, 143.6, 141.1, 139.4, 137.6, 137.1, 131.6, 129.0, 128.9, 
127.3, 127.0, 126.7, 123.4, 62.2, 57.2, 49.4, 49.3, 48.3, 44.6, 44.0, 37.6, 26.8, 23.4, 
22.6, 21.2, 20.6; FTIR (thin film) 2957, 2928, 1744, 1682, 1657, 1362, 1337, 1234, 
1144, 735 cm-1; HRMS calculated for C30H37N5O6SNa (M+Na)+ = 618.2362; found 
618.2360 (TOF MS ES+). 
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(S)-2-((2',6'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-3-isopropyl-5-((1-(4-methoxy 
benzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide-4-one 
5.11g{2} 
 
[α]20D = -70.9 º (c = 2.3, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 7.41 
(d, J = 8.0 Hz, 2H), 7.22 – 7.18 (m, 2H), 7.16 (dd, J = 8.4, 6.5 Hz, 1H), 7.09 (dd, J = 
12.4, 7.8 Hz, 4H), 6.80 (m, 2H), 5.52 (d, J = 14.6 Hz, 1H), 5.37 (d, J = 14.6 Hz, 1H), 
5.00 (d, J = 14.8 Hz, 1H), 4.38 (d, J = 14.8 Hz, 1H), 4.23 – 4.14 (m, 2H), 4.02 (d, J = 
10.7 Hz, 1H), 3.93 (dd, J = 16.8, 3.9 Hz, 1H), 3.69 (s, 3H), 3.47 (d, J = 15.1 Hz, 1H), 
3.21 (dd, J = 14.5, 5.1 Hz, 1H), 3.00 (t, J = 12.4 Hz, 1H), 2.00 (s, 6H), 2.00 (s, 1H), 
0.85 (d, J = 6.4 Hz, 3H), 0.58 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
170.1, 160.2, 144.1, 141.6, 140.8, 136.1, 135.3, 129.7, 129.7, 129.1, 127.4, 127.2, 
126.4, 122.8, 114.8, 65.3, 55.4, 54.1, 49.7, 48.7, 45.3, 44.4, 27.2, 20.9, 20.7, 18.9; 
FTIR (thin film) 2960, 1659, 1514, 1337, 1252, 1153, 733 cm-1; HRMS calculated 
for C33H39N5O4SNa (M+Na)+ = 624.2620; found 624.2620 (TOF MS ES+). 
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(S)-3-isopropyl-5-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(4-
(thiophen-2-yl)benzyl)-1,2,5-thiadiazepin-1,1-dioxide-4-one  5.11h{2} 
 
[α]20D = -40.0 º (c = 1.7, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.9 Hz, 
3H), 7.33 (dd, J = 3.6, 0.9 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H), 7.08 (dd, J = 5.0, 3.7 Hz, 
1H), 6.76 (d, J = 8.5 Hz, 2H), 5.51 (d, J = 14.6 Hz, 1H), 5.33 (d, J = 14.6 Hz, 1H), 
5.03 (d, J = 14.8 Hz, 1H), 4.32 (d, J = 14.8 Hz, 1H), 4.18 (dd, J = 16.6, 11.8 Hz, 1H), 
4.00 (dd, J = 12.5, 9.7 Hz, 2H), 3.92 (dd, J = 16.5, 4.4 Hz, 1H), 3.61 (s, 3H), 3.42 (d, 
J = 15.4 Hz, 1H), 3.19 (dd, J = 14.5, 5.2 Hz, 1H), 2.98 (t, J = 12.9 Hz, 1H), 1.97 (tt, J 
= 12.8, 6.5 Hz, 1H), 0.85 (d, J = 6.3 Hz, 3H), 0.63 (d, J = 6.6 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 170.1, 160.2, 144.1, 141.6, 140.8, 136.1, 135.3, 129.7, 129.7, 129.1, 
127.4, 127.2, 126.4, 122.8, 114.8, 65.3, 55.4, 54.1, 49.7, 48.7, 45.3, 44.4, 27.2, 20.9, 
20.7, 18.9; FTIR (thin film) 3140, 2961, 1655, 1514, 1335, 1252, 1153, 1032, 735 
cm-1; HRMS calculated for C29H33N5O4S2Na (M+Na)+ = 602.1872; found 602.1888 
(TOF MS ES+). 
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(S)-4'-((3-isopropyl-5-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-
dioxido-4-oxo-1,2,5-thiadiazepin-2-yl)methyl)-[1,1'-biphenyl]-3-carbonitrile 
5.11i{3} 
 
[α]20D = -65.8 º (c = 1.9, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H), 7.81 
(dd, J = 7.9, 1.0 Hz, 1H), 7.62 (dd, J = 7.7, 1.1 Hz, 1H), 7.58 – 7.50 (m, 2H), 7.47 (d, 
J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.76 (d, J = 8.6 
Hz, 2H), 5.52 (d, J = 14.6 Hz, 1H), 5.34 (d, J = 14.6 Hz, 1H), 5.04 (d, J = 14.8 Hz, 
1H), 4.34 (d, J = 14.9 Hz, 1H), 4.19 (dd, J = 17.3, 11.1 Hz, 1H), 4.07 (d, J = 15.4 Hz, 
1H), 4.01 (d, J = 10.6 Hz, 1H), 3.93 (dd, J = 16.3, 4.1 Hz, 1H), 3.61 (s, 3H), 3.45 (d, J 
= 15.4 Hz, 1H), 3.21 (dd, J = 14.5, 5.1 Hz, 1H), 3.11 – 3.02 (m, 1H), 1.93 (dq, J = 
18.8, 6.2 Hz, 1H), 0.84 (d, J = 6.3 Hz, 3H), 0.62 (d, J = 6.5 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.0, 160.1, 144.1, 142.0, 138.2, 137.2, 131.5, 130.9, 130.7, 130.0, 
129.8, 129.7, 127.0, 126.4, 122.7, 119.0, 114.7, 113.1, 65.3, 55.3, 54.0, 49.5, 48.3, 
45.4, 44.5, 27.1, 20.5, 19.1. FTIR (thin film) 2928, 2228, 1651, 1514, 1333, 1153, 
789 cm-1; HRMS calculated for C32H34N6O4SNa (M+Na)+ = 621.2260; found 
621.2276 (TOF MS ES+). 
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(S)-2-((3'-acetyl-[1,1'-biphenyl]-4-yl)methyl)-3-isopropyl-5-((1-(4-methoxybenzyl) 
-1H-1,2,3-triazol-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide-4-one   5.11j{2} 
 
 
[α]20D = -63.8 º (c = 2.4, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.20 – 8.15 (m, J = 
1.6, 1H), 7.98 – 7.89 (m, 1H), 7.82 – 7.74 (m, 1H), 7.54 (dd, J = 8.2, 6.6, 4H), 7.38 
(d, J = 8.1, 2H), 7.18 (d, J = 8.6, 2H), 6.76 (d, J = 8.6, 2H), 5.52 (d, J = 14.6, 1H), 
5.34 (d, J = 14.6, 1H), 5.03 (d, J = 14.8, 1H), 4.35 (d, J = 14.8, 1H), 4.19 (dd, J = 
16.6, 11.8, 1H), 4.07 (d, J = 15.4, 1H), 4.01 (d, J = 10.6, 1H), 3.93 (dd, J = 16.7, 3.9, 
1H), 3.61 (s, 3H), 3.47 (d, J = 15.4, 1H), 3.20 (dd, J = 14.5, 5.1, 1H), 3.04 (t, J = 13.1, 
1H), 2.66 (s, 3H), 1.97 (dq, J = 18.9, 6.4, 1H), 0.85 (d, J = 6.4, 3H), 0.64 (d, J = 6.6, 
3H); 13C NMR (126 MHz, CDCl3) δ 198.3, 170.1, 160.1, 144.1, 141.3, 139.6, 137.8, 
136.47, 131.8, 129.9, 129.7, 129.3, 127.5, 127.1, 126.9, 126.4, 122.8, 114.7, 65.3, 
55.3, 54.1, 49.5, 48.4, 45.3, 44.5, 27.1, 27.0, 20.6, 19.1; FTIR (thin film) 2959, 1682, 
1651, 1333, 1151, 783 cm-1; HRMS calculated for C33H37N5O5SNa (M+Na)+ = 
638.2413; found 638.2403 (TOF MS ES+). 
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(S)-2-((2',6'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(furan-2-ylmethyl)-1H-
1,2,3-triazol-4-yl)methyl)-3-isopropyl-1,2,5-thiadiazepin-1,1-dioxide-4-one 
5.11k{2} 
 
[α]20D = -2.71 º (c = 2.1, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.68 (s, 1H), 7.45 
(d, J = 8.0 Hz, 2H), 7.27 (dd, J = 1.9, 0.7 Hz, 1H), 7.16 (dd, J = 8.4, 6.5 Hz, 1H), 7.09 
(dd, J = 9.5, 7.9 Hz, 4H), 6.44 (dd, J = 3.3, 0.5 Hz, 1H), 6.29 (dd, J = 3.3, 1.9 Hz, 
1H), 5.57 (d, J = 15.5 Hz, 1H), 5.48 (d, J = 15.5 Hz, 1H), 5.00 (d, J = 14.8 Hz, 1H), 
4.43 (d, J = 14.8 Hz, 1H), 4.26 (d, J = 15.1 Hz, 1H), 4.19 (dd, J = 16.7, 11.7 Hz, 1H), 
4.04 (d, J = 10.7 Hz, 1H), 3.93 (dd, J = 16.8, 3.6 Hz, 1H), 3.54 (d, J = 15.1 Hz, 1H), 
3.22 (dd, J = 14.4, 4.9 Hz, 1H), 3.11 – 3.02 (m, 1H), 2.09 – 2.02 (m, 1H), 1.99 (s, 
6H), 0.87 (d, J = 6.3, Hz, 3H), 0.61 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
δ 170.3, 147.1, 144.1, 144.0, 141.6, 140.8, 136.1, 135.3, 129.8, 129.1, 127.4, 127.3, 
123.0, 111.0, 110.6, 65.3, 49.6, 48.8, 47.0, 45.3, 44.4, 27.2, 20.9, 20.7, 18.9; FTIR 
(thin film) 2961, 1650, 1331, 1151, 735 cm-1; HRMS calculated for C30H35N5O4SNa 
(M+Na)+ = 584.2307; found 584.2304 (TOF MS ES+). 
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(S)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-isopropyl-2-(4-
(thiophen-2-yl)benzyl)-1,2,5-thiadiazepin-1,1-dioxide-4-one  5.11l{2} 
 
 [α]20D = -2.0 º (c = 1.9, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.63 (s, 1H), 7.54 (d, 
J = 8.3 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.32 (dd, J = 3.6 Hz, 1.1, 1H), 7.29 – 7.27 
(m, 2H), 7.08 (dd, J = 5.1, 3.6 Hz, 1H), 6.44 – 6.41 (m, 1H), 6.30 (dd, J = 3.3 Hz, 1.9, 
1H), 5.54 (d, J = 15.5 Hz, 1H), 5.45 (d, J = 15.5 Hz, 1H), 4.97 (d, J = 15.1 Hz, 1H), 
4.40 (d, J = 14.8, 1H), 4.14 (d, J = 15.5, 2H), 4.00 (d, J = 10.5, 1H), 3.91 (dd, 1H), 
3.59 (d, J = 15.4, 1H), 3.19 (dd, J = 14.5, 5.0, 1H), 3.09 – 2.95 (m, 1H), 2.07 – 1.98 
(m, 1H), 0.87 (d, J = 6.3, 3H), 0.66 (d, J = 6.6, 3H); 13C NMR (126 MHz, CDCl3) δ 
170.3, 147.1, 144.0, 135.9, 134.0, 131.5, 131.2, 130.1, 128.2, 125.8, 125.1, 123.4, 
122.9, 111.0, 110.6, 65.2, 49.6, 48.5, 47.0, 45.1, 44.2, 27.1, 20.6, 19.2; FTIR (thin 
film) 2962, 1651, 1331, 1151, 739 cm-1; HRMS calculated for C26H29N5O4S2Na 
(M+Na)+ = 562.1559; found 562.1550 (TOF MS ES+). 
 205 
N
N
S
OO
N
N
N
O
O
CN
 
(S)-4'-((5-((1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-isopropyl-1,1-
dioxido-4-oxo-1,2,5-thiadiazepin-2-yl)methyl)-[1,1'-biphenyl]-3-carbonitrile 
5.11m{2} 
[α]20D = -2.0 º (c = 1.9, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.86 (t, J = 1.5 Hz, 
1H), 7.83 – 7.79 (m, 1H), 7.66 (s, 1H), 7.62 (dt, J = 7.7, 1.3 Hz, 1H), 7.54 (t, J = 7.8 
Hz, 1H), 7.51 – 7.46 (m, 4H), 7.29 (dd, J = 1.8, 0.7 Hz, 1H), 6.44 (dd, J = 3.3, 0.5 Hz, 
1H), 6.31 (dd, J = 3.2, 1.9 Hz, 1H), 5.56 (d, J = 15.5 Hz, 1H), 5.48 (d, J = 15.5 Hz, 
1H), 5.01 (d, J = 14.9 Hz, 1H), 4.42 (d, J = 14.9 Hz, 1H), 4.25 – 4.15 (m, J = 14.1 Hz, 
2H), 4.04 (d, J = 10.6 Hz, 1H), 3.93 (dd, J = 16.8, 3.6 Hz, 1H), 3.62 (d, J = 15.5 Hz, 
1H), 3.21 (dd, J = 14.5, 4.8 Hz, 1H), 3.15 – 3.06 (m, 1H), 2.03 – 1.95 (m, 1H), 0.87 
(d, J = 6.4 Hz, 3H), 0.65 (d, J = 6.6 Hz, 3H).; 13C NMR (126 MHz, CDCl3) δ 170.1, 
147.1, 144.0, 144.0, 142.0, 138.3, 137.3, 131.6, 130.9, 130.8, 130.1, 129.8, 127.0, 
122.9, 119.0, 113.1, 111.0, 110.7, 65.3, 49.5, 48.5, 47.0, 45.2, 44.3, 27.2, 20.6, 19.2; 
FTIR (thin film) 2961, 2228, 1651, 1478, 1333, 1153, 733 cm-1; HRMS calculated 
for C29H30N6O4SNa (M+Na)+ = 581.1947; found 581.1946 (TOF MS ES+). 
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(S)-2-((3'-acetyl-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-
triazol-4-yl)methyl)-3-isopropyl-1,2,5-thiadiazepin-1,1-dioxide-4-one  5.11n{2} 
[α]20D = -2.9 º (c = 2.6, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.17 (t, J = 1.7 Hz, 
1H), 7.94 – 7.89 (m, 1H), 7.78 (ddd, J = 7.7, 1.7, 1.1 Hz, 1H), 7.65 (s, 1H), 7.53 (dd, 
J = 14.5, 8.0 Hz, 4H), 7.46 (d, J = 8.2 Hz, 2H), 7.28 (dd, J = 1.8, 0.7 Hz, 1H), 6.43 
(dd, J = 3.3, 0.5 Hz, 1H), 6.30 (dd, J = 3.3, 1.9 Hz, 1H), 5.55 (d, J = 15.5 Hz, 1H), 
5.47 (d, J = 15.5 Hz, 1H), 4.99 (d, J = 14.9 Hz, 1H), 4.42 (d, J = 14.9 Hz, 1H), 4.23 – 
4.14 (m, 2H), 4.03 (d, J = 10.6 Hz, 1H), 3.62 (d, J = 15.4 Hz, 1H), 3.20 (dd, J = 14.5, 
4.9 Hz, 1H), 3.11 – 3.03 (m, 1H), 2.65 (s, 3H), 2.07 – 1.97 (m, 1H), 0.87 (d, J = 6.4 
Hz, 3H), 0.66 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 198.3, 170.2, 
147.0, 144.0, 141.2, 139.6, 137.8, 136.5, 131.8, 130.0, 129.2, 127.5, 127.1, 126.9, 
122.9, 111.0, 110.6, 65.3, 49.5, 48.5, 47.0, 45.2, 44.3, 27.2, 27.0, 20.6, 19.2; FTIR 
(thin film) 2961, 2228, 1651, 1478, 1333, 1153, 733 cm-1; HRMS calculated for 
C30H33N5O5SNa (M+Na)+ = 598.2100; found 598.2098 (TOF MS ES+). 
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(S)-2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(2-(methoxymethoxy)ethyl)-
1H-1,2,3-triazol-4-yl)methyl)-3-methyl-1,2,5-thiadiazepin-1,1-dioxide-4-one       
5.13{1,1,1} 
 
[α]20D = -15.3 º (c = 0.60, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.56 
– 7.50 (m, 2H), 7.50 – 7.46 (m, 2H), 7.41 (d, J = 8.3, 2H), 7.15 – 7.08 (m, 2H), 4.87 
(d, J = 14.9, 1H), 4.77 (q, J = 6.8, 1H), 4.63 – 4.54 (m, 5H), 4.40 (t, J = 11.3, 1H), 
4.13 (dd, J = 16.6, 10.4, 1H), 3.97 (ddd, J = 17.0, 5.1, 2.2, 1H), 3.92 (t, J = 5.1, 2H), 
3.82 (d, J = 16.4, 1H), 3.75 (ddd, J = 6.6, 3.4, 1.6, 1H), 3.27 (s, 3H), 3.24 – 3.16 (m, 
2H), 1.25 (d, J = 6.9, 3H).; 13C NMR (126 MHz, CDCl3) δ 171.8, 162.5 (d, 1JCF = 
246.3 Hz), 143.23, 139.34, 137.0, 136.8 (d, 4JCF = 3.2 Hz), 128.59 (d, 3JCF = 8.0 Hz), 
127.93, 126.96, 123.81, 115.62 (d, 2JCF = 21.4 Hz), 96.48, 65.73, 55.49, 54.64, 50.51, 
49.51, 47.97, 44.45, 44.04, 16.26; FTIR (thin film) 3142, 2941, 1659, 1499, 1337, 
1142, 766 cm-1; HRMS calculated for C25H31FN5O5S (M+H)+ = 532.2024; found 
532.2023 (+ESI). 
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(S)-5-((1-(2-(methoxymethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-methyl-2-
((3',4',5'-trimethoxy-[1,1'-biphenyl]-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 
4-one  5.13{1,1,2}  
[α]20D = -13.8 º (c = 0.73, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.74 (s, 1H), 
7.52 – 7.48 (m, 2H), 7.41 (d, J = 8.3 Hz, 2H), 6.76 (s, 2H), 4.88 (d, J = 14.9 Hz, 1H), 
4.77 (q, J = 6.8 Hz, 1H), 4.63 – 4.55 (m, 5H), 4.40 (d, J = 10.9 Hz, 1H), 4.18 – 4.10 
(m, 1H), 4.01 – 3.94 (m, 1H), 3.94 – 3.91 (m, 9H), 3.89 (s, 3H), 3.83 (d, J = 16.4 Hz, 
1H), 3.28 (s, 3H), 3.24 – 3.22 (m, 1H), 1.26 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ ppm 172.0, 153.6, 143.4, 140.7, 137.8, 137.3, 136.9, 128.0, 127.3, 124.0, 
104.5, 96.7, 65.9, 61.2, 56.4, 55.7, 54.9, 50.7, 49.7, 48.2, 44.7, 44.2, 16.5; FTIR (thin 
film) 3138, 2939, 1659, 1589, 1499, 1340, 1126, 766, 733 cm-1; HRMS calculated for 
C29H34N5O7S (M+H)+ = 604.2436; found 604.2434 (+ESI).   
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(S)-2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-
triazol-4-yl)methyl)-3-methyl-1,2,5-thiadiazepin-1,1-dioxide-4-one  5.13{1,2,1} 
 
[α]20D = -12.4 º (c = 0.75, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.63 (s, 1H), 7.57 
– 7.50 (m, 2H), 7.50 – 7.46 (m, 2H), 7.42 – 7.34 (m, 3H), 7.16 – 7.08 (m, 2H), 6.47 
(dd, J = 3.3, 0.6 Hz, 1H), 6.37 (dd, J = 3.3, 1.9 Hz, 1H), 5.53 (q, J = 15.5, 23.2 Hz, 
2H), 4.87 (d, J = 12.1 Hz, 1H), 4.75 (q, J = 6.8, 13.6 Hz, 1H), 4.55 (d, J = 14.9 Hz, 
1H), 4.33 (d, J = 16.4 Hz, 1H), 4.12 (dd, J = 24.8, 12.3 Hz, 1H), 3.98 – 3.91 (m, 1H), 
3.29 – 3.11 (m, 2H), 1.23 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 172.0, 
162.65 (d, 1JCF = 246.4 Hz), 147.1, 144.1, 143.9, 139.5, 137.2, 137.0 (d, 4JCF = 3.3 
Hz), 128.8 (d, 3JCF = 8.1 Hz) 128.1, 127.1, 122.8, 115.8 (d, 2JCF = 21.4 Hz), 111.1, 
110.7, 54.8, 49.7, 48.1, 47.0, 44.8, 44.3, 16.4; FTIR (thin film) 3140, 2940, 1659, 
1500, 1337, 1142, 766  cm-1; HRMS calculated for C26H27FN5O4S (M+H)+ = 
524.1762; found 524.1758 (+ESI). 
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(S)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-methyl-2-((3',4',5'-
trimethoxy-[1,1'-biphenyl]-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 4-one 
5.13{1,2,2} 
[α]20D = -13.1 º (c = 0.84, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.62 (s, 1H), 
7.52 – 7.47 (m, 2H), 7.39 (dt, J = 8.5, 4.4 Hz, 3H), 6.77 (s, 2H), 6.48 (dd, J = 3.2, 0.5 
Hz, 1H), 6.38 (dd, J = 3.3, 1.9 Hz, 1H), 5.53 (q, J = 15.5 Hz, 2H), 4.87 (d, J = 14.9 
Hz, 1H), 4.76 (q, J = 6.7 Hz, 1H), 4.55 (d, J = 14.9 Hz, 1H), 4.37 – 4.30 (m, 1H), 
4.13 (dd, J = 16.6, 11.0 Hz, 1H), 3.97 (dd, J = 5.2, 1.8 Hz, 1H), 3.93 (s, 6H), 3.89 (s, 
3H), 3.78 (s, 1H), 3.27 – 3.20 (m, 1H), 3.20 – 3.11 (m, 1H), 1.24 (d, J = 6.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 172.0, 153.6, 147.1, 144.1, 140.7, 137.8, 137.2, 
136.9, 128.1, 127.2, 122.8, 111.1, 110.8, 104.5, 61.2, 56.4, 54.8, 49.7, 48.1, 47.0, 
44.8, 44.3, 16.4; FTIR (thin film) 3140, 2937, 1659, 1589, 1499, 1340, 1126, 766, 
735 cm-1; HRMS calculated for C29H34N5O7S (M+H)+ = 596.2173; found 596.2169 
(+ESI).   
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(S)-5-((1-(2-(1,3-dioxan-2-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-2-((4'-fluoro-
[1,1'-biphenyl]-4-yl)methyl)-3-methyl-1,2,5-thiadiazepin-1,1-dioxide 4-one 
5.13{1,3,1} 
 
[α]20D = -23.6 º (c = 0.70, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.57 (d, J = 
4.5 Hz, 1H), 7.53 – 7.47 (m, 2H), 7.47 – 7.43 (m, 2H), 7.37 (d, J = 8.3 Hz, 2H), 7.11 
– 7.05 (m, 2H), 4.79 (d, J = 14.9 Hz, 1H), 4.73 (q, J = 6.8 Hz, 1H), 4.56 (d, J = 16.5 
Hz, 1 H), 4.56 − 4.53 (m, 1H), 4.45 (td, J = 7.0, 2.2 Hz, 2H), 4.35 (d, J = 16.4 Hz, 
1H), 4.13 – 4.08 (m, 1H), 4.08 – 4.03 (m, 2H), 3.98 – 3.90 (m, 1H), 3.78 (d, J = 16.4 
Hz, 1H), 3.69 (ddd, J = 12.4, 3.9, 2.5 Hz, 2H), 3.24 – 3.18 (m, 2H), 2.19 – 2.12 (m, 
2H), 2.03 (qt, J = 12.5, 5.0 Hz, 1H), 1.31 (dm, 1H), 1.22 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 172.1, 162.7 (d, 1JCF = 246 Hz), 143.3, 139.53, 
136.8 (d, 4JCF = 3.0 Hz), 128.8 (d, 3JCF = 8.1 Hz), 128.1, 127.2, 123.3, 115.8 (d, 2JCF = 
21.4 Hz) 99.1, 67.1, 54.8, 49.7, 48.2, 45.7, 44.7, 44.3, 35.6, 25.8, 16.5; FTIR (thin 
film) 3138, 2939, 1659, 1589, 1499, 1340, 1126, 766, 733 cm-1; HRMS calculated for 
C27H33N5O5S (M+H)+ = 558.2181; found 558.2176 (+ESI).  
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(S)-5-((1-(2-(1,3-dioxan-2-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-methyl-2-
((3',4',5'-trimethoxy-[1,1'-biphenyl]-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 
4-one 5.13{1,3,2} 
[α]20D = -15.4 º (c = 0.68, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.61 (s, 1H), 
7.52 – 7.48 (m, 2H), 7.40 (d, J = 8.3 Hz, 2H), 6.76 (s, 2H), 4.83 (d, J = 14.9 Hz, 1H), 
4.77 (q, J = 6.6 Hz, 1H), 4.60 (d, J = 14.5 Hz, 1H), 4.57 (d, J = 4.7 Hz, 1H), 4.49 (td, 
J = 7.0, 2.2 Hz, 2H), 4.39 (d, J = 16.4 Hz, 1H), 4.09 (ddd, J = 11.8, 4.9, 1.1 Hz, 3H), 
4.01 – 3.94 (m, 1H), 3.92 (s, 6H), 3.89 (s, 3H), 3.82 (d, J = 16.4 Hz, 1H), 3.77 – 3.69 
(m, 1H), 3.25 (dd, J = 6.1, 3.9 Hz, 1H), 2.22 – 2.16 (m, 2H), 2.06 (qt, J = 12.5, 5.0 
Hz, 1H), 1.39 – 1.32 (m, 1H), 1.26 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
δ ppm 172.1, 153.6, 143.3, 140.7, 137.8, 137.2, 136.9, 128.0, 127.3, 123.3, 104.5, 
99.1, 67.1, 67.1, 61.2, 56.4, 54.9, 49.7, 48.2, 45.7, 44.7, 44.3, 35.6, 25.8, 16.5; FTIR 
(thin film) 3138, 2939, 1659 1589, 1499, 1340, 1126, 766, 733 cm-1; HRMS 
calculated for C30H40N5O8S (M+H)+ = 630.2592; found 630.2591 (+ESI). 
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(±)-2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-3-isopropyl-5-((1-(2-(methoxy 
methoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 4-one 
5.13{2,1,1} 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.75 (s, 1H), 7.57 – 7.52 (m, 2H), 7.48 (s, 4H), 
7.15 – 7.09 (m, 2H), 4.96 (d, J = 14.9 Hz, 1H), 4.55 (q, J = 10.1 Hz, 5.1 Hz, 2H), 4.53 
(s, 2H), 4.50 (d, J = 14.9 Hz, 2H), 4.28 (d, J = 15.4 Hz, 1H), 4.18 (dd, J = 16.6, 11.6 
Hz, 1H), 4.05 (d, J = 10.6 Hz, 1H), 3.99 – 3.92 (m, 1H), 3.90 (t, J = 5.1 Hz, 2H), 3.74 
(d, J = 15.4 Hz, 1H), 3.24 (s, 3H), 3.21 (dd, J = 14.5, 4.9 Hz, 1H), 3.13 – 3.04 (m, 
1H), 2.07 (qt, J = 12.4, 6.2 Hz, 1H), 0.90 (d, J = 6.4 Hz, 3H), 0.69 (d, J = 6.6 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ ppm 170.3, 162.7 (d, 1JCF = 247 Hz), 143.6, 
139.8, 136.9 (d, 4JCF = 3.2 Hz), 135.9, 130.0, 128.8 (d, 3JCF = 8.1 Hz), 127.0, 124.1, 
115.9 (d, 2JCF = 21.5 Hz), 96.7, 65.9, 65.4, 55.7, 50.7, 49.6, 48.6, 45.0, 44.1, 27.2, 
20.7, 19.2; FTIR (thin film) 3142, 2955, 1657, 1499, 1337, 1155, 735 cm-1; HRMS 
calculated for C27H34N5O5S (M+H)+ = 560.2337; found 560.2331 (+ESI).  
 214 
N
N
S
OO
O
N
N
N
O
O
OMe
OMe
OMe
 
(S)-3-isopropyl-5-((1-(2-(methoxymethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-2-
((3',4',5'-trimethoxy-[1,1'-biphenyl]-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 
4-one  5.13{2,1,2} 
 
[α]20D = +1.6 º (c = 0.84, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.75 (s, 1H), 
7.49 (q, J = 13.0, 8.1 Hz, 4H), 6.78 (s, 2H), 4.97 (d, J = 14.9 Hz, 1H), 4.61 – 4.46 (m, 
5H), 4.28 (d, J = 15.6 Hz, 1H), 4.18 (dd, J = 16.3, 11.8 Hz, 1H), 4.05 (d, J = 10.5 Hz, 
1H), 3.96 (m, 1H), 3.93 (s, 6H), 3.90 (m, 1H), 3.88 (s, 3H), 3.75 (d, J = 15.4 Hz, 1H), 
3.25 (s, 3H), 3.22 − 3.18 (m, 1H), 3.09 (t, J = 12.8 Hz, 1H), 2.16 – 2.01 (m, 1H), 0.91 
(d, J = 6.2 Hz, 3H), 0.68 (t, J = 14.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm  
170.3, 153.7, 143.6, 140.9, 137.9, 136.7, 135.9, 129.9, 127.0, 124.0, 104.5, 96.6, 65.9, 
65.4, 61.2, 56.4, 55.7, 50.7, 49.6, 48.6, 45.0, 44.0, 27.2, 20.7, 19.3; FTIR (thin film) 
3138, 2957, 1657, 1589, 1499, 1342, 1155, 1126, 731 cm-1; HRMS calculated for 
C30H42N5O8S (M+H)+ = 632.2749; found 632.2746 (+ESI).  
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(S)-2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-
triazol-4-yl)methyl)-3-isopropyl-1,2,5-thiadiazepin-1,1-dioxide 4-one  5.13{2,2,1} 
 
[α]20D = -0.30 º (c = 1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.64 (s, 1H), 
7.57 – 7.52 (m, 2H), 7.50 – 7.46 (m, 2H), 7.44 (d, J = 8.3 Hz, 2H), 7.29 (dd, J = 1.8, 
0.7 Hz, 1H), 7.15 – 7.10 (m, 2H), 6.44 (dd, J = 3.2, 0.5 Hz, 1H), 6.31 (dd, J = 3.2, 1.9 
Hz, 1H), 5.55 (d, J = 15.5 Hz, 1H), 5.47 (d, J = 15.5 Hz, 1H), 4.97 (d, J = 14.9 Hz, 
1H), 4.43 (d, J = 14.9 Hz, 1H), 4.23 – 4.13 (m, 2H), 4.03 (d, J = 10.6 Hz, 1H), 3.96 – 
3.88 (m, 1H), 3.63 (d, J = 15.4 Hz, 1H), 3.20 (dd, J = 14.5, 4.9 Hz, 1H), 3.09 – 3.02 
(m, 1H), 2.09 – 1.99 (m, 1H), 0.88 (d, J = 6.4 Hz, 3H), 0.67 (d, J = 6.6 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ ppm 170.3, 162.7 (d, 1JCF = 247 Hz), 147.1, 144.1, 139.7, 
136.9, 136.9, 135.9, 130.0, 128.8 (d, 4JCF = 8.0 Hz), 126.90, 122.92, 115.9 (d, 3JCF = 
21.4 Hz), 110.9 (d, 2JCF = 48.8 Hz) 65.3, 49.6, 48.5, 47.0, 45.2, 44.3, 27.2, 20.7, 19.2; 
FTIR (thin film) 3142, 2955, 1657, 1499, 1337, 1155, 1138, 735 cm-1; HRMS 
calculated for C28H31FN5O4S (M+H)+ = 552.2075; found 552.2072 (+ESI). 
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(±)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-isopropyl-2-((3',4',5'-
trimethoxy-[1,1'-biphenyl]-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 4-one 
5.13{2,2,2} 
 
1H NMR (500 MHz, CDCl3) δ ppm 7.64 (s, 1H), 7.51 – 7.48 (m, 2H), 7.44 (d, J = 8.2 
Hz, 2H), 7.30 (dd, J = 1.8, 0.7 Hz, 1H), 6.78 (s, 2H), 6.44 (dd, J = 3.3, 0.5 Hz, 1H), 
6.31 (dd, J = 3.2, 1.9 Hz, 1H), 5.55 (d, J = 15.5 Hz, 1H), 5.47 (d, J = 15.5 Hz, 1H), 
4.98 (d, J = 14.9 Hz, 1H), 4.43 (d, J = 14.9 Hz, 1H), 4.18 (dd, J = 16.0, 11.6 Hz, 2H), 
4.06 – 4.00 (m, 1H), 3.94 (s, 7H), 3.90 (d, J = 10.0 Hz, 4H), 3.65 (d, J = 15.4 Hz, 
1H), 3.20 (dd, J = 14.5, 5.0 Hz, 1H), 3.10 – 3.02 (m, 1H), 2.11 – 2.00 (m, 1H), 0.89 
(d, J = 6.4 Hz, 3H), 0.69 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 
170.3, 153.7, 147.1, 144.1, 144.1, 140.8, 137.9, 136.7, 135.9, 129.9, 127.0, 122.9, 
111.1, 110.7, 104.5, 65.3, 61.2, 56.4, 49.6, 48.6, 47.0, 45.2, 44.3, 27.2, 20.7, 19.2; 
FTIR (thin film) 3142, 2962, 1655, 1589, 1499, 1342, 1153, 1126, 733 cm-1; HRMS 
calculated for C31H38N5O7S (M+H)+ = 624.2486; found 624.2484 (+ESI). 
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(S)-5-((1-(2-(1,3-dioxan-2-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-2-((4'-fluoro-
[1,1'-biphenyl]-4-yl)methyl)-3-isopropyl-1,2,5-thiadiazepin-1,1-dioxide 4-one 
5.13{2,3,1} 
 
[α]20D = -2.3 º (c = 0.49, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.60 (s, 1H), 
7.57 – 7.52 (m, 2H), 7.51 – 7.46 (m, 4H), 7.15 – 7.09 (m, 2H), 4.89 (d, J = 14.9 Hz, 
1H), 4.53 (t, J = 4.8 Hz, 1H), 4.51 (d, J = 15.1 Hz, 1H), 4.48 (td, J = 7.0, 1.5 Hz, 2H), 
4.29 (d, J = 15.4 Hz, 1H), 4.21 – 4.13 (m, 1H), 4.08 (ddd, J = 8.4, 4.5, 2.5 Hz, 1H), 
4.07 – 4.03 (m, 2H), 3.98 – 3.91 (m, 1H), 3.76 (d, J = 8.2 Hz, 1H), 3.70 (tt, J = 12.2, 
2.6 Hz, 2H), 3.26 – 3.19 (m, 1H), 3.18 – 3.10 (m, 1H), 2.20 – 2.14 (m, 2H), 2.12 – 
1.99 (m, 2H), 1.36 – 1.29 (dm, 1H), 0.91 (d, J = 6.4 Hz, 3H), 0.70 (d, J = 6.6 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.4, 162.7 (d, 1JCF = 247 Hz), 143.5, 139.8, 
136.9 (d, 4JCF = 3.2 Hz), 135.8, 130.0, 128.8 (d, 3JCF = 8.0 Hz), 127.0, 123.3, 115.9 (d, 
2JCF = 21.4, Hz), 99.1, 67.1, 65.3, 49.7, 48.7, 45.7, 45.0, 44.0, 35.6, 27.2, 25.7, 20.8, 
19.2; FTIR (thin film) 3140, 2964, 1657, 1499, 1337, 1155, 735 cm-1; HRMS 
calculated for C29H37FN5O5S (M+H)+ = 586.2494; found 586.2493 (+ESI).  
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(S)-5-((1-(2-(1,3-dioxan-2-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-isopropyl-2-
((3',4',5'-trimethoxy-[1,1'-biphenyl]-4-yl)methyl)-1,2,5-thiadiazepin-1,1-dioxide 
4-one 5.13{2,3,2} 
 
[α]20D = +4.1 º (c = 0.52, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ ppm 7.61 (s, 1H), 
7.52 – 7.46 (m, 4H), 6.78 (s, 2H), 4.90 (d, J = 14.9 Hz, 1H), 4.55 – 4.50 (m, 2H), 4.48 
(td, J = 7.0, 1.2 Hz, 2H), 4.29 (d, J = 15.4 Hz, 1H), 4.17 (dd, J = 16.6, 11.3 Hz, 1H), 
4.11 – 4.03 (m, 3H), 3.98 – 3.95 (m, 1H), 3.94 (s, 6H), 3.89 (s, 3H), 3.78 – 3.73 (m, 
1H), 3.70 (tt, J = 12.2, 2.5 Hz, 2H), 3.23 (dd, J = 14.4, 4.4 Hz, 1H), 3.19 – 3.12 (m, 
1H), 2.20 – 2.14 (m, 2H), 2.13 – 1.99 (m, 2H), 1.36 – 1.30 (m, 1H), 0.91 (d, J = 6.3 
Hz, 3H), 0.71 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 170.4, 153.7, 
143.5, 140.8, 137.9, 136.7, 135.9, 129.9, 127.0, 123.3, 104.5, 99.1, 67.1, 65.4, 61.2, 
56.4, 49.6, 48.7, 45.7, 45.0, 44.0, 35.6, 27.2, 25.8, 20.8, 19.3; FTIR (thin film) 3140, 
2963, 1655, 1589, 1340, 1126, 731 cm-1; HRMS calculated for C32H44N5O8S (M+H)+ 
= 658.2905; found 658.2903 (+ESI). 
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Table 6.1  Final Library Data Set – Thiadiazepin-1,1-dioxide 4-ones 
 
entry compound actual yield (mg) 
actual yield 
(%) 
final purity 
(%) 
1 5.14{1,1,1} 34.6 44.9 98.5 
2 5.14{1,2,1} 31.6 41.7 100.0 
3 5.14{1,3,1} 35.5 43.9 100.0 
4 5.14{1,4,1} 37.2 46.3 100.0 
5 5.14{1,5,1} 35.8 45.4 97.7 
6 5.14{2,1,1} 34.3 42.2 100.0 
7 5.14{2,2,1} 29.0 36.2 100.0 
8 5.14{2,3,1} 31.0 36.4 100.0 
9 5.14{2,4,1} 32.4 38.3 100.0 
10 5.14{2,5,1} 33.6 40.5 100.0 
11 5.14{3,1,1} 35.7 42.8 100.0 
12 5.14{3,2,1} 43.0 52.3 100.0 
13 5.14{3,3,1} 38.3 43.9 100.0 
14 5.14{3,4,1} 0.0 0.0 0.0 
15 5.14{3,5,1} 68.9 80.9 100.0 
16 5.14{1,1,2} 36.3 45.5 98.2 
17 5.14{1,2,2} 10.1 12.9 100.0 
18 5.14{1,3,2} 24.4 29.2 100.0 
19 5.14{1,4,2} 34.2 41.2 100.0 
20 5.14{1,5,2} 19.9 24.4 98.3 
21 5.14{2,1,2} 21.0 25.0 100.0 
22 5.14{2,2,2} 23.8 28.8 100.0 
23 5.14{2,3,2} 21.1 24.0 100.0 
24 5.14{2,4,2} 33.3 38.2 97.3 
25 5.14{2,5,2} 25.7 30.0 100.0 
26 5.14{3,1,2} 30.1 35.0 100.0 
27 5.14{3,2,2} 19.5 23.0 94.8 
28 5.14{3,3,2} 28.8 32.0 100.0 
29 5.14{3,4,2} 25.9 29.0 88.8 
30 5.14{3,5,2} 26.1 29.7 100.0 
31 5.14{1,1,3} 18.3 23.7 100.0 
32 5.14{1,2,3} 42.2 55.5 100.0 
33 5.14{1,3,3} 25.8 31.8 100.0 
34 5.14{1,4,3} 39.9 49.6 93.3 
35 5.14{1,5,3} 23.7 30.0 100.0 
36 5.14{2,1,3} 38.9 47.8 100.0 
37 5.14{2,2,3} 31.0 38.7 100.0 
38 5.14{2,3,3} 26.1 30.6 100.0 
39 5.14{2,4,3} 31.7 37.4 98.9 
40 5.14{2,5,3} 30.5 36.7 100.0 
41 5.14{3,1,3} 31.4 37.6 100.0 
42 5.14{3,2,3} 39.2 47.6 100.0 
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43 5.14{3,3,3} 43.3 49.5 100.0 
44 5.14{3,4,3} 34.5 39.7 100.0 
45 5.14{3,5,3} 42.4 49.7 100.0 
46 5.14{1,1,4} 37.3 45.4 100.0 
47 5.14{1,2,4} 26.8 33.1 100.0 
48 5.14{1,3,4} 51.0 59.2 100.0 
49 5.14{1,4,4} 41.8 48.9 100.0 
50 5.14{1,5,4} 47.1 56.1 100.0 
51 5.14{2,1,4} 36.9 42.7 100.0 
52 5.14{2,2,4} 39.1 45.9 100.0 
53 5.14{2,3,4} 28.2 31.2 100.0 
54 5.14{2,4,4} 38.6 43.0 100.0 
55 5.14{2,5,4} 31.8 36.0 100.0 
56 5.14{3,1,4} 50.6 57.2 100.0 
57 5.14{3,2,4} 44.4 50.8 100.0 
58 5.14{3,3,4} 54.5 59.0 100.0 
59 5.14{3,4,4} 36.0 39.2 95.8 
60 5.14{3,5,4} 38.7 42.8 99.3 
61 5.14{1,1,5} 7.6 9.8 25.3 
62 5.14{1,2,5} 4.9 6.4 100.0 
63 5.14{1,3,5} 7.0 8.6 26.7 
64 5.14{1,4,5} 2.9 3.6 100.0 
65 5.14{1,5,5} 6.0 7.5 27.5 
66 5.14{2,1,5} 2.4 2.9 100.0 
67 5.14{2,2,5} 3.5 4.3 92.0 
68 5.14{2,3,5} 3.4 4.0 100.0 
69 5.14{2,4,5} 4.2 4.9 27.2 
70 8.14{2,5,5} 3.8 4.5 100.0 
71 8.14{3,1,5} 2.7 3.2 100.0 
72 8.14{3,2,5} 3.0 3.6 31.1 
73 8.14{3,3,5} 4.8 5.4 67.9 
74 8.14{3,4,5} 4.0 4.6 86.7 
75 8.14{3,5,5} 3.4 4.0 74.2 
76 8.14{1,1,6} 66.0 80.9 98.3 
77 8.14{1,2,6} 53.1 66.1 100.0 
78 8.14{1,3,6} 70.4 82.4 100.0 
79 8.14{1,4,6} 44.9 52.9 94.0 
80 8.14{1,5,6} 9.1 10.9 96.7 
81 8.14{2,1,6} 56.2 65.5 100.0 
82 8.14{2,2,6} 63.9 75.6 99.0 
83 8.14{2,3,6} 12.9 14.4 73.2 
84 8.14{2,4,6} 64.4 72.3 95.6 
85 8.14{2,5,6} 51.3 58.6 100.0 
86 8.14{3,1,6} 66.3 75.5 99.0 
87 8.14{3,2,6} 52.2 60.2 93.1 
88 8.14{3,3,6} 17.1 18.6 21.7 
89 8.14{3,4,6} 49.9 54.7 95.6 
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90 5.14{3,5,6} 13.8 15.4 75.9 
91 5.14{1,1,7} 57.2 72.3 100.0 
92 5.14{1,2,7} 45.2 58.0 100.0 
93 5.14{1,3,7} 59.9 72.1 100.0 
94 5.14{1,4,7} 43.2 52.4 100.0 
95 5.14{1,5,7} 54.4 67.2 99.6 
96 5.14{2,1,7} 53.8 64.5 100.0 
97 5.14{2,2,7} 18.4 22.4 100.0 
98 5.14{2,3,7} 53.2 61.0 100.0 
99 5.14{2,4,7} 41.1 47.4 100.0 
100 5.14{2,5,7} 46.3 54.4 100.0 
101 5.14{3,1,7} 39.0 45.6 100.0 
102 5.14{3,2,7} 38.0 45.1 100.0 
103 5.14{3,3,7} 59.9 67.0 100.0 
104 5.14{3,4,7} 42.4 47.8 97.4 
105 5.14{3,5,7} 55.5 63.6 100.0 
106 5.14{1,1,8} 32.7 38.0 100.0 
107 5.14{1,2,8} 59.7 70.4 85.8 
108 5.14{1,3,8} 69.4 77.1 99.7 
109 5.14{1,4,8} 0.0 0.0 0.0 
110 5.14{1,5,8} 56.1 63.9 100.0 
111 5.14{2,1,8} 62.6 69.4 88.0 
112 5.14{2,2,8} 60.1 67.5 100.0 
113 5.14{2,3,8} 61.9 65.7 93.5 
114 5.14{2,4,8} 42.1 45.0 100.0 
115 5.14{2,5,8} 59.1 64.2 90.4 
116 5.14{3,1,8} 68.3 73.9 93.1 
117 5.14{3,2,8} 48.7 53.4 99.4 
118 5.14{3,3,8} 26.0 27.0 99.1 
119 5.14{3,4,8} 21.3 22.3 100.0 
120 5.14{3,5,8} 56.8 60.3 98.9 
121 5.14{1,1,9} 51.7 61.9 94.9 
122 5.14{1,2,9} 52.8 64.2 94.5 
123 5.14{1,3,9} 57.2 65.4 95.0 
124 5.14{1,4,9} 48.2 55.5 89.9 
125 5.14{1,5,9} 46.6 54.6 93.3 
126 5.14{2,1,9} 52.9 60.3 95.5 
127 5.14{2,2,9} 63.1 72.9 90.9 
128 5.14{2,3,9} 48.0 52.4 92.9 
129 5.14{2,4,9} 52.6 57.8 84.4 
130 5.14{2,5,9} 51.1 57.1 94.2 
131 5.14{3,1,9} 49.9 55.6 92.4 
132 5.14{3,2,9} 56.6 63.9 90.6 
133 5.14{3,3,9} 57.3 61.1 91.6 
134 5.14{3,4,9} 38.3 41.1 82.7 
135 5.14{3,5,9} 50.9 55.6 91.3 
136 5.14{1,1,10} 45.7 52.3 100.0 
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137 5.14{1,2,10} 5.9 6.8 99.8 
138 5.14{1,3,10} 64.9 71.1 100.0 
139 5.14{1,4,10} 48.8 53.8 100.0 
140 5.14{1,5,10} 41.1 46.1 100.0 
141 5.14{2,1,10} 52.6 57.4 100.0 
142 5.14{2,2,10} 59.0 65.3 100.0 
143 5.14{2,3,10} 46.7 48.9 100.0 
144 5.14{2,4,10} 0.0 0.0 0.0 
145 5.14{2,5,10} 56.0 60.0 100.0 
146 5.14{3,1,10} 0.0 0.0 0.0 
147 5.14{3,2,10} 45.0 48.7 100.0 
148 5.14{3,3,10} 42.8 43.9 100.0 
149 5.14{3,4,10} 7.0 7.2 99.8 
150 5.14{3,5,10} 56.3 59.0 100.0 
151 5.14{1,1,11} 41.5 54.7 100.0 
152 5.14{1,2,11} 38.2 51.2 100.0 
153 5.14{1,3,11} 13.5 16.9 96.4 
154 5.14{1,4,11} 36.8 46.5 100.0 
155 5.14{1,5,11} 26.2 33.7 100.0 
156 5.14{2,1,11} 50.6 63.2 100.0 
157 5.14{2,2,11} 30.7 38.9 100.0 
158 5.14{2,3,11} 47.1 56.1 100.0 
159 5.14{2,4,11} 45.0 54.0 100.0 
160 5.14{2,5,11} 37.6 45.9 100.0 
161 5.14{3,1,11} 50.2 61.1 100.0 
162 5.14{3,2,11} 29.1 35.9 100.0 
163 5.14{3,3,11} 56.3 65.4 100.0 
164 5.14{3,4,11} 23.4 27.4 100.0 
165 5.14{3,5,11} 31.0 36.9 100.0 
166 5.14{1,1,12} 45.8 56.1 100.0 
167 5.14{1,2,12} 53.1 66.0 87.9 
168 5.14{1,3,12} 44.1 51.5 88.0 
169 5.14{1,4,12} 34.3 40.3 78.9 
170 5.14{1,5,12} 41.9 50.2 100.0 
171 5.14{2,1,12} 52.6 61.2 96.9 
172 5.14{2,2,12} 54.8 64.7 98.5 
173 5.14{2,3,12} 41.4 46.1 100.0 
174 5.14{2,4,12} 20.3 22.8 93.1 
175 5.14{2,5,12} 32.0 36.5 93.6 
176 5.14{3,1,12} 36.5 41.5 57.1 
177 5.14{3,2,12} 38.1 43.9 55.0 
178 5.14{3,3,12} 28.1 30.6 69.9 
179 5.14{3,4,12} 10.1 11.1 94.7 
180 5.14{3,5,12} 0.0 0.0 0.0 
181 5.14{1,1,13} 53.2 66.6 98.8 
182 5.14{1,2,13} 47.6 60.5 100.0 
183 5.14{1,3,13} 41.3 49.3 100.0 
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184 5.14{1,4,13} 51.3 61.7 98.6 
185 5.14{1,5,13} 37.4 45.8 100.0 
186 5.14{2,1,13} 55.6 66.1 99.4 
187 5.14{2,2,13} 34.9 42.1 100.0 
188 5.14{2,3,13} 44.8 50.9 96.1 
189 5.14{2,4,13} 35.7 40.8 100.0 
190 5.14{2,5,13} 37.6 43.8 93.4 
191 5.14{3,1,13} 42.6 49.4 96.5 
192 5.14{3,2,13} 36.1 42.5 100.0 
193 5.14{3,3,13} 23.9 26.5 100.0 
194 5.14{3,4,13} 14.2 15.9 100.0 
195 5.14{3,5,13} 12.7 14.4 100.0 
196 5.14{1,1,14} 53.0 65.0 100.0 
197 5.14{1,2,14} 52.0 64.7 100.0 
198 5.14{1,3,14} 62.8 73.5 100.0 
199 5.14{1,4,14} 42.0 49.5 98.8 
200 5.14{1,5,14} 46.0 55.2 99.2 
201 5.14{2,1,14} 47.0 54.8 100.0 
202 5.14{2,2,14} 0.0 0.0 0.0 
203 5.14{2,3,14} 50.1 55.9 99.6 
204 5.14{2,4,14} 42.7 47.9 100.0 
205 5.14{2,5,14} 41.1 46.9 100.0 
206 5.14{3,1,14} 48.9 55.7 100.0 
207 5.14{3,2,14} 44.5 51.4 98.1 
208 5.14{3,3,14} 19.2 20.9 97.2 
209 5.14{3,4,14} 31.8 34.9 100.0 
210 5.14{3,5,14} 9.0 10.0 100.0 
211 5.14{1,1,15} 51.5 62.5 100.0 
212 5.14{1,2,15} 43.8 54.0 83.9 
213 5.14{1,3,15} 61.8 71.6 97.0 
214 5.14{1,4,15} 40.4 47.2 69.7 
215 5.14{1,5,15} 42.1 50.0 100.0 
216 5.14{2,1,15} 13.7 15.8 100.0 
217 5.14{2,2,15} 60.3 70.6 92.1 
218 5.14{2,3,15} 42.6 47.1 89.6 
219 5.14{2,4,15} 41.9 46.6 90.8 
220 5.14{2,5,15} 37.7 42.7 19.1 
221 5.14{3,1,15} 44.5 50.2 97.9 
222 5.14{3,2,15} 34.1 39.0 19.7 
223 5.14{3,3,15} 44.6 48.2 89.8 
224 5.14{3,4,15} 6.8 7.4 30.0 
225 5.14{3,5,15} 28.7 31.7 76.9 
 
 
 224 
 
 
 
 
 
 
 
Appendix A 
NMR Spectra 
 225 
Exo carbic anhydride (2.24) 
 
 
 
 
5-Norbornene-2-exo, 3-exo-dimethanol (2.25)  
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5-norbornene-2-exo, 3-exo-dimethyl phosphorochloridate (2.26) (major P-
diastereomer) 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-methyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.50) 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-ethyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.51) 
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(2S,3S,6S)-6-((benzyloxy)methyl)-3-isopropyl-2-phenoxy-3,6-dihydro-2H-1,2-oxa 
phosphinine 2-oxide  (2.52) 
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5-norbornene-2-exo, 3-exo-dimethyl benzylphosphate (2.61) (major P-
diastereomer) 
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Oligomeric benzylphosphate 20mer (OBP20) (2.62) 
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5-norbornene-2-exo, 3-exo-dimethyl (3,4-(Methylenedioxy)benzyl) phosphate 
(2.61a) (major P-diastereomer)  
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5-norbornene-2-exo, 3-exo-dimethyl (2-methyl benzyl) phosphate (2.61e) (major 
P-diastereomer)  
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5-norbornene-2-exo, 3-exo-dimethyl (3,5-dimethoxy benzyl) phosphate (2.61f) 
(major P-diastereomer)  
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 240 
5-norbornene-2-exo, 3-exo-dimethyl (4-bromo-benzyl) phosphate (2.61g) (major 
P-diastereomer) 
 
 
 
 
 
 
 
 
O
O
P
O
O
Br
 241 
 
 
 
5-norbornene-2-exo, 3-exo-dimethyl (4-chloro-benzyl) phosphate (2.61h) (major 
P-diastereomer)  
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5-norbornene-2-exo, 3-exo-dimethyl (4-fluoro-benzyl) phosphate (2.61i) (major 
P-diastereomer) 
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5-norbornene-2-exo, 3-exo-dimethyl (4-nitro-benzyl) phosphate (2.61j) (major P-
diastereomer) 
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 246 
5-norbornene-2-exo, 3-exo-dimethyl (3-dimethylamino benzyl) phosphate (2.61k) 
(major P-diastereomer) 
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5-norbornene-2-exo, 3-exo-dimethyl (3-trifluoromethylbenzyl) phosphate (2.61l) 
(P-diastereomer) 
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N,N-dimethyl-3-(morpholinomethyl)aniline (2.64k) 
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N,N-dimethyl-3-((4-phenylpiperazin-1-yl)methyl)aniline (2.64k′)  
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(S)-2-benzyl-7-bromo-3-phenyl-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine 
1,1-dioxide (2.66a) 
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(S)-7-bromo-2-(3,5-dimethoxybenzyl)-3-phenyl-3,4-dihydro-2H benzo[b] 
[1,4,5]oxathiazepine 1,1-dioxide (2.66b) 
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 (S)-7-bromo-2-(4-fluorobenzyl)-3-phenyl-3,4-dihydro-2H-benzo[b][1,4,5] oxa 
thiazepine 1,1-dioxide (2.66c)  
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 (S)-7-bromo-2-(4-fluorobenzyl)-3-isobutyl-3,4-dihydro-2H-benzo[b][1,4,5] 
oxathiazepine 1,1-dioxide (2.66d) 
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(±) tert-butyl-3,6,7,7a-tetrahydro-2H-3a,6-epoxybenzo[d] isothiazole-2-
carboxylate 1,1-dioxide  (3.15) 
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(±) tert-butyl-5-(4-acetylphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16a) 
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(±) tert-butyl-5-(4-acetylphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16b)  
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(±) tert-butyl 5-(4-(methoxycarbonyl)phenyl)hexahydro-2H-3a,6-epoxybenzo 
[d]isothiazole-2-carboxylate 1,1-dioxide (3.16c) 
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(±)-tert-butyl-5-(4-hydroxyphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-
2-carboxylate 1,1-dioxide (3.16d) 
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(±) tert-butyl-5-(3-fluorophenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16e) 
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(±) tert-butyl 5-(3,5-dimethylphenyl) hexahydro-2H-3a,6 epoxybenzo [d]iso 
thiazole-2-carboxylate 1,1-dioxide (3.16f) 
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(±) tert-butyl-5-(p-tolyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16g) 
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(±) tert-butyl-5-(4-(thiophen-3-yl)phenyl) hexahydro-2H-3a,6-epoxybenzo [d]iso-
thiazole-2-carboxylate 1,1-dioxide (3.16h) 
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(±) tert-butyl-5-(4-(trifluoromethoxy)phenyl) hexahydro-2H-3a,6-epoxybenzo [d] 
isothiazole -2-carboxylate 1,1-dioxide (3.16i) 
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(±) tert-butyl-5-(4-cyanophenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-
carboxylate 1,1-dioxide (3.16j) 
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(±) hexahydro-2H-3a,7-epoxyoxepino[3,4-d]isothiazole 1,1-dioxide (3.19) 
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(±)-3a,5-bis(hydroxymethyl)-2-(4-methoxybenzyl)hexahydrofuro[2,3-d]isothia- 
zole 1,1-dioxide (3.21) 
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(±) 2-((4'-(tert-butyl)-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) hexa-
hydrofuro[2,3-d]isothiazole 1,1-dioxide (3.23a) 
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 (±) 2-((3'-(1-hydroxyethyl)-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) 
hexa-hydrofuro[2,3-d]isothiazole 1,1-dioxide (3.23b) – mixture of diastereomers 
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(±) 4,5-dihydroxy-2-(4-iodobenzyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole 
1,1-dioxide (3.25) 
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(±) 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl)hexahydro 
furo[2,3-d]isothiazole 1,1-dioxide (3.28a) 
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(±) 2-((3'-chloro-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) hexa-
hydrofuro[2,3-d]isothiazole 1,1-dioxide (3.28b) 
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FTIR: Co/C-nanoparticles/ROMPgel (4.6, 4.10) 
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(S)-methyl 2-(N-(4-bromobenzyl)vinylsulfonamido)-3-methylbutanoate  5.6{2} 
 
 
 
 
 
S
N
OO
Br
O
H3CO
 286 
(S)-methyl 2-(N-(4-bromobenzyl)-2-(prop-2-yn-1-ylamino)ethylsulfonamido)-3-
methylbutanoate  5.7{2} 
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(S)-2-(4-bromobenzyl)-3-methyl-5-(prop-2-yn-1-yl)-1,2,5-thiadiazepin-1,1-
dioxide-4-one  5.9{1} 
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(S)-2-(4-bromobenzyl)-3-isopropyl-5-(prop-2-yn-1-yl)-1,2,5-thiadiazepin-1,1-
dioxide-4-one  5.9{2} 
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(S)-2-(4-bromobenzyl)-3-isobutyl-5-(prop-2-yn-1-yl)-1,2,5-thiadiazepin-1,1-
dioxide-4-one  5.9{3} 
 
 
 
 
 
 
3.30;3.22
4.12;3.78
3.56
4.42;3.78
7.45
7.29
1.39;1.54
4.71;3.93
2.32
1.43
0.57
0.85
N
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S
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O
N
N
S
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50.0
43.6
171.5
57.3
48.3
136.4
130.1
131.4
121.9
131.7
130.3
37.7
37.4
78.3
73.5
23.6
22.8
21.4
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(±) 2-(4-bromobenzyl)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-3-
methyl-1,2,5-thiadiazepin-1,1-dioxide 4-one   5.10{1} 
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(S)-2-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-5-((1-(furan-2-ylmethyl)-1H-1,2,3-
triazol-4-yl)methyl)-3-isopropyl-1,2,5-thiadiazepin-1,1-dioxide 4-one  5.13{2,2,1} 
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X-ray Data and Miscellaneous 
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CCD Experimental 
A full hemisphere of diffracted intensities (1850 xx-second frames with a ω scan 
width of 0.30°) was measured at 100K using graphite-monochromated MoKα 
radiation (λ= 0.71073 Å) on a Bruker SMART APEX CCD Single Crystal 
Diffraction System equipped with an Oxford Cryosystems 700 Series Cryostream 
Low Temperature Device.  X-rays were provided by a fine-focus sealed x-ray tube 
operated at 50kV and 30mA.   
 
X-Ray Crystal Structure of Compound 3.21 
 
Comments 
The asymmetric unit contains two crystallographically-independent C15H21NO6S 
molecules.  The two hydroxyl groups in the first crystallographically-independent 
C15H21NO6S molecule are each disordered with two preferred orientations about their 
O-C bonds.  The major occupancy orientation for oxygen atom O(4) is occupied 75% 
of the time and the minor orientation [O(4)] is occupied 25% of the time.  The major 
occupancy orientation for oxygen atom O(5) is occupied 65% of the time and the 
minor orientation [O(5)] is occupied 35% of the time.  The structure was refined as a 
53/47 racemic twin.  All displacement ellipsoids are drawn at the 50% probability 
level. 
 
Experimental Description  
Colorless lathe-shaped crystals of C15H21NO6S are, at 100(2) K, orthorhombic, space 
group P212121 – D24 (No. 19) (1) with a = 9.226(1) Å, b = 10.670(1) Å, c = 32.049(2) 
Å, V = 3154.8(3) Å3 and Z = 8 molecules {dcalcd = 1.446 g/cm3; a(MoK) = 0.236 mm-
1}.  A full hemisphere of diffracted intensities (1850 10-second frames with a scan 
width of 0.30) was measured using graphite-monochromated MoK radiation (= 
0.71073 Å) on a Bruker SMART APEX CCD Single Crystal Diffraction System (2).  
X-rays were provided by a fine-focus sealed x-ray tube operated at 50kV and 30mA.  
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Lattice constants were determined with the Bruker SAINT software package using 
peak centers for 3105 reflections.  A total of 29074 integrated reflection intensities 
having 2((MoK)< 52.00 were produced using the Bruker program SAINT(3); 6217 of 
these were unique and gave Rint = 0.068 with a coverage which was 100.0% complete. 
The data were corrected empirically for variable absorption effects using equivalent 
reflections; the relative transmission factors ranged from 0.827 to 1.000.  The Bruker 
software package SHELXTL was used to solve the structure using “direct methods” 
techniques.  All stages of weighted full-matrix least-squares refinement were 
conducted using Fo2 data with the SHELXTL Version 6.10 software package (4).  
The hydroxyl protons were included in the structural model at fixed idealized 
positions (assuming sp3-hybridization of the oxygen atom and an O-H bond length of 
0.84 Å).  All methyl groups were incorporated into the structural model as rigid 
groups (using idealized sp3-hybridized geometry and a C-H bond length of 0.98 Å) 
that were allowed to rotate about their O-C bonds during least-squares refinement 
cycles.  The remaining hydrogen atoms were included into the structural model as 
idealized atoms (assuming sp2- or sp3-hybridization of the carbon atoms and C-H 
bond lengths of 0.95 – 1.00 Å).  The isotropic thermal parameters of all hydrogen 
atoms were fixed at values 1.2 (nonmethyl) or 1.5 (methyl) times the equivalent 
isotropic thermal parameter of the oxygen or carbon atom to which they are 
covalently bonded.  
The two hydroxyl groups in the first crystallographically-independent C15H21NO6S 
molecule are each disordered with two preferred orientations about their O-C bonds.  
The major orientation for oxygen atom O(4) is occupied 75% of the time and the 
minor orientation [O(4)] is occupied 25% of the time.  The major orientation for 
oxygen atom O(5) is occupied 65% of the time and the minor orientation [O(5)] is 
occupied 35% of the time.  The structure was refined as a 53/47 racemic twin.   
The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms and isotropic thermal parameters for all hydrogen atoms.  A total 
of 438 parameters were refined using no restraints, 6217 data and weights of w = 1/ 
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[2(F2) + (0.0503 P)2 + 1.045 P], where P = [Fo
2 + 2Fc
2] / 3.  Final agreement factors at 
convergence are:  R1(unweighted, based on F) = 0.048 for 5309 independent 
absorption-corrected “observed” reflections having 2(MoK)< 52.00 and I>2(I);  
R1(unweighted, based on F) = 0.060 and wR2(weighted, based on F2) = 0.107 for all 
6217 independent absorption-corrected reflections having 2(MoK)< 52.00.  The 
largest shift/s.u. was 0.000 in the final refinement cycle.  The final difference Fourier 
had maxima and minima of 0.47 e-/Å3 and -0.38 e-/Å3, respectively.   
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Table 1.  Crystal data and structure refinement for C15H21NO6S. 
 
Empirical formula  C15H21NO6S 
Formula weight  343.39 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 – D24 (No. 19) 
Unit cell dimensions a = 9.226(1) Å  = 90.000° 
 b = 10.670(1) Å  = 90.000° 
 c = 32.049(2) Å  = 90.000° 
Volume 3154.8(3) Å3 
Z 8 
Density (calculated) 1.446 Mg/m3 
Absorption coefficient 0.236 mm-1 
F(000) 1456 
Crystal size 0.46 x 0.14 x 0.06 mm3 
Theta range for data collection 2.01° to 26.00° 
Index ranges -11  h  11, -13  k  13, -39  l  39 
Reflections collected 29074 
Independent reflections 6217 [Rint = 0.068] 
Completeness to theta = 26.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.827 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6217 / 0 / 438 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.048, wR2 = 0.103 
R indices (all data) R1 = 0.060, wR2 = 0.107 
Absolute structure parameter 0.0(14) 
Largest diff. peak and hole 0.47 and -0.38 e-/Å3 
R1 =  ||Fo| - |Fc|| /  |Fo|  
wR2 = {  [w(Fo
2 - Fc
2)2] /  [w(Fo
2)2] }1/2  
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for C15H21NO6S.  U(eq) is defined as one third of  the trace of 
the orthogonalized Uij tensor. 
____________________________________________________________________  
 x y z U(eq) 
____________________________________________________________________  
S(1) -543(1) 2889(1) 830(1) 21(1) 
O(1) 2991(2) 1576(2) 766(1) 24(1) 
O(2) -640(3) 4093(2) 1028(1) 32(1) 
O(3) -1812(2) 2468(2) 603(1) 32(1) 
O(6) 2146(2) -931(2) 2782(1) 26(1) 
N(1) 3(3) 1849(2) 1173(1) 18(1) 
C(1) 597(3) 791(3) 935(1) 20(1) 
C(2) 1573(3) 1366(3) 600(1) 19(1) 
C(3) 991(3) 2704(3) 494(1) 20(1) 
C(4) 2240(3) 3572(3) 593(1) 28(1) 
C(5) 3150(3) 2844(3) 901(1) 20(1) 
C(6) 4726(4) 3169(3) 916(1) 34(1) 
O(4) 5347(3) 3193(3) 538(1) 40(1) 
C(6') 4726(4) 3169(3) 916(1) 34(1) 
O(4') 5547(9) 2590(8) 1131(3) 29(3) 
C(7) 1733(4) 518(3) 225(1) 32(1) 
O(5) 2153(4) -632(3) 317(1) 22(1) 
C(7') 1733(4) 518(3) 225(1) 32(1) 
O(5') 502(6) -45(5) 93(2) 20(2) 
C(8) -1019(3) 1535(3) 1512(1) 21(1) 
C(9) -207(3) 889(3) 1855(1) 20(1) 
C(10) 624(3) 1582(3) 2133(1) 23(1) 
C(11) 1420(3) 1022(3) 2447(1) 23(1) 
C(12) 1417(3) -279(3) 2481(1) 19(1) 
C(13) 609(4) -988(3) 2202(1) 24(1) 
C(14) -195(3) -409(3) 1896(1) 21(1) 
C(15) 3026(4) -230(3) 3064(1) 27(1) 
S(21) 5383(1) 2143(1) 3918(1) 23(1) 
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O(21) 2140(2) 3664(2) 4124(1) 19(1) 
O(22) 5087(3) 1067(2) 3664(1) 32(1) 
O(23) 6818(2) 2227(3) 4090(1) 38(1) 
O(24) -127(2) 2485(2) 4581(1) 29(1) 
O(25) 4843(3) 4510(2) 4909(1) 38(1) 
O(26) 2185(3) 6122(2) 2104(1) 28(1) 
N(21) 4902(3) 3410(2) 3663(1) 20(1) 
C(21) 4542(3) 4377(3) 3969(1) 23(1) 
C(22) 3589(3) 3743(3) 4290(1) 19(1) 
C(23) 4106(3) 2362(3) 4334(1) 17(1) 
C(24) 2729(3) 1582(3) 4302(1) 20(1) 
C(25) 1713(3) 2391(3) 4044(1) 18(1) 
C(26) 122(3) 2254(3) 4150(1) 22(1) 
C(27) 3483(4) 4443(3) 4700(1) 25(1) 
C(28) 5794(3) 3771(3) 3301(1) 29(1) 
C(29) 4861(3) 4392(3) 2977(1) 23(1) 
C(30) 4152(3) 3674(3) 2677(1) 25(1) 
C(31) 3266(3) 4210(3) 2378(1) 25(1) 
C(32) 3032(3) 5498(3) 2381(1) 22(1) 
C(33) 3699(3) 6223(3) 2683(1) 24(1) 
C(34) 4622(4) 5685(3) 2973(1) 25(1) 
C(35) 1507(4) 5421(3) 1778(1) 33(1) 
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Table 3.   Bond lengths [Å] for C15H21NO6S. 
____________________________________________________________________ 
S(1)-O(2)  1.436(2) 
S(1)-O(3)  1.449(2) 
S(1)-N(1)  1.642(2) 
S(1)-C(3)  1.789(3) 
O(1)-C(5)  1.428(4) 
O(1)-C(2)  1.430(3) 
O(6)-C(12)  1.368(4) 
O(6)-C(15)  1.427(4) 
N(1)-C(1)  1.469(4) 
N(1)-C(8)  1.476(4) 
C(1)-C(2)  1.530(4) 
C(2)-C(7)  1.511(4) 
C(2)-C(3)  1.562(4) 
C(3)-C(4)  1.513(4) 
C(4)-C(5)  1.511(4) 
C(5)-C(6)  1.496(4) 
C(6)-O(4)  1.341(5) 
C(7)-O(5)  1.321(5) 
C(8)-C(9)  1.499(4) 
C(9)-C(10)  1.389(4) 
C(9)-C(14)  1.392(4) 
C(10)-C(11)  1.382(4) 
C(11)-C(12)  1.392(4) 
C(12)-C(13)  1.388(4) 
C(13)-C(14)  1.375(4) 
S(21)-O(22)  1.434(2) 
S(21)-O(23)  1.437(2) 
S(21)-N(21)  1.641(2) 
S(21)-C(23)  1.794(3) 
O(21)-C(25)  1.437(3) 
O(21)-C(22)  1.441(3) 
O(24)-C(26)  1.422(4) 
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O(25)-C(27)  1.425(4) 
O(26)-C(32)  1.357(4) 
O(26)-C(35)  1.429(4) 
N(21)-C(21)  1.463(4) 
N(21)-C(28)  1.473(4) 
C(21)-C(22)  1.512(4) 
C(22)-C(27)  1.513(4) 
C(22)-C(23)  1.555(4) 
C(23)-C(24)  1.522(4) 
C(24)-C(25)  1.518(4) 
C(25)-C(26)  1.513(4) 
C(28)-C(29)  1.503(4) 
C(29)-C(30)  1.392(5) 
C(29)-C(34)  1.396(4) 
C(30)-C(31)  1.385(5) 
C(31)-C(32)  1.391(5) 
C(32)-C(33)  1.382(5) 
C(33)-C(34)  1.386(5) 
____________________________________________________________________
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Table 4.   Bond angles [°] for C15H21NO6S. 
____________________________________________________________________ 
O(2)-S(1)-O(3) 116.7(2) 
O(2)-S(1)-N(1) 109.1(1) 
O(3)-S(1)-N(1) 112.0(1) 
O(2)-S(1)-C(3) 114.5(2) 
O(3)-S(1)-C(3) 107.6(1) 
N(1)-S(1)-C(3) 94.9(1) 
C(5)-O(1)-C(2) 110.8(2) 
C(12)-O(6)-C(15) 117.5(2) 
C(1)-N(1)-C(8) 116.5(2) 
C(1)-N(1)-S(1) 106.6(2) 
C(8)-N(1)-S(1) 116.7(2) 
N(1)-C(1)-C(2) 106.0(2) 
O(1)-C(2)-C(7) 107.5(2) 
O(1)-C(2)-C(1) 109.9(2) 
C(7)-C(2)-C(1) 112.0(3) 
O(1)-C(2)-C(3) 104.6(2) 
C(7)-C(2)-C(3) 114.1(3) 
C(1)-C(2)-C(3) 108.4(2) 
C(4)-C(3)-C(2) 104.6(2) 
C(4)-C(3)-S(1) 114.1(2) 
C(2)-C(3)-S(1) 104.1(2) 
C(5)-C(4)-C(3) 104.2(3) 
O(1)-C(5)-C(6) 109.2(2) 
O(1)-C(5)-C(4) 103.4(2) 
C(6)-C(5)-C(4) 116.2(3) 
O(4)-C(6)-C(5) 113.0(3) 
O(5)-C(7)-C(2) 114.1(3) 
N(1)-C(8)-C(9) 109.0(2) 
C(10)-C(9)-C(14) 117.7(3) 
C(10)-C(9)-C(8) 120.2(3) 
C(14)-C(9)-C(8) 122.0(3) 
C(11)-C(10)-C(9) 122.0(3) 
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C(10)-C(11)-C(12) 119.1(3) 
O(6)-C(12)-C(13) 116.3(3) 
O(6)-C(12)-C(11) 124.0(3) 
C(13)-C(12)-C(11) 119.7(3) 
C(14)-C(13)-C(12) 120.2(3) 
C(13)-C(14)-C(9) 121.2(3) 
O(22)-S(21)-O(23) 116.3(2) 
O(22)-S(21)-N(21) 108.9(1) 
O(23)-S(21)-N(21) 112.9(2) 
O(22)-S(21)-C(23) 113.6(1) 
O(23)-S(21)-C(23) 108.2(2) 
N(21)-S(21)-C(23) 94.9(1) 
C(25)-O(21)-C(22) 112.1(2) 
C(32)-O(26)-C(35) 118.3(3) 
C(21)-N(21)-C(28) 118.1(2) 
C(21)-N(21)-S(21) 107.9(2) 
C(28)-N(21)-S(21) 117.2(2) 
N(21)-C(21)-C(22) 105.8(2) 
O(21)-C(22)-C(21) 108.3(2) 
O(21)-C(22)-C(27) 106.8(2) 
C(21)-C(22)-C(27) 114.0(3) 
O(21)-C(22)-C(23) 105.2(2) 
C(21)-C(22)-C(23) 107.9(2) 
C(27)-C(22)-C(23) 114.1(2) 
C(24)-C(23)-C(22) 104.8(2) 
C(24)-C(23)-S(21) 115.2(2) 
C(22)-C(23)-S(21) 104.9(2) 
C(25)-C(24)-C(23) 104.0(2) 
O(21)-C(25)-C(26) 108.5(2) 
O(21)-C(25)-C(24) 105.7(2) 
C(26)-C(25)-C(24) 115.0(2) 
O(24)-C(26)-C(25) 111.0(2) 
O(25)-C(27)-C(22) 112.1(3) 
N(21)-C(28)-C(29) 109.9(2) 
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C(30)-C(29)-C(34) 117.6(3) 
C(30)-C(29)-C(28) 120.2(3) 
C(34)-C(29)-C(28) 122.2(3) 
C(31)-C(30)-C(29) 121.9(3) 
C(30)-C(31)-C(32) 119.6(3) 
O(26)-C(32)-C(33) 116.1(3) 
O(26)-C(32)-C(31) 124.7(3) 
C(33)-C(32)-C(31) 119.3(3) 
C(32)-C(33)-C(34) 120.7(3) 
C(33)-C(34)-C(29) 120.8(3) 
____________________________________________________________________ 
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Table 5.   Anisotropic displacement parameters  (Å2x 103) for C15H21NO6S.  The 
anisotropic displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
____________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
____________________________________________________________________ 
S(1) 14(1)  20(1) 28(1)  3(1) 1(1)  7(1) 
O(1) 15(1)  14(1) 43(1)  -7(1) -10(1)  2(1) 
O(2) 39(2)  19(1) 38(1)  3(1) 11(1)  14(1) 
O(3) 15(1)  38(2) 42(1)  10(1) -5(1)  3(1) 
O(6) 30(1)  19(1) 29(1)  1(1) -4(1)  1(1) 
N(1) 16(1)  15(1) 24(1)  1(1) 1(1)  3(1) 
C(1) 17(2)  17(2) 26(2)  0(1) -1(1)  1(1) 
C(2) 14(2)  19(2) 24(2)  -4(1) -4(1)  4(1) 
C(3) 17(2)  26(2) 17(2)  4(1) 3(1)  5(1) 
C(4) 17(2)  24(2) 44(2)  10(2) 4(2)  6(1) 
C(5) 15(2)  16(2) 31(2)  -7(1) 1(1)  0(1) 
C(6) 21(2)  22(2) 60(2)  -6(2) -6(2)  -2(1) 
O(4) 17(2)  69(3) 34(2)  11(2) -1(2)  7(2) 
C(6') 21(2)  22(2) 60(2)  -6(2) -6(2)  -2(1) 
O(4') 13(4)  42(6) 33(5)  11(4) -1(4)  -6(4) 
C(7) 24(2)  36(2) 37(2)  -17(2) 7(2)  -8(2) 
O(5) 17(2)  18(2) 32(2)  -1(2) 4(1)  1(1) 
C(7') 24(2)  36(2) 37(2)  -17(2) 7(2)  -8(2) 
O(5') 18(3)  24(3) 18(3)  -7(2) 1(3)  -7(3) 
C(8) 15(2)  21(2) 29(2)  -3(1) 4(1)  1(1) 
C(9) 17(2)  21(2) 23(2)  -2(1) 6(1)  3(1) 
C(10) 22(2)  15(2) 33(2)  1(1) -1(2)  1(1) 
C(11) 22(2)  17(2) 28(2)  -3(1) -3(1)  -3(1) 
C(12) 18(2)  19(2) 21(2)  3(1) 7(1)  2(1) 
C(13) 30(2)  14(2) 29(2)  -2(1) 8(2)  -5(1) 
C(14) 20(2)  19(2) 24(2)  -3(1) 2(1)  -3(1) 
C(15) 28(2)  24(2) 28(2)  1(1) -5(2)  1(2) 
S(21) 14(1)  22(1) 34(1)  7(1) 1(1)  2(1) 
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O(21) 14(1)  15(1) 29(1)  1(1) -4(1)  -3(1) 
O(22) 37(1)  17(1) 41(1)  -1(1) 9(1)  4(1) 
O(23) 14(1)  48(2) 51(2)  15(1) -6(1)  2(1) 
O(24) 26(1)  23(1) 37(1)  3(1) 12(1)  4(1) 
O(25) 42(2)  41(1) 30(1)  8(1) -14(1)  -21(1) 
O(26) 31(1)  23(1) 30(1)  4(1) 1(1)  5(1) 
N(21) 17(1)  16(1) 27(1)  4(1) 4(1)  1(1) 
C(21) 19(2)  19(2) 31(2)  4(1) -2(1)  -7(1) 
C(22) 14(2)  18(2) 25(2)  2(1) -5(1)  0(1) 
C(23) 14(1)  16(2) 21(2)  4(1) -1(1)  -1(1) 
C(24) 17(2)  16(2) 27(2)  6(1) 0(1)  -3(1) 
C(25) 16(2)  16(2) 21(2)  -1(1) 1(1)  -5(1) 
C(26) 17(2)  20(2) 29(2)  1(1) 1(1)  -3(1) 
C(27) 31(2)  18(2) 27(2)  1(1) -9(2)  -2(1) 
C(28) 19(2)  28(2) 39(2)  7(2) 5(1)  -1(1) 
C(29) 16(2)  23(2) 30(2)  8(1) 12(1)  1(1) 
C(30) 21(2)  12(2) 42(2)  4(1) 10(2)  -1(1) 
C(31) 22(2)  22(2) 30(2)  -2(1) 3(1)  2(1) 
C(32) 17(2)  23(2) 26(2)  3(1) 10(1)  -1(1) 
C(33) 26(2)  17(2) 30(2)  0(1) 12(1)  1(1) 
C(34) 25(2)  21(2) 28(2)  -1(1) 9(1)  -7(1) 
C(35) 37(2)  34(2) 29(2)  4(2) -1(2)  -1(2) 
____________________________________________________________________  
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Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 103) for C15H21NO6S. 
___________________________________________________________________ 
 x  y  z  U(eq) 
___________________________________________________________________ 
H(1A) -194 300 805 24 
H(1B) 1164 230 1119 24 
H(3) 704 2768 194 24 
H(4A) 2803 3769 338 34 
H(4B) 1887 4364 718 34 
H(5) 2724 2935 1187 25 
H(6A) 4839 4002 1049 41 
H(6B) 5236 2548 1093 41 
H(4O) 6253 3186 565 48 
H(6C) 5096 3123 627 41 
H(6D) 4794 4058 1003 41 
H(4O') 6175 2244 980 35 
H(7A) 791 476 77 39 
H(7B) 2446 894 31 39 
H(5O) 3020 -731 243 27 
H(7C) 2131 1018 -9 39 
H(7D) 2451 -140 293 39 
H(5O') 292 213 -147 24 
H(8A) -1792 979 1404 26 
H(8B) -1477 2309 1619 26 
H(10) 646 2469 2107 28 
H(11) 1962 1517 2638 27 
H(13) 610 -1876 2222 29 
H(14) -752 -905 1709 25 
H(15A) 3528 -806 3254 40 
H(15B) 2413 341 3227 40 
H(15C) 3741 256 2907 40 
H(24O) -740 3062 4607 35 
H(25O) 4906 3919 5081 45 
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H(21A) 4018 5079 3835 27 
H(21B) 5432 4709 4102 27 
H(23) 4584 2228 4611 20 
H(24A) 2922 774 4160 24 
H(24B) 2317 1414 4581 24 
H(25) 1859 2200 3742 21 
H(26A) -450 2853 3981 26 
H(26B) -204 1397 4079 26 
H(27A) 3126 5303 4646 30 
H(27B) 2771 4017 4882 30 
H(28A) 6259 3017 3180 34 
H(28B) 6567 4354 3391 34 
H(30) 4279 2791 2679 30 
H(31) 2821 3701 2171 29 
H(33) 3523 7100 2691 29 
H(34) 5098 6201 3172 30 
H(35A) 935 5988 1602 50 
H(35B) 870 4784 1900 50 
H(35C) 2252 5012 1608 50 
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Table 7.  Torsion angles [°] for C15H21NO6S. 
____________________________________________________________________ 
O(2)-S(1)-N(1)-C(1) -159.30(19) 
O(3)-S(1)-N(1)-C(1) 70.0(2) 
C(3)-S(1)-N(1)-C(1) -41.3(2) 
O(2)-S(1)-N(1)-C(8) 68.5(2) 
O(3)-S(1)-N(1)-C(8) -62.2(2) 
C(3)-S(1)-N(1)-C(8) -173.5(2) 
C(8)-N(1)-C(1)-C(2) 178.3(2) 
S(1)-N(1)-C(1)-C(2) 46.0(3) 
C(5)-O(1)-C(2)-C(7) 140.9(3) 
C(5)-O(1)-C(2)-C(1) -96.9(3) 
C(5)-O(1)-C(2)-C(3) 19.3(3) 
N(1)-C(1)-C(2)-O(1) 85.8(3) 
N(1)-C(1)-C(2)-C(7) -154.8(3) 
N(1)-C(1)-C(2)-C(3) -28.0(3) 
O(1)-C(2)-C(3)-C(4) 3.4(3) 
C(7)-C(2)-C(3)-C(4) -113.8(3) 
C(1)-C(2)-C(3)-C(4) 120.6(3) 
O(1)-C(2)-C(3)-S(1) -116.6(2) 
C(7)-C(2)-C(3)-S(1) 126.2(2) 
C(1)-C(2)-C(3)-S(1) 0.6(3) 
O(2)-S(1)-C(3)-C(4) 23.3(3) 
O(3)-S(1)-C(3)-C(4) 154.8(2) 
N(1)-S(1)-C(3)-C(4) -90.3(2) 
O(2)-S(1)-C(3)-C(2) 136.69(19) 
O(3)-S(1)-C(3)-C(2) -91.8(2) 
N(1)-S(1)-C(3)-C(2) 23.1(2) 
C(2)-C(3)-C(4)-C(5) -22.9(3) 
S(1)-C(3)-C(4)-C(5) 90.2(3) 
C(2)-O(1)-C(5)-C(6) -158.4(3) 
C(2)-O(1)-C(5)-C(4) -34.1(3) 
C(3)-C(4)-C(5)-O(1) 34.4(3) 
C(3)-C(4)-C(5)-C(6) 154.0(3) 
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O(1)-C(5)-C(6)-O(4) 66.8(4) 
C(4)-C(5)-C(6)-O(4) -49.6(4) 
O(1)-C(2)-C(7)-O(5) 67.8(4) 
C(1)-C(2)-C(7)-O(5) -53.0(4) 
C(3)-C(2)-C(7)-O(5) -176.7(3) 
C(1)-N(1)-C(8)-C(9) 69.0(3) 
S(1)-N(1)-C(8)-C(9) -163.4(2) 
N(1)-C(8)-C(9)-C(10) 78.4(3) 
N(1)-C(8)-C(9)-C(14) -98.4(3) 
C(14)-C(9)-C(10)-C(11) -1.3(5) 
C(8)-C(9)-C(10)-C(11) -178.2(3) 
C(9)-C(10)-C(11)-C(12) 1.5(5) 
C(15)-O(6)-C(12)-C(13) 177.9(3) 
C(15)-O(6)-C(12)-C(11) -3.8(4) 
C(10)-C(11)-C(12)-O(6) -178.9(3) 
C(10)-C(11)-C(12)-C(13) -0.6(5) 
O(6)-C(12)-C(13)-C(14) 178.0(3) 
C(11)-C(12)-C(13)-C(14) -0.5(5) 
C(12)-C(13)-C(14)-C(9) 0.7(5) 
C(10)-C(9)-C(14)-C(13) 0.2(5) 
C(8)-C(9)-C(14)-C(13) 177.0(3) 
O(22)-S(21)-N(21)-C(21) 153.2(2) 
O(23)-S(21)-N(21)-C(21) -76.0(2) 
C(23)-S(21)-N(21)-C(21) 36.1(2) 
O(22)-S(21)-N(21)-C(28) -70.6(3) 
O(23)-S(21)-N(21)-C(28) 60.2(3) 
C(23)-S(21)-N(21)-C(28) 172.3(2) 
C(28)-N(21)-C(21)-C(22) 178.0(2) 
S(21)-N(21)-C(21)-C(22) -46.2(3) 
C(25)-O(21)-C(22)-C(21) 113.0(3) 
C(25)-O(21)-C(22)-C(27) -123.8(3) 
C(25)-O(21)-C(22)-C(23) -2.2(3) 
N(21)-C(21)-C(22)-O(21) -79.6(3) 
N(21)-C(21)-C(22)-C(27) 161.6(2) 
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N(21)-C(21)-C(22)-C(23) 33.8(3) 
O(21)-C(22)-C(23)-C(24) -15.6(3) 
C(21)-C(22)-C(23)-C(24) -131.1(3) 
C(27)-C(22)-C(23)-C(24) 101.1(3) 
O(21)-C(22)-C(23)-S(21) 106.2(2) 
C(21)-C(22)-C(23)-S(21) -9.3(3) 
C(27)-C(22)-C(23)-S(21) -137.1(2) 
O(22)-S(21)-C(23)-C(24) -13.3(3) 
O(23)-S(21)-C(23)-C(24) -144.1(2) 
N(21)-S(21)-C(23)-C(24) 99.8(2) 
O(22)-S(21)-C(23)-C(22) -128.01(19) 
O(23)-S(21)-C(23)-C(22) 101.2(2) 
N(21)-S(21)-C(23)-C(22) -14.9(2) 
C(22)-C(23)-C(24)-C(25) 26.5(3) 
S(21)-C(23)-C(24)-C(25) -88.2(3) 
C(22)-O(21)-C(25)-C(26) 143.2(2) 
C(22)-O(21)-C(25)-C(24) 19.3(3) 
C(23)-C(24)-C(25)-O(21) -28.2(3) 
C(23)-C(24)-C(25)-C(26) -147.9(3) 
O(21)-C(25)-C(26)-O(24) -62.8(3) 
C(24)-C(25)-C(26)-O(24) 55.4(3) 
O(21)-C(22)-C(27)-O(25) 176.1(2) 
C(21)-C(22)-C(27)-O(25) -64.3(3) 
C(23)-C(22)-C(27)-O(25) 60.3(3) 
C(21)-N(21)-C(28)-C(29) -80.5(3) 
S(21)-N(21)-C(28)-C(29) 147.8(2) 
N(21)-C(28)-C(29)-C(30) -87.6(3) 
N(21)-C(28)-C(29)-C(34) 89.7(4) 
C(34)-C(29)-C(30)-C(31) 1.6(5) 
C(28)-C(29)-C(30)-C(31) 179.0(3) 
C(29)-C(30)-C(31)-C(32) -2.1(5) 
C(35)-O(26)-C(32)-C(33) 178.0(3) 
C(35)-O(26)-C(32)-C(31) -1.6(5) 
C(30)-C(31)-C(32)-O(26) -179.9(3) 
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C(30)-C(31)-C(32)-C(33) 0.5(5) 
O(26)-C(32)-C(33)-C(34) -178.0(3) 
C(31)-C(32)-C(33)-C(34) 1.6(5) 
C(32)-C(33)-C(34)-C(29) -2.2(5) 
C(30)-C(29)-C(34)-C(33) 0.6(4) 
C(28)-C(29)-C(34)-C(33) -176.8(3) 
____________________________________________________________________  
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Table 8.  Hydrogen bonds for C15H21NO6S [Å and °]. 
____________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________  
 O(4)-H(4O)...O(3)#1 0.84 1.95 2.740(4) 157.3 
 O(4')-H(4O')...O(3)#1 0.84 2.23 2.968(9) 147.1 
 O(24)-H(24O)...O(5')#2 0.84 2.25 2.857(6) 129.5 
 O(25)-H(25O)...O(24)#3 0.84 1.85 2.684(3) 172.7 
____________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  #1:  x+1, y, z;  #2:  -x, 
y+1/2, -z+1/2;  #3:   x+1/2, -y+1/2, -z+1.       
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X-Ray Crystal Structure of Compound 3.25 
 
Comments 
The asymmetric unit contains one C14H16INO5S molecule.  All displacement 
ellipsoids are drawn at the 50% probability level. 
 
Experimental Description 
Colorless plate-shaped crystals of C14H16INO5S are, at 100(2) K, orthorhombic, 
space group Pna21 – C2v9 (No. 33) (1) with a = 7.9664(5) Å, b = 34.946(2) Å, c = 
5.2792(4) Å, V = 1469.7(2) Å3 and Z =  4 molecules {dcalcd = 1.976 g/cm3; a(MoK) = 
2.345 mm-1}.   A full hemisphere of diffracted intensities (1850 10-second frames 
with a scan width of 0.30) was measured for a single-domain specimen using 
graphite-monochromated MoK radiation (= 0.71073 Å) on a Bruker SMART APEX 
CCD Single Crystal Diffraction System (2).  X-rays were provided by a fine-focus 
sealed x-ray tube operated at 50kV and 30mA.  Lattice constants were determined 
with the Bruker SAINT software package using peak centers for 6619 reflections.  A 
total of 16743 integrated reflection intensities having 2((MoK)< 61.09 were produced 
using the Bruker program SAINT(3); 4416 of these were unique and gave Rint = 0.098 
with a coverage which was 99.4% complete. The data were corrected empirically for 
variable absorption effects using equivalent reflections; the relative transmission 
factors ranged from 0.786 to 1.000.  The Bruker software package SHELXTL was 
used to solve the structure using “direct methods” techniques.  All stages of weighted 
full-matrix least-squares refinement were conducted using Fo2 data with the 
SHELXTL Version 6.10 software package (4).  
The hydroxyl protons were included in the structural model at fixed idealized 
positions (assuming sp3-hybridization of the oxygen atom and an O-H bond length of 
0.84 Å).  The remaining hydrogen atoms were included into the structural model as 
idealized atoms (assuming sp2- or sp3-hybridization of the carbon atoms and C-H 
bond lengths of 0.95 – 1.00 Å).  The isotropic thermal parameters of all hydrogen 
atoms were fixed at values 1.2 times the equivalent isotropic thermal parameter of the 
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oxygen or carbon atom to which they are covalently bonded.    
The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms and isotropic thermal parameters for all hydrogen atoms.  A total 
of 199 parameters were refined using one restraint, 4416 data and weights of w = 1/ 
[2(F2) + (0.0221 P)2 + 8.007 P], where P = [Fo
2 + 2Fc
2] / 3.  Final agreement factors at 
convergence are:  R1(unweighted, based on F) = 0.057 for 4245 independent 
absorption-corrected “observed” reflections having 2(MoK)<  61.09 and I>2(I);  
R1(unweighted, based on F) = 0.060 and wR2(weighted, based on F2) = 0.113 for all 
4416 independent absorption-corrected reflections having 2(MoK)< 61.09.  The 
largest shift/s.u. was 0.000 in the final refinement cycle.  The top six peaks (1.45 – 
1.05 e-/Å3) in the final difference map were within 0.88 Å of the iodine atom.  The 
minima and next highest maxima in this final difference Fourier were  
–2.69 e-/Å3 and 1.05 e-/Å3, respectively.   
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Table 1.  Crystal data and structure refinement for C14H16INO5S. 
Empirical formula  C14H16INO5S 
Formula weight  437.24 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pna21 – C2v9 (No. 33) 
Unit cell dimensions a = 7.9664(5) Å  = 90.000° 
 b = 34.946(2) Å  = 90.000° 
 c = 5.2792(4) Å  = 90.000° 
Volume 1469.7(2) Å3 
Z 4 
Density (calculated) 1.976 Mg/m3 
Absorption coefficient 2.345 mm-1 
F(000) 864 
Crystal size 0.39 x 0.05 x 0.03 mm3 
Theta range for data collection 2.33° to 30.54° 
Index ranges -11  h  11, -49  k  49, -7  l  7 
Reflections collected 16743 
Independent reflections 4416 [Rint = 0.098] 
Completeness to theta = 30.54° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.786 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4416 / 1 / 199 
Goodness-of-fit on F2 1.143 
Final R indices [I>2sigma(I)] R1 = 0.057, wR2 = 0.112 
R indices (all data) R1 = 0.060, wR2 = 0.113 
Absolute structure parameter 0.00(3) 
Largest diff. peak and hole 1.45 and -2.69 e-/Å3 
-------------------------------------------------------------------------------------------------------
-R1 =  ||Fo| - |Fc|| /  |Fo|  
wR2 = {  [w(Fo
2 - Fc
2)2] /  [w(Fo
2)2] }1/2  
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for C14H16INO5S.  U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor. 
_____________________________________________________________________ 
 x y z U(eq) 
_____________________________________________________________________ 
I -1085(1) 3152(1) 8551(1) 19(1) 
S -1041(2) 803(1) 5986(3) 14(1) 
N -719(6) 1210(1) 4553(9) 13(1) 
O(1) 1598(5) 544(1) 1871(7) 12(1) 
O(2) -1879(5) 521(1) 4431(8) 16(1) 
O(3) -1844(5) 879(1) 8376(11) 23(1) 
O(4) 5269(5) 402(1) 1503(8) 15(1) 
O(5) 4291(5) 1104(1) 1598(9) 17(1) 
C(1) 755(7) 1205(2) 2870(10) 12(1) 
C(2) 1785(6) 859(1) 3629(14) 11(1) 
C(3) 1130(7) 688(2) 6114(11) 15(1) 
C(4) 1609(8) 263(2) 5879(11) 15(1) 
C(5) 2555(6) 271(2) 3328(13) 12(1) 
C(6) 4252(6) 471(1) 3640(16) 12(1) 
C(7) 3698(6) 902(2) 3795(12) 11(1) 
C(8) -2115(7) 1473(2) 4073(10) 15(1) 
C(9) -1777(8) 1871(2) 5049(11) 15(1) 
C(10) -847(7) 1928(2) 7255(13) 19(1) 
C(11) -625(8) 2295(2) 8187(10) 14(1) 
C(12) -1351(7) 2604(2) 6969(11) 15(1) 
C(13) -2272(8) 2552(2) 4787(11) 17(1) 
C(14) -2481(7) 2182(2) 3844(11) 16(1) 
 
 
 319 
Table 3.   Bond lengths [Å] for  C14H16INO5S. 
____________________________________________________________________ 
I-C(12)  2.100(6) 
S-O(3)  1.439(5) 
S-O(2)  1.447(4) 
S-N  1.631(5) 
S-C(3)  1.777(6) 
N-C(8)  1.463(7) 
N-C(1)  1.472(7) 
O(1)-C(5)  1.444(7) 
O(1)-C(2)  1.447(7) 
O(4)-C(6)  1.410(8) 
O(5)-C(7)  1.438(7) 
C(1)-C(2)  1.516(7) 
C(2)-C(3)  1.533(9) 
C(2)-C(7)  1.534(7) 
C(3)-C(4)  1.536(8) 
C(4)-C(5)  1.543(9) 
C(5)-C(6)  1.531(7) 
C(6)-C(7)  1.569(7) 
C(8)-C(9)  1.509(8) 
C(9)-C(14)  1.377(8) 
C(9)-C(10)  1.395(8) 
C(10)-C(11)  1.386(8) 
C(11)-C(12)  1.382(8) 
C(12)-C(13)  1.378(8) 
C(13)-C(14)  1.395(8) 
____________________________________________________________________ 
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Table 4.   Bond angles [°] for  C14H16INO5S. 
____________________________________________________________________ 
O(3)-S-O(2) 114.7(3) 
O(3)-S-N 108.4(3) 
O(2)-S-N 113.9(3) 
O(3)-S-C(3) 116.2(3) 
O(2)-S-C(3) 108.4(3) 
N-S-C(3) 93.6(3) 
C(8)-N-C(1) 120.6(4) 
C(8)-N-S 120.5(4) 
C(1)-N-S 113.2(4) 
C(5)-O(1)-C(2) 96.1(4) 
N-C(1)-C(2) 106.4(4) 
O(1)-C(2)-C(1) 112.4(5) 
O(1)-C(2)-C(3) 102.6(4) 
C(1)-C(2)-C(3) 110.7(5) 
O(1)-C(2)-C(7) 102.3(4) 
C(1)-C(2)-C(7) 118.4(4) 
C(3)-C(2)-C(7) 109.1(5) 
C(2)-C(3)-C(4) 102.9(5) 
C(2)-C(3)-S 102.1(4) 
C(4)-C(3)-S 117.3(4) 
C(3)-C(4)-C(5) 100.1(4) 
O(1)-C(5)-C(6) 102.8(4) 
O(1)-C(5)-C(4) 102.6(4) 
C(6)-C(5)-C(4) 110.2(6) 
O(4)-C(6)-C(5) 110.1(5) 
O(4)-C(6)-C(7) 111.5(5) 
C(5)-C(6)-C(7) 101.3(4) 
O(5)-C(7)-C(2) 109.1(5) 
O(5)-C(7)-C(6) 109.7(5) 
C(2)-C(7)-C(6) 100.5(4) 
N-C(8)-C(9) 112.5(5) 
C(14)-C(9)-C(10) 119.3(6) 
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C(14)-C(9)-C(8) 119.8(5) 
C(10)-C(9)-C(8) 120.7(5) 
C(11)-C(10)-C(9) 119.7(6) 
C(12)-C(11)-C(10) 120.3(5) 
C(13)-C(12)-C(11) 120.6(6) 
C(13)-C(12)-I 120.4(4) 
C(11)-C(12)-I 119.0(4) 
C(12)-C(13)-C(14) 119.0(6) 
C(9)-C(14)-C(13) 121.1(6) 
____________________________________________________________________  
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Table 5.  Anisotropic displacement parameters  (Å2x 103) for C14H16INO5S.  The 
anisotropic displacement factor exponent takes the form:  -22[ h2 a*2U11 ...  + 2 h k a* 
b* U12 ] 
_____________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_____________________________________________________________________ 
I 20(1)  13(1) 23(1)  -3(1) 5(1)  0(1) 
S 16(1)  14(1) 13(1)  -1(1) 4(1)  1(1) 
N 10(2)  9(2) 20(2)  5(2) -1(2)  0(2) 
O(1) 15(2)  10(2) 10(2)  1(1) -3(2)  -1(2) 
O(2) 18(2)  12(2) 20(2)  -1(2) -6(2)  -6(2) 
O(3) 24(2)  34(2) 12(2)  0(2) 8(2)  6(2) 
O(4) 14(2)  15(2) 17(2)  -3(2) 3(2)  3(2) 
O(5) 16(2)  10(2) 26(2)  5(2) 6(2)  1(2) 
C(1) 12(2)  14(3) 10(2)  3(2) 4(2)  2(2) 
C(2) 12(2)  13(2) 9(2)  6(3) 3(3)  0(2) 
C(3) 15(3)  18(3) 10(2)  1(2) 0(2)  0(2) 
C(4) 19(3)  10(2) 15(2)  3(2) -1(2)  5(2) 
C(5) 15(2)  11(2) 9(2)  0(2) -1(2)  3(2) 
C(6) 13(2)  10(2) 14(2)  -5(3) 1(3)  2(2) 
C(7) 12(2)  13(2) 7(3)  -2(2) 4(2)  -2(2) 
C(8) 14(2)  14(2) 16(3)  0(2) -4(2)  2(2) 
C(9) 15(3)  10(2) 21(3)  0(2) 5(2)  -3(2) 
C(10) 15(3)  17(3) 25(3)  -4(2) -8(2)  3(2) 
C(11) 20(2)  18(2) 6(3)  0(2) -2(2)  1(2) 
C(12) 8(3)  16(3) 20(3)  0(2) 3(2)  1(2) 
C(13) 26(3)  14(3) 12(2)  1(2) 0(2)  5(2) 
C(14) 21(2)  20(2) 6(3)  -3(2) -5(2)  0(2) 
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Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
103) for C14H16INO5S. 
_____________________________________________________________________ 
 x  y  z  U(eq) 
_____________________________________________________________________ 
H(4O) 6283 431 1898 18 
H(5O) 4966 965 795 20 
H(1A) 1420 1442 3078 15 
H(1B) 399 1185 1078 15 
H(3) 1683 809 7614 17 
H(4A) 606 97 5806 18 
H(4B) 2345 180 7285 18 
H(5) 2640 14 2503 14 
H(6) 4825 388 5234 15 
H(7) 4062 1026 5411 13 
H(8A) -3140 1371 4896 18 
H(8B) -2327 1485 2227 18 
H(10) -368 1715 8116 23 
H(11) 28 2335 9669 17 
H(13) -2756 2764 3937 21 
H(14) -3120 2143 2346 19 
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Table 7.  Torsion angles [°] for C14H16INO5S. 
___________________________________________________________________  
O(3)-S-N-C(8) -55.6(5) 
O(2)-S-N-C(8) 73.3(5) 
C(3)-S-N-C(8) -174.8(5) 
O(3)-S-N-C(1) 150.8(4) 
O(2)-S-N-C(1) -80.2(4) 
C(3)-S-N-C(1) 31.7(4) 
C(8)-N-C(1)-C(2) -170.2(5) 
S-N-C(1)-C(2) -16.7(6) 
C(5)-O(1)-C(2)-C(1) -173.9(4) 
C(5)-O(1)-C(2)-C(3) -55.0(5) 
C(5)-O(1)-C(2)-C(7) 58.1(5) 
N-C(1)-C(2)-O(1) 103.5(5) 
N-C(1)-C(2)-C(3) -10.5(6) 
N-C(1)-C(2)-C(7) -137.5(6) 
O(1)-C(2)-C(3)-C(4) 31.8(5) 
C(1)-C(2)-C(3)-C(4) 152.0(5) 
C(7)-C(2)-C(3)-C(4) -76.1(5) 
O(1)-C(2)-C(3)-S -90.2(4) 
C(1)-C(2)-C(3)-S 29.9(6) 
C(7)-C(2)-C(3)-S 161.9(4) 
O(3)-S-C(3)-C(2) -147.1(4) 
O(2)-S-C(3)-C(2) 82.1(4) 
N-S-C(3)-C(2) -34.6(4) 
O(3)-S-C(3)-C(4) 101.3(5) 
O(2)-S-C(3)-C(4) -29.5(5) 
N-S-C(3)-C(4) -146.1(4) 
C(2)-C(3)-C(4)-C(5) 3.0(5) 
S-C(3)-C(4)-C(5) 114.1(5) 
C(2)-O(1)-C(5)-C(6) -56.8(5) 
C(2)-O(1)-C(5)-C(4) 57.6(5) 
C(3)-C(4)-C(5)-O(1) -37.3(5) 
C(3)-C(4)-C(5)-C(6) 71.7(5) 
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O(1)-C(5)-C(6)-O(4) -84.6(5) 
C(4)-C(5)-C(6)-O(4) 166.6(4) 
O(1)-C(5)-C(6)-C(7) 33.5(6) 
C(4)-C(5)-C(6)-C(7) -75.3(6) 
O(1)-C(2)-C(7)-O(5) 78.8(5) 
C(1)-C(2)-C(7)-O(5) -45.4(8) 
C(3)-C(2)-C(7)-O(5) -173.1(4) 
O(1)-C(2)-C(7)-C(6) -36.5(6) 
C(1)-C(2)-C(7)-C(6) -160.7(6) 
C(3)-C(2)-C(7)-C(6) 71.6(6) 
O(4)-C(6)-C(7)-O(5) 4.0(6) 
C(5)-C(6)-C(7)-O(5) -113.1(5) 
O(4)-C(6)-C(7)-C(2) 118.9(5) 
C(5)-C(6)-C(7)-C(2) 1.8(7) 
C(1)-N-C(8)-C(9) -81.3(6) 
S-N-C(8)-C(9) 127.1(5) 
N-C(8)-C(9)-C(14) 149.8(5) 
N-C(8)-C(9)-C(10) -34.4(8) 
C(14)-C(9)-C(10)-C(11) -0.8(9) 
C(8)-C(9)-C(10)-C(11) -176.7(6) 
C(9)-C(10)-C(11)-C(12) 1.4(9) 
C(10)-C(11)-C(12)-C(13) -1.4(9) 
C(10)-C(11)-C(12)-I 176.9(5) 
C(11)-C(12)-C(13)-C(14) 0.9(9) 
I-C(12)-C(13)-C(14) -177.4(5) 
C(10)-C(9)-C(14)-C(13) 0.3(9) 
C(8)-C(9)-C(14)-C(13) 176.3(6) 
C(12)-C(13)-C(14)-C(9) -0.4(9) 
____________________________________________________________________  
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 Table 8.  Hydrogen bonds for C14H16INO5S [Å and °]. 
____________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________ 
 O(4)-H(4O)...O(2)#1 0.84 2.01 2.780(6) 152.3 
 O(5)-H(5O)...O(4) 0.84 2.01 2.572(6) 123.2 
____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  #1:  x+1, y, z.       
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I. Introduction 
The dry solvent system is a replacement for conventional distillations of large 
volumes of solvents to be used for virtually all chemistries that take place in an 
organic chemistry research laboratory.  The system is based upon a drying technique 
using activated alumina (Al2O3) whereby solvents are forced through packed columns 
containing the drying agent under inert gas atmosphere and are collected in small 
storage flasks.  The purpose of the following manual is to familiarize the user with the 
system as a whole in order to demonstrate proper usage and maintenance providing 
greater awareness and overall safety for the entire lab. 
 
II. Daily Use and Care 
a. Inert gas replacement and monitoring 
The most important issue for maintaining the solvent system on a daily/weekly 
basis is to closely monitor the total argon pressure.  As the argon tank is being used, 
small periodic changes in pressure may require adjustment of the upper manifold 
metering valves (Figure 1) that control the argon halo over the collection flasks to 
minimize solvent exposure to outside air and moisture.  Careful adjustment of the 
argon pressure aids in minimizing the amount of argon being used throughout the 
week and helps keep the system dry.  Each attached argon bubbler should have a slow 
flow rate (~ 1 bubble/5 seconds).  The lower argon manifold distributes argon to the 
solvent storage tanks.  Each needle valve on this manifold should remain open at all 
times unless isolation from the system is required during regeneration or repair. 
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A. Upper manifold/ 
metering valves 
B. Lower manifold/ 
needle valves 
C. Halo system regulator 
D. Fill valve 
 
 
 
 
Figure 1:  Argon manifold assembly 
 
When the system argon pressure is low (< 50 psi – right-hand gauge) it is best 
to replace the tank before it completely runs out.  The first step is to place the (NO 
ARGON – DO NOT USE!!) sign on the system to alert users that the solvent system 
is down.  Next, sequentially shut off the argon related valves starting with the green 
fill valve located near the halo system regulator followed next by the closure of the 
black valve that is directly attached to the tank regulator.  Lastly, close the argon tank 
valve and disconnect the regulator from the tank.  Place the safety cap back on the 
argon tank and exchange for a full tank.  Once the new tank is secured on the wall 
with the chain, remove the safety cap and reconnect the tank regulator.  While 
tightening the regulator, SLOWLY open the main valve to purge any air from the 
regulator housing and continue to tighten the regulator until the gauges are reading at 
full pressure.  Finish tightening the regulator to an acceptable torque rating and open 
the argon related valves in reverse order starting from the tank.  Allow the system 5-
10 minutes to re-pressurize and readjust the upper manifold metering valves that 
control the argon halo. 
 
b. Solvent replacement and delivery 
 
Replacement of the solvent in the system should only be performed by someone 
who is trained on the system.  This process begins by closing the green fill valve 
(Figure 1) that controls the argon flow to the solvent storage tanks (Figure 2).  After 
 
D
B
A
C
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shutting the valve, locate the tank valve (B) on the storage tank that corresponds to 
the solvent being replaced and close this valve.  Next, remove the argon pressure line 
(C) leading to the tank by pressing down on the larger part of the quick-connect 
assembly until it releases.  Locate the quick-connect bleeder hose and place this on 
the tank to bleed the tank pressure to atmospheric level.  Open the top of the storage 
tank by lifting the lever.  **IMPORTANT**  If the solvent is flammable, double 
check that the tank is securely grounded by tracing the ground wire to the 
source of the ground.  Also, if the solvent container being used to fill is metal, 
attach a ground lead to this container as well prior to opening or filling.  
Continue to fill the tank to the fill line located on the upper outer rim of the tank.  
Once the tank is full, replace the cap loosely and connect the argon pressure line to 
the degassing quick connect valve (A) on the tank by pressing downward on the 
upper, thinner part of the quick connect until it clicks.  Slowly open the green fill 
valve until out-gassing occurs in the tank.  Continue degassing the solvent for 5 
minutes.  After such time pull the cap on the tank closed while the degassing is 
continues.  Switch the argon pressure line from the degassing quick connect valve (A) 
to the pressure inlet quick connect valve (C).  Continue pressurizing the storage tank 
for 5 minutes.  Lastly, reopen the tank valve (B) leading to the column and continue 
pressurizing for another 5 minutes.  The system is now ready to be used. 
 
 
 
A. Degassing quick connect valve 
B. Tank shut-off valve 
C. Pressure inlet quick connect valve 
D. Ground cable connection 
 
 
 
 
 
 
 
Figure 2:  Solvent storage container 
A
B
C
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c. Proper solvent extraction technique 
 
Proper extraction technique is just as vital as maintaining the argon supply as poor 
technique will lead to exposing the system to excess air and moisture.  
**IMPORTANT – Make sure your syringe and needle is clean and dry before 
using to extract solvent from the system.  Only 12 in. long needles should be used 
for this process.  Proceed to enter into the flask by piercing the upper inlet septum 
(A) on the flask (Figure 3) and turn the 2-way valve (C) until the needle can be 
pushed though to the solvent level.  Withdraw the solvent into the syringe barrel 
being careful not to put pressure on the glass joint with the septum (B) as this can 
lead to breakage and possible injury.  Expel excess argon from the top of the syringe 
without returning excess amounts of solution to the flask   This helps prevent 
contamination of the solvent flask.  Once the desired amount is withdrawn, bring the 
needle out of the solvent and pull argon into your syringe.  Withdraw the needle back 
through the two-way valve (C), close the valve and remove from the septum (B).  
**Do not remove the needle through the valve and out the septum in one motion. 
If you are filling the flask to withdraw large quantities of solvent, insure that the 
system is well pressurized before proceeding.  Check the argon level on the tank first 
and proceed to open the green fill valve (five full turns counter clockwise) and wait 
for several minutes.  Remove the lower round bottom flask and place it on the cork 
ring located at the solvent station.  Open the lower two-way valve on the flask and 
collect the desired amount of solvent.  **Do not leave behind large amounts of 
solvent in the flask unless you know you or someone else will be using it. 
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A. Argon halo inlet 
B. Syringe inlet septum 
C. 2-way valve 
D. Dry solvent inlet 
 
 
 
 
 
 
 
 
Figure 3:  Solvent collection flask 
d. Cleaning solvent collection flasks 
 
During the regeneration period it is good practice to go ahead and critically clean 
the solvent collection flask to the corresponding solvent.  Proceed to carefully remove 
the connectors attached to the flask (Figure 3) by un-tightening the connector by hand 
and removing it from the glass joint.  **It is easier to keep the connector together in 
one piece while removing or replacing it in order to keep the seal and ferule properly 
aligned inside of the housing.  Afterwards, carefully remove the flask and begin 
cleaning it using a diluted solution of Micro 90 cleaning soap.  Rinse thoroughly with 
deionized water and acetone and place in a drying oven at 90 ºC overnight.  Replace 
the flask and only connect the upper argon connection.  Proceed to flame dry the flask 
while flowing argon into the flask.  **IMPORTANT** Make sure the solvent feed 
line is empty/dry and there are no flammables nearby.  If the nearby flask on the 
system contains a flammable solvent, empty and dry the flask before proceeding. 
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III. Safety Issues 
a. Static electricity/discharge 
 
Storage containers containing flammable solvents (diethyl ether, THF, and toluene) 
require an external ground wire to be securely attached to a nearby ground source. 
This can be located in Figure 2(D). **Make sure the connection is secure before 
refilling the storage container.  **When refilling flammable solvents, ground the 
solvent can to the storage container being filled.  Also, use caution that other 
people nearby are not using an open flame.  Do not use your cell phone or other 
electronics at or nearby the dry solvent system.  
 
b. Over-pressurization 
Over-pressurization of the system can be easily prevented by carefully monitoring 
the inert gas total pressure on the left-hand (secondary) gauge on the gas regulator.  
By securing the large regulator valve with tape, this will prevent accidental changes 
in pressure due to the occasional brush of an arm by a person walking nearby.  The 
total pressure on the solvent storage containers should not exceed 20 psi.  A good 
working pressure is 15-20 psi. 
 
c. Solvent overflow 
Overflowing the solvent system can be kept at a minimum by carefully thinking 
your way through the process of using the system.  **If an overflow occurs, quickly 
absorb the solvent/oil off the floor and report it to the person in charge.  The inert gas 
bubbler corresponding to this solvent will need to be emptied and refilled with light 
mineral oil located near the system.  If significant damage has occurred to the vinyl 
tubing, then it should be replaced as well. 
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IV. Column Regeneration 
a. Materials and Apparatus 
 
• Activated alumina beads (2-5 mm dia) 
• Inert gas tank and regulator 
• ¼ in. Swagelok drying tube w/ dessicant 
• Heating blanket (Figure 7) 
• 110 V Voltage regulator 
• Digital thermometer and probe 
• Glass wool 
• Nickel Anti-Seize Tape 
• Particulate breathing mask 
• Small plastic funnel 
• Two large crescent wrenches 
• Rubber mallet 
 
b. Regeneration Procedure 
 
1. Turn off the solvent storage tank valve located on top of the tank corresponding to 
the column needing regeneration.  **Leave the storage tank under inert gas during 
this process. 
2. Disconnect the upper feed line at the glass collection flask and plug the glass feed 
stem with a 14/20 septum. 
3. Disconnect the lower and upper feed lines leading at the valves on the column 
using caution to slowly bleed the solvent remaining in each line. 
4. Loosen the large U clamps that secure the column to the wall with the aid of 
another person and lower the column out of the clamps. 
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5. Carry and place the end of the column in the top of an open solvent waste 
container and slowly open the valve to allow the excess solvent to spray and drain 
from the column. 
6. Once the majority of the solvent is removed, place the column in a hood and 
attach an air line to one end.  Apply pressure to the column and open both valves 
to purge out any remaining solvent liquid or vapor. 
7. Once the column is dry, use two large crescent wrenches to loosen each threaded 
valve adapter – removing one adapter and valve on any given end. 
8. Empty the dry spent alumina beads into the solid waste container and attach an air 
line to the other valve to help force out any remaining beads. 
9. When the column is empty, unthread and remove the remaining valve assembly.  
Each valve assembly contains glass wool plugs that should be replaced.  **Do not 
over pack. 
10. Replace the nickel anti-seize tape on threads and replace.  Wrap one loop over the 
threads in a clockwise direction with the glass wool plug facing your direction.  
Remove any remaining tape on the inner threads of the column before replacing 
each adapter and valve assembly. 
11. Thread one adapter and valve assembly onto one end of the column as tight as 
possible with a wrench leaving the other end of the column open. 
12. Using a dust/particulate mask over your mouth and safety glasses, place the small 
funnel in the end of the column upright.  With the help of another person, slowly 
pour the beads into the column.  Use the rubber mallet to occasionally rap the side 
of the column to ensure proper packing/settling of the beads. 
13. Once the column is full and packed well, replace the other valve adapter assembly 
and concentrically tighten each assembly using both persons and both crescent 
wrenches until firmly tight (55-60 ft.lbs – torque). 
14. Place the column in the heating blanket with the un-insulated end of the 
temperature probe and tie up the column with the probe securing them well in the 
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blanket. **Check to make sure there is no plastic insulation touching the blanket 
as it will melt and catch fire. 
15. Connect one end of the column to the drying tube and the inert gas tank regulator.  
Set the regulator to 6 psi while flowing inert gas through the column.  Continue 
gas flow until regeneration is finished.  Test the flow is sufficient with a small 
drop of water on your wrist. 
16. **Important – Before beginning the heating process, remove the valve on the 
opposite end of the column as excess steam being ejected will damage the valve.  
This valve should be replaced once the column is finished and cool to the touch.  
17. Connect the heating blanket to the voltage regulator and slowly increase the 
voltage until the desired temperature has been reached. (375 ºC) 
18. Continue heating at 375 ºC for 6-8 hours.  Place a caution sign nearby to alert 
people of the high temperature and closely monitor the column during this time 
period. 
19. After such time, carefully untie the blanket and allow the column to return to 
room temperature while maintaining inert gas flow.  Use a fan to speed up the 
process. 
20. Once the column has reached room temperature, reconnect the end valve to the 
threaded valve adapter and align each set of valve handles with each other.  
21. Close the valves on the column starting from the end furthest from the inert gas 
inlet to seal off the column from the outer atmosphere. 
22. Disconnect the column from the inert gas and reattach it to the U clamps on the 
wall. 
23. Reattach the feed lines in no specific order. Do not over-tighten. 
24. Make sure there is pressure on the corresponding solvent storage tank. 
25. **Important - Open the storage tank valve and loosen the lower feed line at the 
valve on the column to bleed the solvent up to the valve. 
26. Once the solvent is up to the valve, open the lower valve to the column.  Wait a 
few minutes and open the upper valve on the column slowly.  **Important – 
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Excess heat generated from the adsorption in the column can cause the solvent to 
boil creating a large amount of volatile fumes.  If this occurs, remove the feed line 
at the glass collection flask and place it directly in an open 4 L bottle until the 
column cools and the vapor begins to condense back to a liquid. **Also, make 
sure no one in the vicinity is using an open flame if the solvent is flammable. 
27. Check the system for leaks and tighten any needed fittings. 
28. Monitor the argon flow and pressure and make any necessary adjustments. 
 
